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Abstract 
Background 
Poverty drives TB rates but the current TB control approach is disproportionately biomedical. In 
2015, the World Health Organisation’s End TB Strategy explicitly identified the need to address the 
social determinants of TB through socioeconomic interventions. However, evidence concerning 
poverty-reduction and costs-mitigation strategies is limited. My PhD research aimed to address this 
knowledge gap. 
Methods  
During this PhD, I aimed to develop as an independent researcher while addressing the social 
determinants of TB in impoverished shantytown communities of Callao, Peru, through integrated 
projects. The research was divided into two phases: 
1) Final follow-up, data collection, analysis, and write-up of: a case-control study defining the TB-
poverty association; an ecological study assessing poverty-related risk factors for TB infection and 
disease; and a cohort study identifying TB-related costs of TB-affected families and creating a 
clinically-relevant catastrophic costs threshold. 
2) Conception, design, implementation, data collection, analysis, and write-up of a household-
randomized controlled study of a socioeconomic intervention to improve TB cure and prevention. 
Results 
The first phase showed that TB remains a disease of people living in poverty, that “free” TB care was 
expensive for impoverished TB-affected families to afford, and that incurring catastrophic costs 
explained as many adverse outcomes as multi-drug resistant (MDR) TB. 
The second phase showed that, in households receiving the TB-specific socioeconomic intervention, 
TB-affected households were less likely to incur catastrophic costs, household contacts were more 
likely to start and adhere to TB preventive therapy, and TB patients were more likely to be cured.  
Conclusion 
In impoverished Peruvian shantytowns, poverty remains associated with TB and incurring 
catastrophic TB-related costs predicted adverse TB outcome. A novel TB-specific socioeconomic 
intervention reduced catastrophic costs and improved TB preventive therapy uptake and TB cure. 
The impact of the intervention on TB control will now be evaluated during the Community 
Randomized Evaluation of a Socioeconomic Intervention to Prevent TB (CRESIPT) study.   
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General Introduction 
 
150 years ago, Virchow recognised that TB was a social disease.1 Since then, Koch’s discovery of the 
bacillus and the discovery of streptomycin and other antimicrobials provided humankind with a 
means to both diagnose and treat TB disease. Yet TB rates in Europe were falling during the 
industrial revolution, prior to either the discovery of the TB bacillus or TB anti-microbial therapy. This 
decrease was predominantly mediated through social determinants with improvements in 
socioeconomic position leading to, among other factors, better living conditions2,3 and nutrition.4,5  
In the modern era, global rates of TB are declining slowly and remain unacceptably high: a third of 
the world’s population is estimated to be infected with TB and 1.5 million people died of TB in 2014, 
the majority of whom were impoverished people living in resource-constrained settings.6 However, 
the global TB control strategy and TB-related research continued to be disproportionately focused 
on a biomedical rather than socioeconomic response to the epidemic. It is clear that despite helping 
to cure millions of people of TB disease,7  the current global response to TB alone will not be enough 
to eradicate TB within this century.  
Thus, 150 years on from Virchow’s astute observation, TB remains a social disease inextricably linked 
in a vicious cycle with poverty. Specifically, being poor increases the risk of acquiring TB infection 
and disease;7–9 and having TB disease worsens poverty in TB-affected households.10–12 Therefore, a 
more holistic approach is required to eliminate TB globally, which addresses not only biomedical 
responses but also the broader socioeconomic determinants of this disease of poverty.11,13–16 
Addressing the social determinants of TB is not a new concept: almost 100 years ago the Papworth 
study (a socio-medical experiment performed at the Papworth Village Settlement in England) 
showed that stable employment and adequate housing and nutrition for households of parents with 
active TB disease decreased the incidence of TB infection and disease in their children.2 
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Nevertheless, since the advent of the antibiotic era, such social and economic support interventions 
received less attention and the response to TB became focused almost solely on the biomedical.  
In the post-2015 End TB Strategy, the World Health Organisation - for the first time in the modern 
era of TB control – cited mitigation of TB-related costs and provision of socioeconomic support to 
TB-affected households as key pillars in the global response to TB.16 However, rigorous evidence 
with which to guide TB civil society, policy-makers, and national TB programs on the implementation 
of costs mitigation and TB-specific socioeconomic interventions (e.g. focused only on TB-affected 
people) remains extremely limited.9,17,18 In addition, the intricacies of the social determinants 
mediating the causal pathway from poverty to TB disease continue to be poorly understood and 
require further evaluation if socioeconomic interventions are to provide a targeted response to TB 
with optimal impact on TB control.  
This thesis builds on a decade of research by the Innovation For Health and Development (IFHAD, 
www.ifhad.org) research group, including the Innovative Socioeconomic Interventions Against TB 
(ISIAT) project.15 Generally, this PhD research aimed to identify and address poverty-related risk 
factors for TB infection, disease and adverse TB treatment outcome. Specifically, this PhD research 
aimed to: assess the association of TB and poverty; measure catastrophic costs of TB care and their 
impact on treatment outcomes; and implement a TB-specific socioeconomic intervention to improve 
TB prevention and cure in TB-affected households of shantytown communities of Callao, Peru.  
In addition to the goals above, this research aimed to provide the candidate with comprehensive, 
structured, training in epidemiological field research principles and practices, in order that he could 
develop as an independent investigator. Therefore, the scope of the training was necessarily broad 
to enhance the depth of experience for the candidate. Over the three years of this PhD research, a 
planned, progressive series of six research projects was undertaken to address the existing 
knowledge gaps in global TB control strategy identified above. Each project is described in detail in 
its own chapter, and each chapter includes a specific, comprehensive literature review.  
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Chapter 1: This initial project trained the candidate in data analysis and assessed the association of 
TB and poverty in study site communities using data from a case-control study nested within a 
previous cohort study. The project also evaluated the application of a novel composite poverty score 
of stable variables of socioeconomic position, including household assets and education level.   
Chapter 2: Having established that poverty was more common in TB patients than controls, this 
second study went on to explore this relationship further by examining the social determinants 
mediating the causal pathway from poverty to TB in the study site. To do this, an ecological analysis 
of the relationship between proxy variables of poverty (including household crowding and vitamin D 
deficiency), TB infection, and incident TB disease was performed using data from a cohort study. 
Chapter 3: The projects detailed in Chapters 1 and 2 demonstrated the effect of poverty on 
developing TB disease. We then took this further by examining the effect of poverty on outcomes of 
TB treatment. To do this, final cohort follow-up was completed and - using the data collected to 
measure TB-related costs of TB-affected families - an innovative, clinically-relevant catastrophic 
costs threshold was created that has since been endorsed by WHO as part of global TB policy. 
Chapter 4: Having identified risk factors for incident TB disease and adverse TB treatment outcomes, 
the candidate worked with the multi-disciplinary IFHAD team in Peru to conceive, design, and 
subsequently lead the implementation of a household-randomized controlled evaluation of a 
socioeconomic intervention including conditional cash transfers to improve access to TB prevention 
and cure. This chapter describes: a systematic review of the existing evidence concerning 
socioeconomic and conditional cash transfers interventions to control TB; and - in order to inform 
policy makers, implementers, and national TB programs – provides a practical description of the 
design, implementation, and refinement of the novel socioeconomic intervention. 
Chapter 5: evaluated the extent to which TB-related and catastrophic costs were mitigated by the 
intervention. In addition to exploring the limitations of the intervention, this chapter also suggests 
refinements to the intervention, with which to improve its impact on TB control during the larger-
scale Community Randomized Evaluation of a Socioeconomic Intervention to Prevent TB (CRESIPT). 
Chapter 6: assessed the impact of the intervention on TB prevention and cure. The primary outcome 
was TB preventive therapy uptake by eligible household contacts of recruited TB patients. The 
secondary outcome was cure of TB patients confirmed by the Peruvian National TB Program. 
In summary, this PhD research: addressed knowledge gaps concerning the association between 
poverty and TB including TB-related costs of “free” TB treatment; and designed a TB-specific 
14 
 
socioeconomic intervention that improved access to TB preventive therapy and TB treatment, 
mitigated the catastrophic costs of TB, and thereby improved TB cure and prevention measures. 
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Chapter 1: Poverty and TB 
 
This chapter is adapted from a section of the peer-reviewed, published paper Wingfield et al 
“Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with 
multi-drug resistance: a prospective cohort study, Peru.” PLOS Medicine. 2014 Jul 
15;11(7):e1001675. doi: 10.1371/journal.pmed.1001675.19 The paper is bound in PDF format in 
Appendix 2 of this thesis. The candidate’s contribution to this study was final data collection, data 
management, data analysis and analysis strategy, study write-up and dissemination of findings. The 
candidate was not involved in study design nor initial data collection, which took place as part of a 
cohort study of TB-affected households in Ventanilla/Callao, Peru, that has been ongoing for the 
past 15 years. 
 
Introduction 
 
Tuberculosis (TB) disease kills 1.5 million per year and remains a major global health problem.6 Many 
low and middle income countries are unlikely to meet the Millennium Development Goals for 
reduction of TB disease prevalence and mortality.6 This is due in part to poorer people experiencing 
inequitable healthcare provision and access20 and suffering a disproportionate burden of morbidity 
and mortality from TB disease.9,21 Poverty increases TB risk22 and TB exacerbates poverty, affecting 
the most economically productive age group.23–25 We aimed to measure poverty in TB patients 
versus healthy controls. The study hypothesis was that TB patients would be poorer than healthy 
controls, thus confirming the recognised association of socioeconomic position and TB disease. 
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Methods 
 
Ethical approval 
The internationally accredited ethical committees of the Universidad Peruana Cayetano Heredia, 
Peru, and Imperial College London, UK, approved the project. All interviewed participants gave 
written informed consent.  
Study design and participants 
We conducted a case-control study comparing TB patients with healthy controls. From October 2002 
to November 2009, in collaboration with the Peruvian TB program, all consecutive patients with 
laboratory-proven pulmonary TB were invited to participate in the study. This included those 
patients starting TB treatment by the Peruvian TB Program without confirmed culture or with 
confirmed smear positivity or culture; patients who were diagnosed and treated in military or non-
governmental facilities in the study site were not invited to participate as outcome data was not 
available for such patients. All interactions between the research team and the participants occurred 
during household visits. From December 2006 to December 2007, healthy control households were 
also recruited. This was achieved using an up to date satellite map which identified 
houses/residences in the study site which were all numbered sequentially by a research nurse. 
Buildings known to be commercial enterprises, hospitals, offices, or government buildings were not 
numbered. All identified houses were then numbered sequentially across each district map, selected 
using random number tables, and a household visit made in order to invite the household members 
to participate in the study as a healthy control household. If all control participants were unavailable 
or declined then the nearest neighbouring household was instead invited to participate. Inclusion 
criteria in both cases and healthy controls included age more than 15 years. Exclusion criteria 
included declining or being unable to give informed written consent. The sample size was 
opportunistic and consequently no power calculations were performed.  
17 
 
Study setting 
The study was conducted in Ventanilla, 16-periurban contiguous shantytowns in northern 
Lima/Callao, Peru, with an estimated population of 277,895 people, and frequent poverty (32% of 
inhabitants live on ≤1 US dollar per day). During the study period, the annual TB notification rate in 
Ventanilla was 162 new cases per 100,000 people, higher than the rest of the country which was 
estimated to be 106 per 100,000 people annually.26 
Data source and measurement 
A questionnaire was developed locally, piloted, refined, and then used to interview patients and 
collect socio-demographic data concerning household income and expenses throughout TB illness. 
Interviews were conducted with both TB patients and healthy controls. Questions characterized 
earnings, income, expenses, employment (paid or unpaid), days unable to work due to illness, 
additional household food expenditure due to TB illness, and crowding. For all participants, height and 
weight were measured and body mass index (BMI) was calculated. Poverty was measured using a 
composite household poverty index in arbitrary units derived by principal component analysis from 
13 variables, as described in our research group’s previous work.15  
Data analysis 
Means were compared with the Student’s t-test. Categorical data were summarised as proportions 
with 95% CI and were compared with the z-test of proportions. Univariable regression analyses 
examining differences between patients with MDR and non-MDR TB and controls were adjusted for 
sex because of under-recruitment of male healthy controls due to their availability.  
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Results 
 
Participants 
During the study period, the Peruvian TB program within the study site of Ventanilla registered 1,014 
patients. We located 99% of these registered TB patients of whom 95% (n=966) met inclusion 
criteria. Of these eligible patients, 1% (n=10) declined, 8% (n=80) were excluded because they 
completed fewer than half of our planned research interviews. Data are presented for the remaining 
91% (n=876) participants. 11% (n=93) of patients recruited had MDR TB. 487 healthy controls were 
also recruited and had only a baseline interview. The characteristics of the study population are 
summarized in Table 1 (Page 20). 
Descriptive data 
TB patients were more likely than healthy controls to be younger (31 versus 34 years old, 3 years 
difference [95% CI 2-4], p=0.001), to be male (59% versus 37% male, 22% difference [95% CI 21-23], 
p<0.001), to have a lower body mass index (21 versus 26 units of individuals, 5 units difference [95% 
CI 4-6], p<0.001), to have lower earnings (510 versus 651 Peruvian soles, 141 Peruvian soles 
difference [95% CI 114- 168], p<0.001), to not be in paid work at recruitment (81% versus 63%, 18% 
difference [95% CI 15-23], p<0.001), and to have had a previous TB episode (18% versus 5.4% of 
individuals, 13% difference [95% CI 12-13], p<0.001). Patients with MDR TB were more likely than 
patients with non-MDR TB to have had a previous TB episode (40% versus 15% of individuals, 25% 
difference [95% CI 17-32], p<0.001), to have longer pre-treatment symptom duration (83 versus 52 
days, 31 days difference [95% CI 0-73], p<0.001), to not be in paid work (90% versus 80% of 
individuals, 10% difference [95% CI 7-13], p<0.03), and to have had more days not working pre-
treatment due to TB-related illness (29 versus 18 days, 11 days difference [95% CI 0-34], p=0.004).  
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Discussion 
 
Social determinants are important in the causal pathway of TB disease.27 Indeed, reduction of 
poverty, advocating improved equity of access and universal health care, and eliminating 
catastrophic costs in TB-affected households are key components of the World Health Organisation’s 
post-2015 Global TB strategy.14,28–30 Our results demonstrate that TB predominantly affects poorer 
people.8,9,21,31 In this study we did not find any strong evidence that non-MDR and MDR TB differed 
in their association with poverty. Our poverty score used time-stable variables such as household 
assets, education level, and housing;32 thus poverty can be assumed to have preceded TB disease.  
The study was limited by the healthy control selection process. Using satellite maps and identifying 
households to randomly select to participate may have meant that there was selection bias against 
the poorest members of the communities, who may: have established residences after the satellite 
map images were taken (i.e. the maps are out of date as soon as they are published with the ever-
expanding population of the Callao shantytowns); be living in buildings not identified as 
residences/houses (e.g. in a room at the back of a commercial enterprise); or live in smaller, 
peripheral accommodation not identified by the satellite map. In addition, the extent and effect of 
poverty may be underestimated in our study given that geographical and socioeconomic barriers 
and stigma may particularly preclude the poorest people from seeking healthcare.33 
 
Conclusions 
 
In impoverished shantytowns of Callao, Peru, having TB disease was associated with being poor. This 
research confirms that TB remains a social disease. Thus, in order to control TB, the global response 
may benefit from socioeconomic as well as biomedical approaches.
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Table 1: Study population baseline data. Note ‘CI’ indicates confidence intervals, ‘SD’ is standard 
deviation, and IQR is interquartile range. All data are at individual level and pre-treatment except where indicated. ‘NA’ 
indicates not applicable. The column “Controls” refers to “Healthy Controls”. 
 Controls   TB patients  P value* 
 
Non-MDR 
TB 
 MDR TB   P value* 
Participants 487  876  .  783  93  . 
Demographics            
Age; mean years 34  31  0.001  31  31  0.8 
[SD] [20 - 48]  [18 - 44]    [30 - 32]  [17 - 45]   
Sex; % males 37  59  <0.001  59  59  0.9 
[95% CI] [33 - 41]  [55 - 62]    [55 - 62]  [49 - 69]   
Health and finances            
Secondary complete;% 46  44  0.3  45  36  0.1 
[95% CI] [41 - 50]  [41 - 47]    [42 - 49]  [26 - 46]   
Household crowding            
   Above mean; %  66  57  0.07  57  61  0.5 
   [95% CI] [59 - 72]  [54 - 61]    [53 - 60]  [51 - 71]   
   People per house 5.1  4.9  0.8  4.9  4.9  0.9 
   [IQR] [4.6 - 5.6]  [4.8 - 5.0]    [4.7 - 5.0]  [4.5 - 5.4]   
Body mass index; 
(kg/m2)  
26  21  <0.001 
 
21  21  0.3 
[95% CI] [25 - 26]  [21 - 22]    [21 - 22]  [20 - 21]   
Previous TB; % 5.4  18  <0.001  15  40  <0.001 
[95% CI] [3.3 - 7.4]  [15 - 20]    [13 - 18]  [30 - 50]   
Monthly earnings**            
   Pre-treatment  651 (1.40)  510 (1.09)  <0.001  511 (1.09)  497 (1.07)  0.8 
   [95% CI] [595 - 707]  [481 - 539]    [482-540]  [381-613]   
   During treatment .  434 (0.93)  .  436 (0.94)  418 (0.90)  0.6 
   [95% CI] .  [415 - 453]    [416-456]  [341-495]   
   Intensive phase  .  379 (0.81)  .  379 (0.81)  376 (0.81)  0.9 
   [95% CI] .  [358 - 400]    [357-401]  [295-457]   
   Continuation phase .  454 (0.97)  .  457 (0.98)  424 (0.91)  0.4 
   [95% CI] .  [431 - 477]    [434-480]  [339-509]   
Debt*** 812 (1.7)  383 (0.82)  0.004  377 (0.81)  435 (0.93)  0.7 
[95% CI] [507 - 1117]  [292 – 474]    [283 – 471]  [87 – 872]   
Not in paid work; % 63  81  <0.001  80  90  <0.03 
[95% CI] [56 - 69]  [79 - 84]    [77 - 83]  [84 - 96]   
Poverty score            
Above control 
mean;%  
51  58  <0.02 
 
58  60  0.8 
 [95% CI] [47 - 56]  [55 - 61]    [54 - 61]  [50 - 70]   
Current tuberculosis            
Symptom duration             
  Mean days .  55  .  52  83  <0.001 
  [SD]   [0 - 127]    [0 - 118]  [0 - 192]   
Too unwell to work            
  Mean days .  19  .  18  29  0.004 
  [SD]   [0 - 51]    [0 - 47]  [0 - 81]   
Time to health centre            
  Mean minutes .  13  .  13  13  0.9 
  [SD]   [0 - 30]    [0 - 30]  [0 - 33]   
MDR tuberculosis; %  .  11  .  .  .  . 
[95% CI]   [9 - 13]    .  .   
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*univariable regression adjusted for sex. The central p value corresponds to comparison of controls (n=487) with all TB 
patients regardless of MDR status (n=876). The right-hand column p value corresponds to comparison of non-MDR TB 
patients (n=783) with MDR TB patients (n=93).  
**Household earnings per month during different treatment stages represented as mean Peruvian Soles and, in 
parenthesis, as a proportion of TB patients’ mean monthly household earnings throughout entire illness. Confidence 
intervals are those of mean monthly earnings in Peruvian Soles.  
***Debt at recruitment represented as mean Peruvian Soles and, in parenthesis, as a proportion of TB patients’ mean 
monthly household earnings. Debt at recruitment was used in the final multivariable regression model rather than total 
debt (sum of debt at recruitment plus debt at 24 weeks of treatment) as only 461 patients had 24-week debt data available   
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Chapter 2: Examining poverty-related TB risk factors: The seasonality 
of tuberculosis, sunlight, vitamin D, and household crowding 
 
This chapter is adapted from the peer-reviewed, published paper Wingfield et al  
“The seasonality of tuberculosis, sunlight, vitamin D, and household crowding.” J Infect Dis. 2014 Sep 
1;210(5):774-83. doi: 10.1093/infdis/jiu121. Epub 2014 Mar 4.5 The paper is bound in PDF format in 
Appendix 3 of this thesis. The candidate’s contribution to this study was design of the ecological 
study analysis, data collection concerning hours of sunlight, final follow-up and data collection, data 
management, data analysis and analysis strategy, study write-up and dissemination of findings. Apart 
from the data concerning hours of sunlight, which were gathered by the candidate, all other data 
used for this analysis was collated from a randomized placebo-controlled trial examining the effect of 
micronutrient supplementation (vitamins A, D, and zinc) on the incidence of secondary TB disease. 
The candidate was not involved in the conception, design, or data collection of this micronutrient 
supplementation trial, which was nested in the ongoing cohort study mentioned in Chapter 1.   
Following evaluation of the association between TB and poverty, this PhD research next aimed to 
assess specific poverty-related risk factors for TB infection and disease through an ecological study 
examining seasonality.  
 
Introduction 
Although the incidence of certain infectious diseases is seasonal,34 the seasonality of tuberculosis 
(TB) is incompletely understood. TB infects approximately a third of the world’s population, causing 
symptomatic disease in 8.7 million people annually.6 Prior to antibiotics, spring peaks were noted in 
TB illness.35 Later studies in the antibiotic era from Cameroon,36 India,37 Britain,38 Kuwait,39 Spain,40 
America,41 Japan,42 and South Africa43,44 also revealed TB seasonality. contrary to recognized patterns 
of acute respiratory illnesses,45 most studies report a nadir of new TB cases during winter and a peak 
in spring and summer. This seasonal variation is presumed to relate more to recent transmission than 
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TB reactivation.44,46 However, interpretation of seasonality studies is complicated by heterogeneity in 
definition of season and seasonal variables studied (i.e. temperature, rainfall).36,39,43 
Vitamin D is an important determinant of adaptive and innate immunity. The principal active 
metabolite of vitamin D, 25-hydroxy-vitamin D (hereafter referred to as “vitamin D”), has 
immunosuppressive effects on T-helper and dendritic cells but, conversely, an immuno-stimulatory 
effect on monocytes and macrophages.47,48 Low vitamin D concentrations contribute to an increased 
risk of TB contacts’ tuberculin skin test (TST) converting to positive49 and a higher likelihood of active 
TB disease in people with specific vitamin D receptor polymorphisms.50 Apart from diet, humans 
derive a proportion of their vitamin D through synthesis from 7-dehydrocholesterol on exposure of 
skin to sunlight.51 Historically, both ultraviolet light and vitamin D supplementation were used in the 
treatment of pulmonary and cutaneous TB.52 More recently vitamin D supplementation during TB 
treatment was investigated but did not improve treatment outcomes.53,54 This TB and vitamin D 
interaction has stimulated interest in seasonal variation in vitamin D concentrations as a potential 
risk factor for TB susceptibility.43,46,53–56 
Poverty and social determinants are associated with TB infection and disease.9,15,57 In diverse 
settings, household crowding (hereafter referred to as “crowding”) is associated with poverty, TB 
infection, and TB disease in household contacts.58–61 
Understanding TB seasonality and its potential associations with both endogenous and exogenous 
factors, including vitamin D and crowding, may inform the health effects of climate change and 
influence TB prevention through interventions to reduce crowding and vitamin D deficiency. We 
therefore studied the seasonal relationship between putative TB risk factors (crowding, hours 
without sunlight, and vitamin D concentrations), TB infection (measured by TST and interferon-
gamma release assays, “IGRA”), and subsequent TB illness (symptom onset and disease) within 
impoverished communities of Callao, Peru.  
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Methods 
 
Design overview 
This was an ecological analysis of seasonality conducted during a cohort study investigating risk 
factors for incident TB amongst household contacts of TB patients.15  
For the current research, the TB patients had their date of symptom onset and diagnosis recorded 
and their TB-exposed cohabitants were tested for TB infection and vitamin D deficiency whilst 
sunlight levels were recorded. An ongoing nested trial of micronutrient supplementation also 
assessed whether micronutrient supplementation prevents TB but all data reported here involved 
participants who declared they had not taken micronutrient supplements. 
 
Setting and climate data 
The study took place over four years from 1st January 2003 until December 31st 2006 in Ventanilla, a 
periurban shantytown with high rates of poverty and TB disease (162/100,000/year) but low rates of 
HIV-TB co-infection (<2%). The study time period was chosen because it was the same as the time 
period over which the nested micronutrient supplementation trial and follow-up took place. 
Hours without direct sunlight were studied because we hypothesised that these would be associated 
with vitamin D deficiency. The Peruvian Ministry for Environment provided data defining the 
presence or absence of direct sunlight in the area over the 32,640 consecutive hours of the study 
period. Direct sunlight was present during daylight hours when cloud cover was minimal or absent. 
Conversely, direct sunlight was absent during hours of darkness or when cloud cover prevented the 
measuring apparatus from directly receiving sunlight. Northern Lima/Callao has two main seasons: 
we defined winter as the six consecutive months with fewest hours of direct sunlight. Summer was 
defined as the rest of the year.  
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Participants 
Inclusion criteria were adult TB patients with laboratory-proven (sputum smear or culture positive) 
pulmonary TB and, with respect to latent TB infection and vitamin D levels, their adult TB-exposed 
household cohabitants. Adults in this setting were defined as aged 16 years or older. TB-exposed 
cohabitants were individuals who reported being in the same house as these TB patients for over two 
hours per day at least three times per week. Exclusion criteria were declining or inability to give 
informed written consent (Figure 1, Page 38). 
The national TB program registered 1,058 patients with pulmonary TB during the study period. We 
located 99%, and 93% (n=852) of those who met our inclusion criteria (n=912) consented to 
participate. We concurrently aimed to recruit all TB-exposed cohabitants of these patients and 73% 
(n=2,004) of those who met our inclusion criteria (n=2737) consented to participate. Thus 3,589 
members of TB-affected households were recruited. The internationally accredited ethics 
committees of the Universidad Peruana Cayetano Heredia, Peru, and Imperial College London, UK, 
approved the project. 
 
Procedures 
At enrolment, a questionnaire was completed with all participants to record baseline data. For TB 
patients this questionnaire included information defining the date of symptom onset (see Table 2, 
Page 35) and the date of diagnosis. 
For all participants, height and weight were measured and body mass index (BMI) was calculated. 
Socioeconomic position was measured using a composite household poverty index incorporating 13 
variables including education, housing, services and assets.15 A household unit was defined as a 
house (a building or connected buildings of the same property with walls and a roof, constructed 
purposefully to accommodate people) and its occupants or members (the people who sleep at the 
house for the majority of nights of the week). 
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Crowding was measured by number of people per room at the initial visit within two weeks of the 
patient of the household initiating treatment. This was calculated as the number of people sleeping 
in the house (including household members of any age) divided by the total number of rooms in the 
house. This method was felt to be appropriate as it followed existing World Health Organisation 
guidance and, following research team focus groups, was felt to be the most locally-appropriate and 
accurate reflection of the number of people in the household, as opposed to number of people 
eating which can vary widely in the study setting. 
At enrolment, all TB-exposed cohabitants were asked to undergo testing for latent tuberculosis with 
TST as described.62 From 7th March 2005 to 9th November 2006, additional resources became 
available that allowed all consecutive recruited TB-exposed cohabitants who agreed to provide a 
blood sample to also undergo IGRA using the QuantiFERON TB-Gold® assay (Cellestis). From this 
date, 68% (n=576) of cohabitants agreed to provide a blood sample and had interpretable IGRA 
results. As recommended by the manufacturer, IGRA results were reported qualitatively as positive, 
negative or indeterminate, not quantitatively.  
 
Vitamin D concentrations 
Of the TB-exposed cohabitants enrolled in the micronutrient supplementation trial who had TST and 
IGRA results, a subset (n=102) selected using random-number tables provided blood samples at 
recruitment. These TB-exposed cohabitants stated that they were not taking micronutrient 
supplements. Those TB-exposed cohabitants who did not receive micronutrient supplements also 
provided blood samples one (n=48) and six months (n=45) post-recruitment. Therefore, a total of 195 
(102 + 48 + 45) blood samples were taken. Vitamin D concentrations were measured by radio-
immunoassay using inductively-coupled mass spectrometry. Plasma concentrations of <50 nmol/L 
vitamin D were considered to be deficient and ≥50 nmol/L replete.53 
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Statistical analysis 
Raw data and 6-month moving averages (a series of averages of time-series data subsets used to 
highlight longer-term trends/cycles) were analysed to examine seasonal variation and divided into 
“peak” season (3-months prior to and after the peak value for that variable) and “the rest of the 
year” (the remaining 6-months). Power calculations for sample size were not performed. Continuous 
data with a Gaussian distribution were summarised as means with their 95% confidence intervals (CI) 
and compared by Student’s t-test. Continuous data with a non-Gaussian distribution were converted 
to categorical data above or below the median value (for crowding 2 people/room and for poverty 
arbitrary units were used), summarised as proportions with their 95% CI and compared with the z-
test of proportions. For multiple regression analyses, non-contributory variables were removed in a 
backwards-stepwise manner according to the likelihood-ratio test. Relative risks (RR) were calculated 
using generalized linear model and binomial analysis. The regression model was repeated using 
season as both a categorical variable (summer versus winter) and as a continuous variable (days from 
lowest “trough” number of hours of direct sunlight). TB incidence was calculated using the 
population of Ventanilla of 307,623 people estimated by national census during the study period. All 
p-values were two-sided and analyses, including calculation of population attributable fractions 
(PAF), used the Stata program (version 12). 
 
Results 
 
Study population 
The study population is summarised in Table 2 (Page 35). Amongst participants, TB-exposed 
cohabitants were older, had lower education level, were more often female and were more likely to 
be overweight than TB patients (all p<0.05). There was a median household average of 2.0 (IQR 1.5-
3.0) people per room.  
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Vitamin D 
Figure 2 (Page 39) shows the average vitamin D concentrations and figure 3 (Page 40) the proportion 
of vitamin D replete samples, both analysed by season and sex. The mean vitamin D concentration 
was 48.6 nmol/L [95% CI 46.9–50.3]. 
The proportion of samples that were vitamin D replete (≥50 nmol/L) was 43.1% [95% CI 36.1–50.1]. 
During summer the average vitamin D concentration was 51.0 nmol/L and significantly higher than 
during the winter (45.8 nmol/L, p<0.003, Figure 2, Page 39). Male sex and summer were significantly 
associated with greater likelihood of being vitamin D replete (Figure 3, Page 40).  
The randomly-selected subgroup of TB-exposed cohabitants who had vitamin D assays were more 
likely to be poor (p=0.0006) and have more crowding (p<0.003) than the entire cohort of TB-exposed 
cohabitants. However, neither poverty nor crowding were associated with vitamin D concentrations 
or being vitamin D replete (all p>0.1, Table 3, Page 36). There were no other differences between this 
subgroup and the other TB-exposed cohabitants.  
  
Seasonal association of crowding, sunlight, vitamin D deficiency, and TB 
Figure 4 (Page 41) demonstrates the seasonality of TB risk factors, infection and illness: the mid-
winter peak in putative TB risk factors (crowding, hours without direct sunlight, and vitamin D 
deficiency), the sequential late-winter (TST) and early-spring (IGRA) peak in TB infection and finally 
the mid-summer peak in TB symptom onset followed after three weeks by subsequent TB diagnosis. 
Table 4 (Page 37) shows the analysis by season of crowding, hours without direct sunlight, vitamin D 
deficiency, TB infection and illness.  
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TB risk factors 
Crowding: The peak in proportion of households with crowding occurred in mid-winter in July prior 
to both the peak in hours without direct sunlight and vitamin D deficiency (Figure 4, Page 41). During 
the six months with most crowding, the proportion of crowded households was 13% points higher 
than the rest of the year (p<0.001, Table 4, Page 37). 
Hours without direct sunlight: The peak in proportion of hours without direct sunlight occurred in 
August, mid-winter, as can be seen in Figure 4 (Page 41). The proportion of hours without direct 
sunlight was 19% points higher in winter than summer (p<0.0001, Table 4, Page 37).   
Vitamin D deficiency: Vitamin D deficiency was detected in 56.9% (111/195) of samples (Table 4, 
Page 37). Figure 4 (Page 41) demonstrates that the peak proportion of samples with vitamin D 
deficiency occurred in midwinter in the week following the peak in hours without direct sunlight. 
During the six months around this peak the proportion of samples that were vitamin D deficient was 
17% points higher than the rest of the year (p=0.01, Table 4, Page 37).  
 
TB infection in TB-exposed cohabitants  
TST: Six weeks following the peak in vitamin D deficiency, the peak in the proportion of positive TST 
results occurred in late winter (Figure 4, Page 41). During the six months around this peak the 
proportion of positive TST results was 8% points higher than the rest of the year (p=0.003, Table 4, 
Page 37).  
IGRA: The peak in the proportion of positive IGRA tests occurred in early summer, 12 weeks following 
the peak in proportion of positive TST results. During the six months around the IGRA peak the 
proportion of positive IGRA tests was 9% points higher than the rest of the year (p<0.04, Table 4, 
Page 37). 
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TB disease in laboratory-proven TB patients 
TB symptom onset: Five months after the peak in TB infections as indicated by TST, the peak in TB 
symptom onset occurred in midsummer (Figure 4, Page 41). During the six months around this date 
14% more patients had TB symptom onset than the rest of the year (p<0.05, Table 4, Page 37).   
TB diagnosis: The peak in TB diagnosis occurred in late summer, three weeks following the peak in TB 
symptom onset (Figure 4, Page 41). During the six months around this date 13% more patients were 
diagnosed with TB than the rest of the year (p<0.01, Table 4, Page 37).  
 
Regression analyses 
Table 2 (Page 35) shows the multiple regression analysis of the association between vitamin D 
concentrations (and the likelihood of being vitamin D replete) and the characteristics of the study 
population. Male sex (RR 2.0, PAF 24%, p<0.001) and summer (RR 1.4, PAF 19%, p<0.05) were 
associated with greater likelihood of being vitamin D replete (i.e. lower likelihood of deficiency). To 
assess the robustness of these findings, additional analyses of vitamin D concentrations (instead of 
being vitamin D replete) were performed and showed the same pattern of significance (Table 3, Page 
36; Figure 2, Page 39 and Figure 3, Page 40).  
 
Discussion 
 
Vitamin D deficiency was common in this high-risk group of TB-exposed people, more common in 
females, and peaked in midwinter, shortly after peak crowding and hours without direct sunlight.  
This was followed by a peak in TB infections in late winter and, after the known 5-month median TB 
incubation period,63 by a peak in TB symptoms in midsummer. Finally, after the three week interval 
required for TB case finding in this setting,64 TB diagnoses subsequently peaked in late summer. 
These findings suggest that seasonal vitamin D deficiency and crowding may explain the previously 
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enigmatic interval from the mid-winter peak in TB risk factors until the late-summer peak in TB 
diagnoses.  
Vitamin D deficiency was found in over half of this Peruvian cohort of TB-exposed cohabitants. 
Deficiency associated closely with hours without direct sunlight as reported in temperate climates in 
Europe65 and North America.66 Defining vitamin D deficiency is controversial.51 We selected the 
threshold of vitamin D concentrations <50 nmol/L as recently suggested in international guidance 
and relevant studies.53,67 While such a threshold may be suitable at a population level to predict 
diseases like osteomalacia, it may fail to detect significant linear associations between vitamin D 
concentrations and non-skeletal disease risk (such as type-2 diabetes, ischaemic heart disease or 
cancer).68 Therefore, we examined vitamin D as both a categorical and linear dependent variable and 
found the results to be concordant. 
Female sex was associated with greater likelihood of vitamin D deficiency, independent of season. 
This is important because international vitamin D supplementation guidelines do not generally 
differentiate between gender, apart from pregnancy or lactation. The predominance of vitamin D 
deficiency in females in our study may relate to genetic predisposition or diet. However, the most 
likely explanation may be difference in behaviour because in this setting men spend more time 
outside working.69  
Vitamin D deficiency is a biologically plausible risk factor for TB infection and disease because it 
suppresses immune responses specific to TB infection.48 and has been epidemiologically associated 
with TB disease.43,55 The active metabolite of vitamin D (1,25-dihydroxyvitamin D) up-regulates the 
cellular vitamin D receptor to inhibit mycobacterial growth70 and increases cathelicidin expression by 
macrophages which promotes mycobacterial cell death.47,48 Therefore, increasing vitamin D 
concentrations in spring may potentially lead to a “seasonal immune reconstitution” with increased 
granuloma formation, tissue inflammation and corresponding symptoms in people subsequently 
diagnosed with TB in summer. Moreover, although current in-vivo evidence suggests no effect,53,54 
there is some in-vitro evidence that vitamin D supplements could theoretically improve the 
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treatment response of patients with TB disease through immunostimulatory responses including 
increased cathelicidin production.55 Work in a similar Peruvian population has demonstrated that 
vitamin D receptor polymorphisms were associated with TB patients’ time to sputum culture 
conversion.71 Thus, vitamin D deficiency, immunology and genetic factors imply a role in TB 
susceptibility. 
The temporal association we observed between peak crowding and vitamin D deficiency followed by 
TB infection as indicated by the peak in TST positivity extends previous TST conversion findings in TB-
exposed cohabitants in Spain.49 The 12-week interval we observed from peak TST positivity until the 
peak IGRA positivity may be explained by differences in time to conversion between these tests: the 
optimum timing of IGRA testing remains to be defined72 and in TB outbreaks IGRA conversion 
occurred three73 to six months74 after exposure, often later than TST conversion.75 Moreover, serial 
IGRA analysis has shown high rates of both initial conversion and subsequent reversion in healthcare 
workers without known TB exposure, complicating interpretation.76 However, our study did not 
measure TST or IGRA conversion but the proportion of positive tests at different cross-sectional time-
points. A final possible explanation for the difference between IGRA and TST is that their accuracy for 
TB infection may be influenced by vitamin D concentrations: work in the study setting has shown that 
other micronutrients affect TST sensitivity.4 Thus, the temporal discrepancy we found between 
seasonal proportion of positive IGRA and TST tests is novel and the mechanisms behind such a 
discrepancy require further exploratory research. 
The seasonality of winter vitamin D deficiency and summer TB diagnoses that we characterised in TB-
exposed cohabitants extends findings in TB patients in Europe50 and South Africa.43 Low vitamin D 
concentrations and more vitamin D deficiency in midwinter may have led to increased host-
susceptibility to TB infection seen in late winter and to the subsequent progression to TB disease, 
after a five-month incubation period. This five-month incubation period is the same as that found in 
a study that used DNA fingerprinting to accurately identify progression from household TB exposure 
to TB infection and disease.63 Although our findings are relevant to both, we were unable to 
determine which episodes of TB disease were a result of recent TB infection versus reactivation of 
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latent TB. However, other recent studies showed that TB seasonal variation was more pronounced in 
children and clustered cases suggesting recent infection as the more likely explanation.46 
The interaction of social determinants along the causal pathway from TB exposure to infection and 
disease is complex and likely relates to increased transmission (greater exposure through crowding, 
increased time spent indoors and poorer ventilation58), susceptibility (poorer nutrition, lower 
immunity) and marginalisation (health-seeking behaviour, education). Our study measured crowding 
- potential TB exposure that in winter may contribute to the seasonality we observed. Crowding is a 
known marker of poverty and both crowding and poverty are independently associated with TB.58,59 
However, crowding is complex, poorly defined and specific to geographical settings.60 Research in 
high-resource countries has defined crowding as >1 person/room and severe crowding as >1.5 
people/room,61 which would have classified virtually all of our households as crowded, preventing 
meaningful analysis. The World Health Organisation suggests that measuring floor space60 can be 
problematic and that it may be more appropriate to consider crowding as above the mid-point 
number of persons/room. We used this a priori definition as a locally-appropriate crowding definition 
in this current research and also in ventilation research that is being published separately. Our 
finding of more crowding in winter than summer is novel. The reasons behind this crowding 
seasonality require further investigation and may include economic migration (seasonal 
employment), schooling, public holidays, and selling food produce after harvests. As noted in another 
recent study,77 it is unlikely that crowding and increased transmission in winter alone is the factor 
responsible for TB seasonality. Our findings suggest that both crowding and vitamin D deficiency are 
independently associated with TB seasonality. 
Temporal associations cannot prove causation and other confounding factors may have contributed 
to TB seasonality. For example, diet was not examined in our study. However, there is little variation 
in foodstuff availability and consumption in Ventanilla and BMI was used as a proxy nutrition 
indicator. Climate-related confounding factors could include temperature,45 humidity, rain, and 
climate change. Despite high humidity all-year round, annual rainfall in northern Lima/Callao is very 
low (10-30mm) and there is minimal variation in temperature (average 14oC in winter and 20oC in 
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summer). An important confounder not measured in the present study was seasonal variation in 
healthcare seeking and access. Healthcare-seeking behaviour may vary with work-market, harvest or 
school season as may provision of medical care at health posts and hospitals. Such variations may 
extend to the number of people tested for TB. Other confounding factors include: concomitant 
respiratory tract infections, smoke inhalation, and air quality. With regards to vitamin D 
concentrations, the inductively coupled mass spectrometry assay we used is now recognised to be 
prone to inter-laboratory variations and isotope-dilution liquid chromatography tandem mass 
spectrometry may be preferable78 but was not widely available during our study. In addition to this 
ecological analysis, it would be valuable to perform larger future studies to test for associations 
between baseline vitamin D concentrations in TB-exposed household contacts and subsequent 
progression to TB disease although such a study would be confounded by the seasonality of vitamin 
D concentrations that we report here. Vitamin D concentrations were measured in a random subset 
of TB-exposed cohabitants who happened to be poorer and live in more crowded households than all 
TB-exposed cohabitants. This chance occurrence does not appear to have been important because 
multiple regression demonstrated that neither crowding nor poverty were independently associated 
with vitamin D concentrations or being vitamin D replete.  
 
Conclusions 
 
The sequential peaks in midwinter crowding, vitamin D deficiency, TB infection, TB symptom onset 
and finally late summer TB diagnoses potentially explain the previously enigmatic seasonality of TB. 
These findings suggest that climate change and recommendations to reduce the risk of skin cancer by 
avoiding sun exposure may influence TB susceptibility. The associations that we have identified 
between season, crowding, vitamin D and TB emphasise the potential for correcting vitamin D 
deficiency and mitigating poverty to contribute to TB prevention. 
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Table 2: Study population baseline data.  
 
  TB-exposed cohabitants  TB patients 
 
All  
Randomly selected 
individuals 
for plasma vitamin D 
measurement 
 All 
      
Number of participants     1389  102  852 
Number of blood vitamin D 
analyses 
N/A  195  N/A 
      
Demographics      
Sex; % males [95% CI] 37  31  60 
[34 - 39]  [25 - 38] [56 - 63] 
Age; mean years [95% CI] 34  34  31 
[33 - 34]  [32 - 36] [30 - 32] 
      
Socioeconomic factors      
Any post-primary education; % 
[95% CI] 
75  72  81 
[73 - 78]  [65 - 78] [78 - 84] 
Household crowding; % [95% 
CI] above median people (>2) 
per rooma  
57  69  NA 
[55 - 60]  [64 - 74]  NA 
 
Household poverty score; % 
[95% CI] above median scoreb 
 
50 
  
63 
  
NA 
[47 – 53]  [57 – 68]  NA 
 
Anthropometry 
     
Overweight; % [95% CI] above 
median body mass index (>25 
kg/m2)c 
48  46  12 
[45 - 50]  [40 - 52] [10 - 14] 
      
 
Note ‘CI’ indicates confidence intervals; ‘NA’ indicates not applicable, because these variables were 
assessed at the household rather than individual level.  
aA continuous measure of crowding was calculated by people sleeping in the house divided by 
number of rooms in the house. The median of this continuous crowding variable was exactly 2 
people per room. The variable ‘household crowding’ shown below refers to the percentage of 
household’s containing more people per room than the cohort median (2). When splitting into above 
and below this median, “2” cannot be split and therefore those houses with exactly 2 people per 
room were apportioned to the “crowded” (i.e. above the median) households. This results in 57% of 
cohort households being above the cohort median people per room and thus crowded.  
 
bThe variable household poverty score refers to the percentage of households with a poverty score 
above the household median.  
 
cThe variable ‘overweight’ refers to the percentage of individuals whose body mass index was above  
the median body mass index of the entire cohort of TB-exposed cohabitants and patients and is the 
same as that defined by the World Health Organisation (>25kg/m2). 
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Table 3: Regression analysis of associations with vitamin D levels. This table shows the results of linear regression of vitamin D plasma concentrations in nmol/L as the 
outcome variable and binomial regression with odds of being vitamin D replete (≥50 nmol/L) as the outcome variable.  
 
  
Vitamin D 25OHD plasma concentrations (nmol/L), linear regression 
 
Vitamin D replete (≥50 nmol/L), binomial regression 
 Univariate regression  Multiple regression  Univariate regression   Multiple regression 
 Coefficient  
(95% CI)  
P value  Coefficient  
(95% CI) 
P value  Relative risk 
(95% CI) 
P value   Adjusted PAF Relative risk   
(95% CI) 
P value 
             
Sex (male) 9.3 <0.001  9.3 <0.001  2.00 <0.001  24 2.0 <0.001 
(4.4 - 14) (5.8 - 13)  (1.4 - 2.9)   (9 - 36) (1.4 - 2.8) 
Season (summer) a 5.2 0.001  5.3 <0.001  1.4 0.03  19 1.4 <0.05 
(2.2 – 8.3) (2.0 - 8.5)  (1.0 - 2.0)  (1 - 33) (1.0 – 1.9) 
Age; years 0.11 0.2     1.0 0.3     
(-0.088 - 0.30)    (0.99 - 1.0)      
Any post-primary 
education 
2.0 0.4     1.3 0.2     
(-2.8 - 6.8)     (0.83 – 2.2)      
Household crowding; 
above median people 
per room 
 
-1.2 0.6     1.0 0.9     
(-6.2 - 3.9)     (0.68 - 1.6)      
Household poverty 
score; above median 
score  
 
-1.006 0.6     0.78 0.2     
(-5.7 - 3.7)     (0.53 - 1.2)      
Overweight; above 
median BMI (>25 
kg/m2) b 
 
3.1 0.2     1.1 0.7     
(-1.9 – 8.1)     (0.73 – 1.6)      
Note ‘Adjusted PAF’ indicates population attributable fraction derived from multiple logistic regression using the “aflogit” function of STATA. All analyses presented above were clustered by individual 
because some individuals had more than one blood sample taken. Specifically, 102 TB exposed cohabitants provided blood samples at recruitment, and 48 and 45 of these individuals provided blood 
samples again at 1 and 6 months following recruitment, respectively. Therefore, a total of 195 blood samples were taken. Blank cells indicate variables that did not meet the criteria for inclusion in 
the multiple regression analysis. 
aIn addition to the analysis of season shown, when univariate and multiple linear regression analyses were repeated using “days from trough in hours of direct sunlight” as a continuous variable in 
place of “season”, male sex and days from trough in hours of direct sunlight remained associated with greater likelihood of being vitamin D replete or having higher vitamin D concentrations.  
bBMI indicates body mass index (weight in kilograms divided by height in metres squared).   
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Table 4: Seasonality of TB risk factors, TB infection and TB disease. The peak seasons for the TB risk factors, TB infection and TB disease and the proportion occurring 
during the peak season versus the rest of the year is shown.a  
 
 
Peak season and dates 
 
6 month proportions 
 
 Season start date Peak date Season end date  Peak season Rest of year P value 
TB risk factors        
Household crowding;                    
% (n/N) [95% CI] 
April 8th 
July 8th 
(midwinter) 
October 7th  
58.9% (206 / 350) 46.2% (171 / 370) 
<0.001 
 [53.7 - 64.0] [41.1 - 51.3] 
        
Hours without direct sunlight; % 
(n/N) [95% CI] 
May 20th 
August 18th 
(midwinter) 
November 18th 
 92.7% (15622 / 16848) 74.4% (11746 / 15792) 
<0.0001 
 [92.3 - 93.2] [73.7 - 75.1] 
        
Vitamin D deficient (<50 nmol/L); 
% (n/N) [95% CI] 
May 24th 
August 23rd 
(midwinter) 
November 22nd   
 66.7% (58 / 87) 49.1% (53 / 108) 
0.01 
 [56.8 - 76.6] [39.6 - 58.5] 
        
TB infection        
TST positivity; % (n/N) [95% CI] July 8th 
October 7th 
(late winter) 
January 6th  
 62.5% (388 / 621) 54.7% (420 / 768) 
0.003 
 [58.7 - 66.3] [51.2 - 58.2] 
        
IGRA positivity; % (n/N) [95% CI] October 4th 
January 3rd 
(early summer) 
April 4th 
 59.1% (166 / 281) 50.5% (149 / 295) 
<0.04 
 [53.3 - 64.8] [44.8 - 56.2] 
        
TB disease        
TB symptom onset incidence; % 
(n/N) [95% CI] b 
December 1st 
March 2nd  
(midsummer) 
June 1st  
 0.14% (416 / 307623) 0.12% (361 / 307623) 
<0.05 
 [0.12 - 0.15] [0.11 - 0.13] 
        
TB diagnosis incidence; % (n/N) 
[95% CI]c 
December 24th 
March 24th 
(late summer) 
June 23rd  
 0.15% (466 / 307623) 0.13% (390 / 307623) 
<0.01 
 [0.14 - 0.17] [0.11 - 0.14] 
                
Note ‘CI’ indicates confidence intervals. aThese observed 6-monthly actual count data differ slightly from the 6-month moving average data shown in Figure 4 (Page 41) because of differences in the way these data are 
calculated.  bTB symptom onset was calculated using longest duration of symptoms including cough (with or without phlegm or blood), weight loss, fever and night sweats. More general symptoms (e.g. headache and nausea) 
were not included in symptom onset calculations. Incidence is shown as the total number of people with onset of symptoms that were subsequently diagnosed to be caused by laboratory-proven pulmonary TB over four 6-
month periods as a percentage of the total population of the study site estimated in a national census during the study period. cIncidence is shown as the total number of people diagnosed with laboratory-proven pulmonary 
TB over four 6-month periods as a percentage of the total population of the study site estimated in a national census during the study period.  
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Figure 1: Study design. Abbreviations: TST = tuberculin skin test; IGRA = Interferon gamma 
release assay; TB = tuberculosis 
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Figure 2: Vitamin D plasma concentration; for the entire study population (n=195) by sex and season. Bars represent 95% confidence intervals.  
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Figure 3: Vitamin D replete (25OHD concentrations ≥50 nmol/l) for the entire study population (n=195) by sex and season. Bars represent 95% 
confidence intervals.  
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Figure 4: Schematic demonstrating the seasonality of TB risk factors in midwinter, 
infection in late winter and early summer, and disease in midsummer. Letters represent 
months of the year. Trendlines represent 6-month moving averages of raw data that differ slightly 
from the 6-monthly actual counts shown in Table 4 (Page 37) owing to the latter being raw data. In 
the “TB risk factors” section, hours without sunlight is represented by the thin continuous black 
trendline, vitamin D deficiency by the dashed black line, and crowding by the thick continuous black 
trendline. The numbers stated for the incidence of TB symptom onset and TB diagnoses are the 6-
month moving average data corresponding to those in Table 4 (Page 37).
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Chapter 3: Defining catastrophic costs and comparing their 
importance for adverse tuberculosis outcome with multi-drug 
resistance: a prospective cohort study, Peru  
 
This chapter is adapted from the peer-reviewed, published paper Wingfield et al “Defining 
catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug 
resistance: a prospective cohort study, Peru.” PLOS Medicine. 2014 Jul 15;11(7):e1001675. doi: 
10.1371/journal.pmed.1001675.19 The paper is bound in PDF format in Appendix 2 of this thesis. The 
candidate’s contribution to this study was final data collection, data management, data analysis and 
analysis strategy, study write-up and dissemination of findings. The candidate was not involved in 
study design or original data collection. 
Following evaluation of the association between TB and poverty including assessment of seasonal 
poverty-related risk factors such as vitamin D deficiency and household crowding, this PhD research 
went on to describe hidden costs of TB illness and create a clinically-relevant catastrophic TB-related 
costs threshold. The threshold was subsequently endorsed by the World Health Organisation for use 
in measurement of catastrophic costs during its roll-out of a TB Costs Measurement Tool in sentinel 
country sites in 2015.79 
 
Introduction 
 
Whilst many countries aim to offer “free” TB treatment to their patients, this may only cover some 
diagnostic tests and anti-mycobacterial medications. Patients and their households may incur hidden 
costs, be they direct “out-of-pocket” expenses such as transport, symptom-relieving medicines, 
additional food or indirect expenses associated with lost income.24,25,80,81 
In its “Global TB strategy for tuberculosis prevention, care and control” at the 67th World Health 
Assembly in May 2014, the World Health Organization adopted a target of eradicating catastrophic 
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costs for TB-affected families by 2035.14 However, hidden TB-related costs remain understudied and, 
at the time of writing, consensus about defining catastrophic costs is awaited.14,22,28,82,83 Some 
catastrophic costs definitions have incorporated symptoms of financial shock and coping 
mechanisms.84,85 Others have used operational thresholds of total costs of 10-25% of that 
household’s annual income 83,86,87 or 40% or more of that household’s “capacity to pay”.88,89 Recently, 
concerns have been raised that the current approach of measuring catastrophic costs using “out-of-
pocket” payments is too narrow because it overlooks lost income and consequently risks 
misinforming policy makers.23,24 Thus, there is an urgent need to improve indicators of financial risk 
to better inform health policy guidance.13,90,91 However, although there is broad agreement that 
some vulnerable TB-affected households will require social protection (such as socioeconomic 
support) to avoid catastrophic costs, more evidence is needed to define such costs and characterise 
their importance.13,25,28,29,88–93 
We prospectively quantified changes in income and hidden costs prior to and throughout treatment 
of patients with non-MDR and MDR TB in impoverished shantytowns surrounding northern 
Lima/Callao, Peru. The aims of the study were to better characterise TB-related costs, their 
association with adverse TB outcome, and contribute to an evidence-based definition of catastrophic 
costs that is both clinically and financially relevant. The study hypothesis was that catastrophic costs 
of TB-affected households are independently associated with adverse TB outcomes in TB patients. 
 
Methods 
 
Ethical approval 
The internationally accredited ethical committee of the Universidad Peruana Cayetano Heredia, Peru, 
and Imperial College London, UK, approved the project. All interviewed participants gave written 
informed consent.  
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Study design and participants 
We conducted a prospective cohort study of TB patients and a baseline case-control study comparing 
them with healthy controls. From October 2002 to November 2009, in collaboration with the 
Peruvian TB program, all consecutive patients with laboratory-proven pulmonary TB were invited to 
participate in the study. All interactions between the research team and the participants occurred 
during household visits. Until November 2012, patients were followed-up for recurrent TB by 
monitoring TB treatment records and re-visiting each household approximately every 3 years to 
enquire about TB diagnoses. From December 2006 to December 2007, control households were 
selected using random number tables from an up to date satellite map and were invited to 
participate during a household visit. In the case that all control participants were unavailable or 
declined then the nearest neighbouring household was instead invited to participate. Controls were 
not matched to cases because the study aimed to characterise the effect of relevant exposures 
including sex, age and socioeconomic position on the outcome variables of catastrophic costs and 
adverse TB outcome. Inclusion criteria in both cases and controls included age more than 15 years. 
Exclusion criteria included declining or being unable to give informed written consent. Both for the 
cohort and the baseline case control study, the sample size was opportunistic and consequently no 
power calculations were performed. 
Study setting 
The study was conducted in Ventanilla, 16-periurban contiguous shantytowns in northern 
Lima/Callao, Peru, with an estimated population of 277,895 people, and frequent poverty (32% of 
inhabitants live on ≤1 US dollar per day). During the study period. the annual TB notification rate in 
Ventanilla was 162 new cases per 100,000 people, higher than the rest of the country which was 
estimated to be 106 per 100,000 people annually.26 
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TB was treated by the National TB Program in community health posts where sputum smear was 
offered free of charge to all patients and chest radiographs to selected patients. TB patients received 
their anti-TB directly observed therapy (DOT) free of charge at their local health post, administered 
by the National TB program.  
Variables   
Operational definitions of the key study variables (TB disease, TB treatment phases, TB adverse 
outcome, and TB costs) are summarised in Box 1. 
Patients were defined as having MDR TB if they were initially prescribed an MDR treatment regimen 
or sputum testing was positive for MDR TB by the Microscopic-Observation Drug-Susceptibility 
(MODS) assay or the proportions assay. All other patients recruited to the study were defined as 
having non-MDR TB.  
For both patients with MDR and non-MDR TB, stages of treatment were operationally defined as 
follows: “pre-treatment” was from self-reported onset of TB-related symptoms until treatment 
initiation; “intensive treatment phase” was the first two months of TB treatment; “continuation 
treatment phase” was the four months immediately following the “intensive treatment phase”; 
“during treatment” was the period of time from the start of “intensive treatment phase” to the end 
of the “continuation treatment phase”; and “entire illness” was from TB-related symptom onset to 
the end of the “continuation treatment phase”. 
Early TB treatment outcome for each patient was assessed by the TB program at the time of 
treatment cessation and was not influenced by this research. These early TB treatment outcome 
assessments were based on sputum microscopy results that are insensitive to treatment failure.94,95 
Therefore, we also collaborated with the TB program in continuous surveillance of TB program 
treatment records and re-visited each patient in their home to check for TB recurrence that we 
defined as TB re-treatment within 30 months from the date that treatment started (in most cases 2 
years from treatment cessation). We defined good TB outcome as cure without recurrence. We 
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defined adverse TB outcome as death during treatment, treatment abandonment, treatment failure 
or recurrence. Patients who were transferred away or were lost to follow-up were considered to 
have undefined outcome. 
Data source and measurement 
A questionnaire was developed locally, piloted, refined, and then used to interview patients and 
collect socio-demographic data concerning household income and expenses throughout TB illness. 
Interviews were conducted at baseline with both TB patients and controls. For patients this baseline 
interview occurred prior to or at the time that treatment commenced. The baseline (but not 
subsequent) interview included detailed assessment of: household assets ownership; access to basic 
services; and education level. Patients were subsequently interviewed after 2, 4, 6, 8, 12, 16, 20 and 
24 weeks of treatment. At all baseline and subsequent interviews, questions characterized earnings, 
income, expenses, employment (paid or unpaid), days unable to work due to illness, additional 
household food expenditure due to TB illness, and crowding. Household debts were assessed at 
recruitment and subsequently at 24 weeks of treatment. 
As in previous research, TB-related costs were categorized as “direct expenses” 25,79,96,97 and “lost 
income” 79,96,98 incurred since the previous interview. All costs and incomes were quantified in cash 
amounts in Peruvian Soles (average 1 US dollar equivalent to 2.9 Peruvian Soles during the study 
period). Inflation and especially exchange rates varied considerably during the study period, so actual 
costs were reported without adjustments in order to be more informative to users including policy 
makers. Table 5 (Page 60) shows the table of annual inflation in Peru and average annual exchange 
rates 2002-2009. To further facilitate interpretation internationally, costs were also expressed as the 
proportion of the average monthly income of all patient households. Also, to assess impact on the 
patient households, costs were calculated as a proportion of the same household’s annual income.   
“Direct (“out-of-pocket”) expenses” included direct medical expenses (medical examinations and 
prescribed medicines) and direct non-medical expenses (natural non-prescribed remedies, TB-care 
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related transport, extra food, and other miscellaneous expenses). “Lost income” (indirect expenses) 
was the income the patient estimated that the household lost due to TB illness or tuberculosis-
related time off work (such as attending clinics) since the previous interview, measured in Peruvian 
Soles. Days of work lost due to TB illness could not be used to directly calculate lost income because 
salaried employment with fixed rates of remuneration were uncommon in this setting. “Total 
expenses” were direct expenses plus lost income. “Earnings” were defined as the monthly money 
actually received by the household and “income” was defined as the monthly money earned by the 
household plus lost income. Household debts at recruitment and total household debts (sum of 
debts at recruitment plus debts at 24 weeks of recruitment) included both formal debts (e.g. bank 
loans) and informal debts (e.g. money borrowed from friends and family). 
For all participants, height and weight were measured and body mass index (BMI) was calculated. 
Poverty was measured using a composite household poverty index in arbitrary units derived by 
principal component analysis from 13 variables, as described.15 
A threshold for catastrophic costs was calculated by plotting the sensitivity, specificity and 
population attributable fraction for adverse TB outcome against total household expenses as a 
proportion of annual income. In order to assess the strength of this new definition of catastrophic 
costs and in accordance with relevant recent studies,83,87 a sensitivity analysis was also performed 
comparing the association of other existing catastrophic costs thresholds (including total expenses 
equal to or greater than 10%, 15% or 25% of annual income) with adverse TB outcome. 
Data analysis 
Continuous data were summarized by their arithmetic means and their 95% confidence intervals (CI) 
whether the data was Gaussian or non-Gaussian because this approach is considered to be robust for 
health economics data analysis.23,99,100 Furthermore, because of the skewed nature of some 
expenditure data, most median values were 0 or close to 0 limiting the descriptive usefulness of 
presenting median values. Any direct expenses, lost income, or annual income recorded as “zero” or 
 48 
missing was replaced with 0.5 soles per day (i.e. the midpoint of zero and the lowest unit of 
measurement, 1 Peruvian Sol). Means were compared with the Student’s t-test. Categorical data 
were summarised as proportions with 95% CI and were compared with the z-test of proportions. 
Univariable regression analyses examining differences between patients with MDR and non-MDR TB 
and controls were adjusted for sex because of under-recruitment of male controls due to their 
availability.  
The association between catastrophic costs and adverse TB outcome was explored through both 
univariable and multivariable analysis to determine odds ratios (OR). The likelihood ratio test was 
used to test for trend and interaction between variables. Non-Gaussian continuous variables such as 
total costs as a proportion of annual income were transformed to their base-10 logarithm for 
regression analysis. All the variables associated (p<0.15) with adverse TB outcomes in univariable 
analysis and all predetermined presumed confounding variables (age, poverty score, previous TB 
episode, symptom duration, and current MDR TB) were concurrently included in a multivariable 
model.101  
Population attributable fractions were calculated using the Stata program “aflogit” function, which 
computes population attributable fraction estimates while adjusting for the reciprocal confounding 
effect of covariates on the association of interest. The population attributable fraction of an 
exposure was interpreted as the proportion of adverse TB outcomes that would be averted by 
eliminating that exposure, both unadjusted and adjusted for known confounding factors. All p-values 
were two-sided and statistical analyses were performed using the Stata program (StataCorp, version 
10).  
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Results 
 
Participants 
During the study period, the Peruvian TB program within the study site of Ventanilla registered 1,014 
patients. We located 99% of these registered TB patients of whom 95% (n=966) met inclusion 
criteria. Of these eligible patients, 1% (n=10) declined, 8% (n=80) were excluded because they 
completed fewer than half of our planned research interviews and data are presented for the 
remaining 91% (n=876). 11% (n=93) of patients recruited had MDR TB. 487 controls were also 
recruited and had only a baseline interview. The characteristics of the study population were 
summarized in Table 1, Page 20, Chapter 1. 
Earnings and debt 
Patients earned more per month pre-treatment than during treatment (510 [95% CI 481-539] versus 
434 [95% CI 415-453] Peruvian Soles, p<0.001, Table 6, Page 61) or the continuation treatment phase 
(454 [95% CI 431-477] Peruvian Soles, p<0.001) and earned least during the intensive treatment 
phase (379 Peruvian soles [95% CI 358-400], p<0.001). During all treatment phases, patients with 
MDR TB tended to earn less than TB patients with non-MDR TB (Table 6, Page 61). Household debts 
at recruitment were greater in controls than patients with TB (812 [95% CI 507-1117] versus 383 
[95% CI 292-474] Peruvian Soles, p=0.004) but there was no difference between household debts of 
patient with MDR and non-MDR TB (497 [95% CI 381-613] versus 511 [95% CI 482-540] Peruvian 
soles, p=0.8). Household debts decreased from 383 Peruvian soles [95% CI 292-474] at recruitment 
to 296 Peruvian soles [95% CI 176-414] at 24 weeks of treatment. Households with above cohort 
median total debt were more likely to incur catastrophic costs (OR 1.58 [95% CI 1.17-2.14] p=0.003). 
Households with above cohort median increase in debt from recruitment to 24 weeks were also 
more likely to incur catastrophic costs (OR 1.74 [95% CI 1.10-2.77] p=0.003).  
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Outcome data 
725 (83%) of patients had a defined TB outcome at follow-up. Of these patients, 166 (23%) had 
adverse TB outcome, 40% (n=67) due to treatment abandonment, 22% (n=36) due to treatment 
failure, 12% (n=15) due to death during treatment, and 26% (n=48) due to TB recurrence. 
 
Costs data  
Constituent direct expenses and lost income: Constituent direct expenses and lost income are 
summarized in Figure 5 (Page 70). Throughout the entire illness, medical and non-medical expenses 
were similar (49% [95% CI 43-55] versus 51% [95% CI 47-54] of total direct costs, p=0.7). Medical 
expenses were greatest pre-treatment, were higher than non-medical costs and constituted almost 
two-thirds of overall direct expenses (0.20 [95% CI 0.18-0.22] versus 0.13 [95% CI 0.11-0.15] monthly 
incomes, p<0.001). Conversely, during treatment non-medical expenses were higher than medical 
expenses and constituted approximately two-thirds of overall direct expenses (0.22 [95% CI 0.20-
0.24] versus 0.14 [95% CI 0.12-0.16] monthly incomes, p<0.001). Direct expenses were higher pre-
treatment than during treatment (0.52 [95% CI 0.46-0.59] versus 0.41 [95% CI 0.37-0.44] monthly 
incomes, p<0.001) whereas lost household income was lower pre-treatment than during treatment 
(0.60 [95% CI 0.50-0.69] versus 0.75 [95% CI 0.68-0.82] monthly incomes, p<0.005). Lost household 
income was higher than direct expenses throughout all treatment phases with the greatest 
difference during the intensive treatment phase (69% lost income [95% CI 61–77], Figure 5, Page 70). 
Total expenses: In addition to direct expenses and lost income, total expenses are summarized in 
Figure 5, Page 70. Total expenses were similar pre-treatment versus during treatment (1.1 [95% CI 
1.0-1.2] versus 1.2 [95% CI 1.1-1.2] monthly incomes, p=0.6). Total expenses (1.12 [95% CI 0.99-1.25] 
versus 0.62 [95% CI 0.56-0.68] monthly incomes, p<0.001), direct expenses (0.52 [95% CI 0.46-0.59] 
versus 0.19 [95% CI 0.16-0.22] monthly incomes, p<0.001) and lost income (0.6 [95% CI 0.50-0.69] 
versus 0.43 [95% CI 0.38-0.48], p=0.001) were significantly higher pre-treatment than during 
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intensive treatment phase. Total expenses (0.62 [95% CI 0.56-0.68] versus 0.54 [95% CI 0.49-0.59] 
monthly incomes, p=0.01) and lost income (0.43 [95% CI 0.38-0.48 versus 0.32 [95% CI 0.28-0.36], 
p<0.001) were higher in intensive than continuation treatment phase but there was no difference in 
direct expenses between these treatment phases (0.19 [95% CI 0.16-0.22] versus 0.22 [95% CI 0.20-
0.23], p=0.07). When total expenses were examined per month, monthly intensive treatment phase 
total expenses were approximately double those of continuation treatment phase.  
Poverty and expenses: TB patients were poorer than controls (58% [95% CI 55-61] versus 51% [95% 
CI 47-56] above control mean, p<0.02, Table 1, Chapter 1, Page 20). In poorer households, direct 
expenses were lower (mean direct expenses of poorest households 330 [95% CI 287-373], poor 
households 418 [95% CI 351-485], and least poor households 435 Peruvian soles [95% CI 380-490], 
p<0.001, Figure 6, Page 72) but total expenses made up a greater proportion of that household’s 
annual income (poorest households 48% [95% CI 35-50], poor households 47% [95% CI 24-70], and 
least poor households 27% [95% CI 20-34], p<0.001, Figure 6, Page 72).  
 
Main findings 
Catastrophic costs: A threshold of 20% of total expenses as a proportion of annual household income 
was defined as catastrophic because this threshold had the highest sensitivity, specificity and 
population attributable fraction for association with adverse outcome (Figure 7, Page 73). 
Catastrophic costs were incurred by 345 households (39%). Incurring catastrophic costs was 
independently associated with MDR TB (OR 1.61 [95% CI 0.98-2.64], p<0.06), more days not working 
pre-treatment (OR 1.00 [95% CI 1.00-1.01], p=0.03), greater debts at recruitment (OR 1.00 [95% CI 
1.00-1.00], p=0.02), being male (OR 2.16 [95% CI 1.57-2.96], p<0.001), older (OR 1.01 [95% CI 1.00-
1.03], p=0.02), poorer (OR 1.25 [95% CI 1.15-1.36], p<0.001) and not in paid employment (OR 1.86 
[95% CI 1.23-2.79], p=0.003, Table 7, Page 62). Households of patients who had MDR TB were more 
likely to incur catastrophic costs (54% MDR [95% CI 43-64] versus 38% non-MDR [95% CI 34-41], 
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p<0.003, Figure 8, Page 74). When the catastrophic costs multivariable regression analyses were 
repeated with total costs as a proportion of annual income analysed as a continuous outcome 
variable (instead of a dichotomous variable above versus below a threshold indicating catastrophic 
costs), the results and patterns of significance were similar (Table 8, Page 63).  
Catastrophic costs and adverse TB outcome: Of the 725 patients with both TB outcome and 
catastrophic costs data, 166 (23%) had an adverse TB outcome. In multivariable regression analysis, 
having MDR TB was most strongly associated with adverse TB outcome (OR 8.4 [95% CI 4.7–15], 
p<0.001). Having had previous TB (OR 2.1 [95% CI 1.3-3.5], p=0.005), having more days off work prior 
to TB diagnosis (OR 1.01 [95% CI 1.00-1.01], p=0.02) and incurring catastrophic costs (OR 1.7 [95% CI 
1.1–2.6], p=0.01, Table 9, Page 64, and Figure 9, Page 75) were also independently associated with 
adverse TB outcome. When the adverse TB outcome multivariable regression analyses were 
repeated with total costs as a proportion of annual income analysed as a continuous outcome 
variable (instead of a dichotomous variable above versus below a threshold indicating catastrophic 
costs), the results and patterns of significance were similar (Table 10, Page 65). The likelihood ratio 
test did not reveal any interaction between having MDR TB and incurring catastrophic costs (whether 
analysed using quantiles of costs as a continuous variable or using our catastrophic costs threshold). 
Population attributable fraction.  The unadjusted population attributable fraction of adverse TB 
outcomes explained by catastrophic costs was 26% [95% CI 14–36], similar to MDR TB 23% [95% CI 
17–28]. When catastrophic costs, MDR TB and previous TB episode were included in the 
multivariable regression model, the adjusted population attributable fraction of adverse TB 
outcomes explained by catastrophic costs and MDR TB was similar; 18% [95% CI 6.9–28] for 
catastrophic costs and 20% [95% CI 14–25] for MDR TB. 
Sensitivity analysis of other catastrophic costs thresholds. Using a threshold of total costs of 10% or 
more of annual income, 578 patients (66%) incurred catastrophic costs. When this threshold was 
increased to total costs of 15% or more of annual income, 457 patients (52%) incurred catastrophic 
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costs. Finally, at a threshold of total costs of 25% or more of annual income, 281 patients (32%) 
incurred catastrophic costs. When these thresholds were included in the multivariable regression 
models, it was found that catastrophic costs at a threshold of 10% or more, or 15% or more, of 
annual income were not independently associated with adverse TB outcome (Table 11, Page 66, and 
Table 12, Page 67). Conversely, catastrophic costs at a threshold of 25% of annual income were 
independently associated with adverse TB outcome (Table 13, Page 68).  
 
Discussion 
 
In this prospective cohort study of impoverished TB patients in Peruvian shantytowns, accessing free 
TB care was expensive for poor TB patients, especially those with MDR TB. Our novel findings also 
define the evidence-based threshold of total costs greater than 20% of annual income as 
catastrophic for TB-affected households. Moreover, an additional sensitivity analysis revealed that 
other recognised catastrophic costs thresholds (such as expenses equal to or greater than 10% and 
15% of annual income) did not identify any association between catastrophic costs and adverse TB 
outcome in this setting. Our new definition is innovative in demonstrating the strong association 
between this 20% catastrophic costs threshold and the increased chances of adverse TB outcome, 
independent of MDR TB status. Our population attributable fraction analysis supports this 
observation by implying that a similar proportion of adverse TB outcomes may be averted by 
eliminating catastrophic costs or MDR TB from the study population. Overall, our findings suggest 
that the costs imposed on TB-affected households are not only financially but also clinically relevant 
and highlight the importance of financial circumstances on TB epidemiology, outcome and control. 
As in previous studies,24,25,80 poorer people incurred the most catastrophic costs which they were less 
able to afford, probably causing further impoverishment.23,33 In agreement with other findings, our 
results indicate that costs as a proportion of that household’s income indicate economic challenge 
better than actual monetary expenditures: this highlights the “medical poverty trap” that as incomes 
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decrease, proportional costs increase.79,102 In addition to exemplifying this medical poverty trap, our 
results also show that being poorer was independently associated with incurring catastrophic costs. 
Catastrophic costs in poor households can lead to financial shock: reducing consumption below 
minimum needs; selling assets; and taking children out of education. These actions may in turn 
increase stigmatization.84,85,103,104 Moreover, TB principally affects the most economically productive 
age group and patient and household income decreases post-diagnosis 79 and may not return to pre-
diagnosis levels. Our study adds a new dimension to the social protection TB literature by showing 
how catastrophic costs can also have significant clinical implications: loss of income and increasing 
hidden costs have previously been associated with poor treatment adherence and high dropout rates 
in TB patients 25,33,105 but their independent effect on long term TB outcome has not been previously 
characterized. We hypothesize that the relationship we found between catastrophic costs and 
adverse TB outcome may relate to a number of factors along the causal pathway from TB 
susceptibility to illness to recurrence including: inadequate nutrition due to lower food spending, 
more severe disease (both MDR and non-MDR TB), and barriers to cure due to the disproportionate 
hidden costs associated with adherence to and completion of treatment. These adverse TB outcomes 
associated with catastrophic costs may increase TB and MDR-TB transmission, especially in poorer 
households. Thus catastrophic costs may worsen TB control. 
Regardless of the mechanisms mediating the association between catastrophic costs and adverse TB 
outcome, the policy implications of our findings are clear: future TB prevention strategies should 
incorporate social protection to mitigate decreased economic production, loss of employment, TB-
associated poverty, and reduce the clinical vulnerability of TB patients. This highlights the potential 
role of social protection not just as a poverty-reduction strategy, but also as a tool to improve 
disease control and, ultimately, health.90,91 
Our previous social protection intervention project “ISIAT” provided evidence that in Peru 
multidisciplinary social protection intervention can improve adherence and completion of TB 
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treatment and prophylaxis.15 Social protection interventions targeting disadvantaged and vulnerable 
populations have shown much promise in Latin America 106 with conditional cash transfer projects 
such as “Progresa” in Mexico.107 In order for these programs to be adopted on a larger scale and 
reduce the social health gradient, they require a rigorous evidence base that is currently lacking. Our 
present study suggests that by reducing catastrophic costs, social protection has the potential to 
protect families from TB illness and deepening poverty.84,108 
Despite TB treatment being free of direct charges in Peru, overall TB-affected households’ costs were 
high and similar pre-treatment versus during treatment. Regardless of MDR status, higher total 
expenses were incurred in those who had longer symptom duration, consistent with the known 
association of increased expenses and diagnostic delay.30 A strength of our study is that it analysed 
patients with both MDR and non-MDR TB and found that expenses as a proportion of household 
annual income were significantly higher in MDR patients as has been noted in other Latin American 
countries.109,110 
Medical expenses made up the largest proportion of pre-treatment direct expenses, probably 
because TB care was only provided free of charge when TB was being tested for or after TB was 
diagnosed. Consequently, formal medical care for the presenting illness was often expensive for the 
patient prior to TB being suspected and/or diagnosed.32,111 We found no evidence of healthcare 
providers requesting the “informal” or “under the table” costs that have been reported in other 
countries.32 
Extending findings from previous studies,25,79,80 lost income formed the majority of the economic 
burden of total expenses and TB patients, especially those with MDR TB, were more likely than 
controls to have a lower income, to be without paid work or to be missing work due to TB-related 
illness. In addition, having more days off work due to TB illness was independently associated with 
having an adverse TB outcome. These results suggest that the socioeconomic and employment 
situation of TB patients is often precarious and this may negatively impact their health, as has been 
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found in another study.112 Indeed, our finding that having more days off work due to TB illness was 
independently associated with both incurring catastrophic costs and having an adverse TB outcome 
suggests that TB illness in such patients may be more severe or advanced and financial shock more 
likely. 
Some definitions of catastrophic costs incorporate signs of financial shock when a household is 
forced to employ coping mechanisms such as: sacrifice of basic needs; selling assets; selling 
household items; removing children from education; and incurring formal or informal 
debt.84,85,103,104,113,114 Others have defined costs as catastrophic when they exceed 10-40% of annual 
household or individual income 82,84,113,115 or 40% or more of a household’s “capacity to pay” (the 
effective income remaining for non-food spending 88,89,103,116–118 but this approach may be too narrow 
and potentially misleading to policy makers because it overlooks lost income.90,91 A strength of the 
threshold of catastrophic costs that our results defined is that it includes not only “out-of-pocket” 
direct expenses but also lost income and that it is proven to be clinically relevant. Specifically, our 
definition was calculated from serial, prospective data 82,85 of household expenses, actual household 
income 23,115 and long-term TB outcomes of a cohort of impoverished TB patients in Peruvian 
shantytowns. It has been estimated that 4% of households in Peru incur catastrophic health 
expenditure when aiming to meet overall health needs.116 Rates of catastrophic health expenditure 
in our cohort were much higher than the general population. This may be due to TB-affected 
households being poorer, the TB treatment model in Peru having greater hidden costs for TB patients 
or that we included lost income to calculate catastrophic costs whereas only direct expenses were 
used in some other studies.119 
The sensitivity analysis we performed showed that the proportion of patient households incurring 
catastrophic costs was similar to other studies that used varying thresholds: at a threshold of total 
costs of 10% or more of annual income, 65% of our cohort incurred catastrophic costs compared to 
66-75% in related studies from Africa;83,87 at a threshold of total costs of 15% and 25% or more of 
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annual income, 52% and 32% of our cohort had catastrophic costs compared to 68% and 48% 
respectively in a cohort from Africa.87 More importantly, the sensitivity analysis also showed that 
thresholds of total costs of 10% and 15% or more of annual income were not independently 
associated with adverse TB outcome in this setting. Our results demonstrate that these previously 
published arbitrary thresholds for catastrophic costs that were defined without patient follow-up 
were not associated with adverse tuberculosis outcomes of TB patients in our setting. Thus our 
findings provide the first evidence-based threshold for clinically-relevant catastrophic costs and 
demonstrate a methodology to assess the generalizability of this threshold in other settings. 
This study has several limitations. Firstly, cases and controls were not matched in this study because 
controls were specifically included to provide an estimate of typical income and expenditure in this 
community to be compared with TB patients at baseline. Matching would have impaired this 
comparison. A baseline difference was noted in debts at recruitment, a proxy for “dissaving”. Poorer 
households have diminished access to establishments that offer formal loans (e.g. banks) because of 
their uncertain repayment capacity and/or lack of requisites such as a national identity card.15 
However, even if controls had been matched to cases, controls may still have had higher debt than 
patients because households were not eligible for some loans due to serious ill health or if they were 
extremely poor.15 Apart from debt, no other data was collected on specific “dissaving” coping 
mechanisms (including using savings, taking loans, taking children out of education, and selling 
assets). In the CRESIPT study (see Chapters 5 and 6), we overcame this deficiency and collected 
comprehensive dissaving data for analysis complementary to the direct and indirect costs data. In 
addition, despite costs being calculated at a household level (i.e. transport costs included both 
patients’ and/or carers’ transport costs), data was not collected on the indirect costs of lost 
work/labour for patients’ guardians/carers for whom the loss may not be monetary (e.g. pastoralists 
or houseworkers). Secondly, the data available did not allow assessment of an existing WHO 
definition of catastrophic costs (40% or more of a household’s capacity to pay)120 against which other 
studies have compared.12 Moreover, while the catastrophic costs threshold of ≥20% established by 
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this research was appropriate because adjusted population attributable fraction showed it to be 
associated with the greatest number of adverse TB treatment outcomes (hence eliminating 
catastrophic costs at this threshold would have the greatest impact on reducing adverse TB 
treatment outcomes), the sensitivity and specificity of the threshold were both low. However, the 
threshold was never intended to be equivalent to a “rule-in” or “rule-out” prognostic marker of the 
possibility of adverse TB outcome. Thirdly, we may have underestimated the financial effects of MDR 
TB because our questionnaires quantifying costs continued for only 6-months whereas patients with 
MDR TB are usually treated for 18 months or more. We decided a priori to analyse the catastrophic 
costs of both MDR and non-MDR patients together given their equal follow-up and small numbers of 
MDR TB patients. Fourthly, the study did not collect qualitative data on how the patients and their 
household members viewed the financial strain placed upon the household and what they perceived 
as “catastrophic”; this omission was corrected in the initial phase of the CRESIPT study as described 
in Chapters 5 and 6. Finally, our research demonstrates a new methodology that should be repeated 
in other settings to assess the external validity of our findings. 
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Conclusions 
 
Despite free TB care, having TB disease was expensive for impoverished TB patients in Peru to afford. 
Higher relative costs were associated with greater likelihood of adverse TB outcome. Having MDR TB 
and incurring catastrophic costs were independently associated with a similar adjusted population 
attributable fraction for adverse TB outcome. Thus, catastrophic costs were an indicator of both 
financial and clinical vulnerability. Mitigating catastrophic costs through  social protection 
interventions as well as diagnosing and treating MDR TB deserve attention in TB control programs. In 
conclusion, control interventions must consider TB as an infectious and socioeconomic problem and 
address both the clinical and financial aspects of this public health challenge. 
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Table 5: Annual inflation rate of the Peruvian Sol and exchange rate of the Peruvian Sol 
to the United States (US) Dollar, 2002-2009 
 
Source: International Monetary Fund –World economic outlook 2011: a survey by the staff of the 
International Monetary Fund. Washington, DC: International Monetary Fund, 1980-2011; ISBN 978-1-
61635-119-9 
http://www.imf.org/external/pubs/ft/weo/2011/02/pdf/text.pdf 
  
Year Inflation rate (%) Exchange rate Peruvian Soles to US 
Dollar 
2002 0.192 0.284 
2003 2.261 0.287 
2004 3.662 0.432 
2005 1.618 0.484 
2006 2.001 0.305 
2007 1.779 0.319 
2008 5.788 0.342 
2009 
 
2.935 
 
0.334 
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Table 6: Comparison of mean monthly earnings of patient households by treatment 
stage. Mean monthly earnings are shown in Peruvian Soles and in brackets as a proportion of mean 
monthly average cohort earnings. Confidence intervals below earnings are those of mean monthly 
earnings in Peruvian Soles. P values represent the difference in earnings between treatment stages 
by Student’s t test. From left to right, data and p values correspond to all patients, non-MDR patients 
and MDR patients. In addition to the p values shown in the table, there was also a significant 
difference between intensive and continuation treatment phases in all (p<0.001) and non-MDR 
(p<0.001) patients but not in MDR (p=0.1) patients. 
 
 
Earnings as mean monthly Peruvian Soles and proportion of mean monthly 
average cohort earnings [95% CI] 
 
All patients 
(n=876) 
p value 
Non-MDR 
patients 
(n=783) 
p value 
MDR 
patients 
(n=93) 
p value  
Pre-treatment 
(n=876) 
510 (1.09) . 511 (1.09) . 497 (1.07) . 
[481 - 539]  [482 - 540]  [381 - 613]  
During treatment 
(n=876) 
434 (0.93) <0.001 436 (0.94) <0.001 418 (0.90) 0.09 
[415 - 453]  [416 - 456]  [341 - 495]  
Intensive 
treatment phase 
(n=876) 
379 (0.81) <0.001 379 (0.81) <0.001 376 (0.81) 0.1 
[358 - 400]  [357 - 401]  [295 - 457]  
Continuation 
treatment phase 
(n=876) 
454 (0.97) 0.001 457 (0.98) 0.0003 424 (0.91) 0.1 
[431 - 477]  [434 - 480]  [339 - 509]  
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Table 7: Factors associated with incurring catastrophic costs. Factors associated (p<0.15) 
with catastrophic costs in univariable regression were included in the multivariable regression 
analysis (those not included are marked with a dot). 95% confidence intervals (95% CI) are shown in 
parenthesis. All patients (n=876) had data available and entered the univariable and multivariable 
logistic regression analyses. NA indicates that earnings at recruitment was not entered into multiple 
regression analysis because it is strongly and acutely affected by having TB disease  
             
 
 
Univariable  
Multivariable logistic 
regression 
  OR P  OR p 
Demographics       
Age; mean years [95% CI]  1.02 0.001  1.01 0.02 
  [1.01-1.03]   [1.00-1.03]  
Sex; males [95% CI]  1.86 <0.001  2.16 <0.001 
  [1.40-2.47]   [1.57-2.96]  
       
Socioeconomic and health 
factors 
 
     
Completed secondary school; 
[95% CI] 
 
0.73 <0.03  1.06 0.7 
  [0.55-0.96]   [0.77-1.46]  
BMI; [95% CI]  0.97 0.2  . . 
  [0.92-1.01]   .  
Previous TB episode; [95% CI]   1.48 0.03  1.16 0.5 
  [1.04-2.10]   [0.79-1.71]  
Earnings at recruitment; [95% 
CI] 
 
0.99 <0.001  NA NA 
  [0.99-1.00]   NA  
Patient without paid 
employment; [95% CI] 
 
1.42 <0.06  1.86 0.003 
  [0.99-2.05]   [1.23-2.79]  
Debts at recruitment;* [95% CI]  1.00 0.1  1.00 0.02 
  [0.99– 1.00]   [1.00 - 1.00]  
Poverty; [95% CI] household 
poverty score 
 
1.26 <0.001  1.25 <0.001 
  [1.17-1.35]   [1.15-1.36]  
Current tuberculosis episode       
Symptom duration; % [95% CI]  1.003 0.002  1.00 0.06 
  [1-1.005]   [1.00-1.00]  
MDR; % [95% CI]  1.92 0.003  1.61 <0.06 
  [1.25-2.96]   [0.98-2.64] . 
Days too unwell to work prior 
to treatment; [95% CI] 
 
1.01 <0.001  1.00 0.03 
  [1.00-1.02]   [1.00-1.01] . 
             
       
* Debt at recruitment was used in the final multivariable regression model rather than total debt (debt at 
recruitment plus debt at 24 weeks of treatment) as only 461 patients had 24-week debt data available   
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Table 8: Factors associated with total costs as a proportion of annual income. Total costs 
as a proportion of annual income data had a non-Gaussian distribution so this variable was transformed to its 
base-10 logarithm for regression analysis. Factors associated (p<0.15) with increasing costs in univariable linear 
regression were included in the multivariable analysis (those variables not included are marked with a dot). 
95% confidence intervals are shown in parentheses. NA indicates that earnings at recruitment was not entered 
into multiple regression analysis because it is strongly and acutely affected by having TB disease. All patients 
(n=876) had data available and were included in the univariable and multivariable linear regression analyses.  
            
 Univariable  
Multivariable logistic 
regression 
 Coefficient P  Coefficient P 
Demographics      
Age; mean years [95% CI] 0.0053 <0.001  0.0038 0.002 
 [0.0028-0.077]   [0.0014-0.0061]  
Sex; males [95% CI] 0.12 <0.001  0.12 <0.001 
 [0.056-0.19]   [0.060-0.19]  
      
Socioeconomic and health 
factors 
     
Completed secondary 
school; [95% CI] 
-0.19 <0.001  -0.012 0.7 
 [-0.18 - -0.054]   [-0.078-0.055]  
BMI; [95% CI] -0.0056 0.3  . . 
 [-0.016 - 0.047]   .  
Previous TB episode; [95% 
CI]  
0.12 0.004  0.074 0.08 
 [0.039-0.21]   [-0.0077-0.16]  
Earnings at recruitment; 
[95% CI] 
-0.00029 <0.001  NA NA 
 
[-0.00036 - -
0.00021] 
  NA  
Patient without paid 
employment; [95% CI] 
0.094 <0.03  0.13 0.001 
 [0.010-0.18]   [0.031-0.065]  
Debts at recruitment; [95% 
CI] 
0.000014 0.2  . . 
 
[0.000006 – 
0.000038] 
  .  
Poverty; [95% CI] household 
poverty score 
0.060 <0.001  0.048 <0.001 
 [0.044-0.076]   [0.034-0.067]  
Current tuberculosis episode      
Symptom duration; % [95% 
CI] 
0.0011 <0.001  0.00080 <0.001 
 [0.00070-0.0016]   [0.00037-0.0012]  
MDR; % [95% CI] 0.17 0.001  0.075 0.2 
 [0.068-0.29]   [-0.028-0.18]  
Days too unwell to work 
prior to treatment; [95% CI] 
0.0024 <0.001  0.0010 <0.05 
 [0.0014-0.0034]   [0.000059-0.0020] . 
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Table 9: Univariable and multivariable logistic regression of factors associated with 
adverse TB outcome. Adverse TB outcome was defined as death during treatment, treatment 
failure or abandonment, and recurrence of TB within 30 months of starting treatment. Factors 
associated (p<0.15) with adverse TB outcome in univariable regression were included in the 
multivariable regression analysis. NA indicates that earnings at recruitment was not entered into 
multiple regression analysis because it is strongly and acutely affected by having TB disease. 725/876 
(83%) of patients had TB outcome data available and entered the univariable and multivariable 
logistic regression analyses.  
  
          
 Univariable  Multivariable logistic regression 
 OR p  OR P 
      
Demographics      
Age; mean years [95% CI] 1.01 0.06  1.00 0.6 
 [1.0-1.02]   [0.99-1.02]  
Sex; males [95% CI] 1.53 0.02  1.25 0.3 
 [1.07-2.20]   [0.80-1.95]  
      
Socioeconomic/health factors      
Completed secondary school; [95% 
CI] 
0.66 <0.03  0.71 0.1 
 [0.46-0.95]   [0.45-1.11]  
BMI; [95% CI]  0.93 0.01  0.95 0.2 
 [0.87-0.98]   [0.89-1.03]  
Previous TB episode; [95% CI]  2.95 <0.001  2.11 0.005 
 [1.92-4.52]   [1.26-3.54]  
Income at recruitment; per month in 
Peruvian soles; [95% CI] 
1.00 0.2  NA NA 
 [0.99 - 1.00]     
Patient without paid employment at 
treatment; [95% CI] 
1.47 0.1  1.25 0.5 
 [0.79-1.02]   [0.70-2.24]  
Debt at recruitment;* [95% CI] 1.00 0.1  1.00 0.7 
 [0.99-1.00]   [0.89-1.12]  
Poverty; [95% CI] household poverty 
score 
1.10 <0.05  1.00 1.0 
 [1.00-1.20]   [1.00-1.01]  
Current tuberculosis illness      
MDR; [95% CI] 8.38 <0.001  8.37 <0.001 
 [5.04-13.93]   [4.67-15.0]  
Symptom duration; [95% CI] 1.00 <0.05  1.00 0.7 
 [1.00-1.01]   [1.00-1.01]  
Days too unwell to work prior to 
treatment; [95% CI] 
1.01 <0.001  1.01 0.02 
 [1.00-1.01]   [1.00-1.01]  
Catastrophic TB costs (20% or more 
of annual income); [95% CI] 
2.36 <0.001  1.72 0.01 
 [1.62-3.43]   [1.11-2.64]  
            
* Debt at recruitment was used in the final multivariable regression model rather than total debt (the sum of 
debt at recruitment plus debt at 24 weeks of treatment) as only 461 patients had 24-week debt data available   
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Table 10: Univariable and multivariable logistic regression of factors (including costs as 
a continuous variable) associated with adverse outcome. Adverse outcome is defined as death 
during treatment, treatment failure or abandonment, and recurrence of TB within 30 months of starting 
treatment. Total costs as a proportion of annual income data had a non-Gaussian distribution so this variable 
was transformed to its base-10 logarithm for regression analysis. Factors associated (p<0.15) with adverse 
outcome in univariable logistic regression were included in the multivariable logistic regression analysis. NA 
indicates that earnings at recruitment was not entered into multiple regression analysis because it is strongly 
and acutely affected by having TB disease. 725/876 (83%) of patients had outcome data available.   
            
 Univariable  Multivariable logistic regression 
 OR P  OR P 
      
Demographics      
Age; mean years [95% CI] 1.01 0.06  1.00 0.7 
 [1.0-1.02]   [0.99-1.02]  
Sex; males [95% CI] 1.53 0.02  1.26 0.3 
 [1.07-2.20]   [0.81-1.95]  
      
Socioeconomic and health factors      
Completed secondary school; [95% CI] 0.66 <0.03  0.72 0.2 
 [0.46-0.95]   [0.46-1.13]  
BMI; [95% CI]  0.93 0.01  0.95 0.2 
 [0.96-1.00]   [0.89-1.02]  
Previous TB episode; [95% CI]  2.95 <0.001  2.07 0.006 
 [1.92-4.52]   [1.24-3.48]  
Income at recruitment; per month in 
Peruvian soles; [95% CI] 
1.00 0.2  NA NA 
 [0.99 - 1.00]     
Patient without paid employment at 
treatment; [95% CI] 
1.47 0.1  1.24 0.5 
 [0.79-1.02]   [0.69-2.22]  
Debts; [95% CI] 1.00 0.1  1.00 0.8 
 [0.99-1.00]   [1.00-1.00]  
Poverty; [95% CI] household poverty 
score 
1.10 <0.05  1.00 1.0 
 [1.00-1.20]   [1.00-1.00]  
Current tuberculosis illness      
MDR; [95% CI] 8.38 <0.001  8.38 <0.001 
 [5.04-13.93]   [4.68-15.0]  
Symptom duration; [95% CI] 1.00 <0.05  1.0 0.7 
 [1.00-1.01]   [1.00-1.00]  
Days too unwell to work prior to 
treatment; [95% CI] 
1.01 <0.001  1.00 0.2 
 [1.00-1.01]   [1.00-1.01]  
Total costs as a proportion of annual 
income (log transformed)*; [95% CI] 
2.53 <0.001  1.84 0.007 
 [1.77-3.61]   [1.18-2.88]  
            
*if the non-Gaussian original total costs as a proportion of annual income is used instead of the 
transformation to base-10 logarithm the association is similar: Univariable logistic regression OR 1.69 
[95% CI 1.33-2.15] p<0.001, multivariable logistic regression (same pattern of significance as shown) 
OR 1.56 [95% CI 1.22-1.98], p<0.001  
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Table 11: Univariable and multivariable logistic regression of factors (including 10% 
threshold for catastrophic costs) associated with adverse outcome. Adverse outcome is 
defined as death during treatment, treatment failure or abandonment, and recurrence of TB within 30 months 
of starting treatment. Factors associated (p<0.15) with adverse outcome in univariable logistic regression were 
included in the multivariable logistic regression analysis. NA indicates that earnings at recruitment was not 
entered into multiple regression analysis because it is strongly and acutely affected by having TB disease. 
725/876 (83%) of patients had outcome data available and entered the univariable and multivariable logistic 
regression analyses. In contrast to Table 9 (Page 64), in this table total costs ≥10% of annual income were used 
as the threshold for catastrophic costs 
            
 Univariable  Multivariable logistic regression 
 OR p  OR P 
      
Demographics      
Age; mean years [95% CI] 1.01 0.06  1.01 0.5 
 [1.0-1.02]   [0.99-1.02]  
Sex; males [95% CI] 1.53 0.02  1.37 0.2 
 [1.07-2.20]   [0.89-2.12]  
      
Socioeconomic and health factors      
Completed secondary school; [95% 
CI] 
0.66 <0.03  0.72 0.1 
 [0.46-0.95]   [0.46-1.12]  
BMI; [95% CI]  0.93 0.01  0.95 0.2 
 [0.96-1.00]   [0.89-1.03]  
Previous TB episode; [95% CI]  2.95 <0.001  2.13 0.004 
 [1.92-4.52]   [1.28-3.57]  
Income at recruitment; per month in 
Peruvian soles; [95% CI] 
1.00 0.2  NA NA 
 [0.99 - 1.00]     
Patient without paid employment at 
treatment; [95% CI] 
1.47 0.1  1.34 0.3 
 [0.79-1.02]   [0.75-2.39]  
Debts; [95% CI] 1.00 0.1  1.00 0.9 
 [0.99-1.00]   [1.00-1.00]  
Poverty; [95% CI] household poverty 
score 
1.10 <0.05  1.03 0.6 
 [1.00-1.20]   [0.92-1.16]  
Current tuberculosis illness      
MDR; [95% CI] 8.38 <0.001  8.76 <0.001 
 [5.04-13.93]   [4.90-15.7]  
Symptom duration; [95% CI] 1.00 <0.05  1.0 0.9 
 [1.00-1.01]   [1.00-1.01]  
Days too unwell to work prior to 
treatment; [95% CI] 
1.01 <0.001  1.00 0.2 
 [1.00-1.01]   [1.00-1.01]  
Catastrophic costs threshold ≥10% of 
annual income; [95% CI] 
1.47 <0.05  1.03 0.9 
 [1.01-2.14]   [0.65-1.63]  
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Table 12: Univariable and multivariable logistic regression of factors (including 15% 
threshold catastrophic costs) associated with adverse outcome. Adverse outcome is defined 
as death during treatment, treatment failure or abandonment, and recurrence of TB within 30 months of 
starting treatment. Factors associated (p<0.15) with adverse outcome in Univariable logistic regression were 
included in the multivariable logistic regression analysis. NA indicates that earnings at recruitment was not 
entered into multiple regression analysis because it is strongly and acutely affected by having TB disease. 
725/876 (83%) of patients had outcome data available and entered the Univariable and Multivariable logistic 
regression analyses. In contrast to Table 9 (Page 64), in this table total costs ≥15% of annual income were used 
as the threshold for catastrophic costs 
            
 Univariable  Multivariable logistic regression 
 OR P  OR p 
      
Demographics      
Age; mean years [95% CI] 1.01 0.06  1.00 0.5 
 [1.0-1.02]   [0.99-1.02]  
Sex; males [95% CI] 1.53 0.02  1.3 0.2 
 [1.07-2.20]   [0.84-2.02]  
      
Socioeconomic and health factors      
Completed secondary school; [95% 
CI] 
0.66 <0.03  0.72 0.1 
 [0.46-0.95]   [0.46-1.12]  
BMI; [95% CI]  0.93 0.01  0.95 0.2 
 [0.96-1.00]   [0.89-1.03]  
Previous TB episode; [95% CI]  2.95 <0.001  2.14 0.004 
 [1.92-4.52]   [1.28-3.58]  
Income at recruitment; per month in 
Peruvian soles; [95% CI] 
1.00 0.2  NA NA 
 [0.99 - 1.00]     
Patient without paid employment at 
treatment; [95% CI] 
1.47 0.1  1.30 0.4 
 [0.79-1.02]   [0.73-2.32]  
Debts; [95% CI] 1.00 0.1  1.0 0.8 
 [0.99-1.00]   [1.0-1.0]  
Poverty; [95% CI] household poverty 
score 
1.10 <0.05  1.01 0.8 
 [1.00-1.20]   [0.90-1.14]  
Current tuberculosis illness      
MDR; [95% CI] 8.38 <0.001  8.61 <0.001 
 [5.04-13.93]   [4.82-15.4]  
Symptom duration; [95% CI] 1.00 <0.05  1.0 0.8 
 [1.00-1.01]   [1.00-1.00]  
Days too unwell to work prior to 
treatment; [95% CI] 
1.01 <0.001  1.00 0.2 
 [1.00-1.01]   [1.00-1.01]  
Catastrophic costs threshold ≥15% of 
annual income; [95% CI] 
1.78 0.002  1.35 0.2 
 [1.25-2.53]   [0.88-2.09]  
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Table 13: Univariable and multivariable logistic regression of factors (including 25% 
threshold catastrophic costs) associated with adverse outcome. Adverse outcome is defined 
as death during treatment, treatment failure or abandonment, and recurrence of TB within 30 months of 
starting treatment. Factors associated (p<0.15) with adverse outcome in univariable logistic regression were 
included in the multivariable logistic regression analysis. NA indicates that earnings at recruitment was not 
entered into multiple regression analysis because it is strongly and acutely affected by having TB disease. 
725/876 (83%) of patients had outcome data available and were included in the univariable and multivariable 
logistic regression analyses. In contrast to Table 9 (Page 64) in this table total costs ≥25% of annual income 
were used as the threshold for catastrophic costs  
            
 Univariable  Multivariable logistic regression 
 OR p  OR P 
      
Demographics      
Age; mean years [95% CI] 1.01 0.06  1.00 0.8 
 [1.0-1.02]   [0.99-1.02]  
Sex; males [95% CI] 1.53 0.02  1.23 0.4 
 [1.07-2.20]   [0.79-1.92]  
      
Socioeconomic and health factors      
Completed secondary school; [95% 
CI] 
0.66 <0.03  0.70 0.1 
 [0.46-0.95]   [0.45-1.10]  
BMI; [95% CI]  0.93 0.01  0.95 0.2 
 [0.96-1.00]   [0.89-1.03]  
Previous TB episode; [95% CI]  2.95 <0.001  2.18 0.003 
 [1.92-4.52]   [1.30-3.65]  
Income at recruitment; per month in 
Peruvian soles; [95% CI] 
1.00 0.2  NA NA 
 [0.99 - 1.00]     
Patient without paid employment at 
treatment; [95% CI] 
1.47 0.1  1.23 0.5 
 [0.79-1.02]   [0.69-2.20]  
Debts; [95% CI] 1.00 0.1  1.00 0.8 
 [0.99-1.00]   [1.00-1.00]  
Poverty; [95% CI] household poverty 
score 
1.10 <0.05  1.00 0.9 
 [1.00-1.20]   [0.89-1.13]  
Current tuberculosis illness      
MDR; [95% CI] 8.38 <0.001  8.30 <0.001 
 [5.04-13.93]   [4.63-14.9]  
Symptom duration; [95% CI] 1.00 <0.05  1.00 0.8 
 [1.00-1.01]   [1.00-1.00]  
Days too unwell to work prior to 
treatment; [95% CI] 
1.01 <0.001  1.00 0.2 
 [1.00-1.01]   [1.00-1.01]  
Catastrophic costs threshold ≥25% of 
annual income; [95% CI] 
2.59 <0.001  1.98 0.002 
 [1.81-3.71]   [1.28-3.07]  
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Box 1: Glossary of operational definitions of TB disease, treatment, outcome, and costs 
*These treatment definitions apply to all TB patients, irrespective of whether they had MDR or non-MDR TB
  
TB Disease 
MDR: Those patients initially prescribed an MDR treatment regimen or who had a sputum test positive 
for MDR TB by the Microscopic-Observation Drug-Susceptibility (MODS) assay or the proportions assay 
     Non-MDR TB: All patients recruited to the study not meeting the definition for MDR TB 
TB Treatment Phases*  
Pre-treatment: the period of time from self-reported onset of TB-related symptoms until treatment 
initiation 
Intensive treatment phase: the first two consecutive months of TB treatment 
Continuation treatment phase: the four consecutive months immediately following intensive 
treatment phase 
During treatment: the period of time spanning from the beginning of the intensive phase to the end of 
continuation treatment phases 
Entire illness: the period of time from the onset of TB-related symptoms to the end of the continuation 
treatment phase 
TB Treatment Outcome 
Adverse tuberculosis outcome: patients who died during treatment (irrespective of cause), 
abandoned treatment, had treatment failure or had recurrent TB disease within 30 months of 
starting TB treatment 
No adverse tuberculosis outcome: patients who were declared cured by the TB program and had no 
recurrence of TB disease within 30 months of starting treatment were defined as having good 
treatment outcome. Patients who were transferred away or were lost to follow-up were considered 
to have undefined outcome 
TB Costs 
Direct (“out of pocket”) expenses: the sum of the direct medical expenses and direct non-medical 
expenses 
Direct medical expenses: costs of medical examinations and medicines  
Direct non-medical expenses: costs of natural remedies, TB-care related transport, extra food, and 
other miscellaneous expenses 
Lost income (indirect expenses): the income the patient estimated that the household lost due to TB 
illness or tuberculosis-related time off work (such as attending clinics) since a) symptom onset until 
the recruitment interview and since b) the previous interview date until subsequent interviews 
Total expenses: direct expenses plus lost income 
Earnings: the monthly money actually received by the household 
Income: the monthly money that would have been earned by the household if it were not TB-affected 
(earnings plus lost income) 
Catastrophic costs: the threshold at which total household expenses as a proportion of annual 
income were most strongly associated with adverse tuberculosis outcome. The strength of the 
association was assessed by the highest sensitivity, specificity and population attributable fraction 
for adverse outcome 
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Figure 5: Lost income, constituent direct expenses, and total expenses by treatment 
stage in mean soles and as a proportion of mean monthly household income. The top 
row shows lost income in mean Peruvian Soles and, in parenthesis, as a percentage of total expenses. 
The next 6 rows show constituent direct expenses in mean Peruvian Soles and, in parenthesis, as a 
percentage of total direct expenses. “Medical” expenses are defined as the sum of direct expenses 
for medicines (blue bar) and clinical exams (dark blue bar); “non-medical” expenses are defined as 
the sum of direct expenses for natural remedies, TB-care related transport, extra food, and other TB-
related expenses. The lowermost two rows show total direct expenses (i.e. sum of medicines, clinical 
exams, natural remedies, transport, extra food, and other expenses) and total expenses in mean 
Peruvian soles and, in parenthesis, as a percentage of total expenses. P values represent the 
difference between treatment stages by Student’s t test. 23/876 (2.6%) of the TB patient cohort had 
direct expenses of “0” Peruvian soles and 14/876 (1.6%) had total expenses of “0” Peruvian soles and 
thus these zero values were replaced with 0.5 Peruvian soles per day  
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Figure 6: Expenses and economic burden of TB illness across poverty terciles. a. Total expenses as proportion of annual income (left sided graph) b. Direct 
expenses (right-sided graph). P values represent Pearson’s coefficient of trend. Bars represent confidence intervals. The numbers in the three left-sided dark grey bars 
of part a. refer to the left hand y-axis of total expenses as a proportion of annual household income. The numbers in the three right-sided light grey bars of part b. refer 
to the right hand y-axis of direct expenses in mean Peruvian soles. 
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Figure 7: Sensitivity, specificity and univariable population attributable fraction of the association of total expenses as a proportion of annual 
income with adverse TB outcome. Total household TB-associated costs were defined as catastrophic when they exceeded 20% of household annual income 
because this threshold had the highest sensitivity, specificity and population attributable fraction for association with adverse outcome. 
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Figure 8: Patient households incurring catastrophic costs by TB resistance profile and adverse TB outcome. Error bars represent 95% confidence 
intervals. P values represent association in univariable logistic regression.  
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Figure 9: Percentage of patients experiencing an adverse TB outcome analysed by poverty, education level, symptom duration, previous TB, 
catastrophic costs, and resistance profile. Error bars represent 95% confidence intervals. P values correspond to the association of each variable with adverse TB 
outcome in univariable logistic regression except for poverty and symptom duration that were analysed as continuous variables. In multivariable regression analysis, 
the following variables remained independently associated with adverse TB outcome: time too unwell to work (p=0.02); catastrophic costs (p=0.003); having had a 
previous episode of TB (p=0.004); and currently having MDR TB (p<0.0001).
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Chapter 4: Designing and implementing a socioeconomic intervention to 
enhance TB control: operational evidence from the CRESIPT project in Peru 
 
This chapter is adapted from the peer-reviewed, published paper Wingfield et al “Designing and 
implementing a socioeconomic intervention to enhance TB control: operational evidence from the CRESIPT 
project in Peru.” BMC Public Health. 2015 Aug 21;15(1):810. doi: 10.1186/s12889-015-2128-0.121 The paper 
is bound in PDF format in Appendix 4 of this thesis. With the support of the multi-disciplinary Innovation 
For Health And Development team and the team leader and PhD supervisor, Dr Carlton Evans, the 
candidate led this project from conception, design, implementation, and refinement of the intervention. In 
addition, the candidate led the data analysis, manuscript write-up, and dissemination of results, including 
as part of the World Health Organisation’s Task Forces on Catastrophic Costs and Social Protection.  
Having identified poverty-related TB risk factors and TB-related catastrophic costs, the next part of this PhD 
research focused on addressing these findings by designing and implementing one of the world’s first TB-
specific socioeconomic interventions including cash transfers. The new knowledge generated by this paper 
aimed to provide preliminary evidence with which to guide policy-makers in implementing the 
socioeconomic interventions mandated in the World Health Organisation’s End TB Strategy. 
This chapter describes the design and implementation of the intervention with particular focus on the 
evolution of the elements of social and economic support provided to TB-affected households. Given its 
descriptive contents, the chapter does not follow the standard scientific structure of Introduction, 
Methods, Discussion, Results, and Conclusion and is instead divided into the headings: Introduction; 
Conceiving the intervention; Designing and implementing the intervention; Lessons learnt and persisting 
knowledge gaps; and Conclusions. Details concerning outcome measures, sample size calculation, 
adjustment for clustering, randomisation, and recruitment are explored in more detail in Chapters 5 and 6. 
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Introduction 
 
Tuberculosis kills 5000 people per day,6 mostly in resource-constrained settings. TB has long been 
recognised as an illness inextricably linked with social deprivation and marginalisation.122,123 Poverty 
predisposes individuals to TB5,22 and hidden costs associated with even free TB treatment can be 
catastrophic: exacerbating poverty,24 leading to adverse TB treatment outcome, increasing TB transmission, 
and potentially worsening TB control.19 Nevertheless, the global model for TB prevention, management and 
research has been principally focused on biomedical rather than social approaches.124,125 There is a pressing 
need to expand the traditional TB control paradigm based on case finding and treatment, in order to 
embrace more holistic approaches that encompass the wellbeing of people and households living with TB 
and communities affected by TB.9,126–130 This vision has been formally acknowledged in the World Health 
Organisation’s post-2015 global TB strategy14 which, for the first time in the modern era of TB control, 
explicitly identifies poverty reduction strategies, including universal health coverage and socioeconomic 
interventions, as key pillars of the future global response to TB.14,80  
Social protection and socioeconomic interventions consist of policies and programs designed to 
reduce poverty and vulnerability by improving people’s capacity to manage social and/or economic risks,131 
and includes health insurance, food assistance, travel vouchers, and cash transfers.132 Cash transfers 
generally provide economic support to impoverished people with the aim of moving them out of extreme 
poverty and vulnerability whilst improving human capital.133–138 Cash transfers are already used to modulate 
behaviour in HIV/AIDS139,140 and improve maternal health.141 Mitigating poverty-related TB risk factors of 
TB-affected households using cash transfers may be a cost-effective investment from a societal 
perspective142 because it may support TB treatment, improve TB prevention and cure, and potentially 
enhance TB control.143 However, there is little operational evidence to guide implementation or evaluate 
the impact of TB-related socioeconomic support including cash transfer interventions.9,15,17,18,132–134,144–150  
For over a decade, our research group (www.ifhad.org) has worked with TB-affected households in 
the shantytowns of Callao, Peru. From 2007 to 2011, we conducted an assessment of Innovative 
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Socioeconomic Interventions Against TB (ISIAT).15 The interventions had two dimensions: i) education, 
community mobilization, and psychosocial support to increase uptake of TB care; and ii) food transfers, 
microcredit, microenterprise and vocational training to reduce poverty. This intervention increased 
preventive chemotherapy in household contacts and HIV testing and TB treatment completion in TB 
patients.15  
Building on the lessons learnt during the ISIAT project, we designed a larger 6-year research project 
called CRESIPT: a “Community Randomized Evaluation of a Socioeconomic Intervention to Prevent TB” to 
test for impact on TB control. This paper aims to describe the challenges of implementation, lessons learnt, 
and refinement of this complex social protection intervention to control TB, focusing on set up of a TB-
specific cash transfer scheme, and thus provide research groups, non-governmental organisations (NGOs), 
civil-society representatives, policy-makers, stake-holders and the wider TB community with an interim 
guidance document concerning the operational logistics of TB-adapted social protection interventions 
involving cash transfers in resource-constrained settings. 
 
Conceiving the intervention 
 
Intervention objectives 
The CRESIPT project aims to evaluate a socioeconomic intervention to support prevention and cure of TB in 
TB-affected households and, ultimately, improve community TB control. The CRESIPT socioeconomic 
intervention was developed over seven months in two contiguous suburbs in north of Peru’s capital, Lima: 
Ventanilla, 15 peri-urban shantytown communities in which our research group has been recruiting 
patients to an on-going cohort study for over a decade;15 and Callao, an area including 17 impoverished 
urban communities. 
The CRESIPT project was informed by our previous research,15 extensive expert consultation,132 and a 
systematic review133 of cash transfer interventions published in 2011.  
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We built upon an a priori conceptual framework reflecting the postulated pathways through which the 
intervention could lead to improved TB control in the study site (Figure 10, Page 95). The intervention 
outputs related to shared CRESIPT project and Peruvian National TB program goals: i. screening for TB in 
household contacts and MDR-TB in TB patients; ii. adhering to TB treatment and preventive therapy; and iii. 
engaging with CRESIPT social activities. Thus, our intervention targeted defined outcomes along the TB 
causal pathway. In TB patients, we aimed to improve early diagnosis and treatment, provide support to 
increase adherence to and completion of treatment, and achieve sustained cured. Amongst household 
contacts living with these TB patients, we aimed to prevent TB.  
The previous systematic review of cash transfer interventions was updated in 2014: Medline, Embase, 
Global Health and HMIC databases were searched from 1st January 2011 onwards using the term 
"Tuberculosis/economics"[Mesh] OR "Tuberculosis, pulmonary/economics"[Mesh] OR 
"Tuberculosis/prevention and control"[Mesh] AND "Economic support" OR "Cash transfers”. This search 
found only one randomized controlled trial of economic support to improve tuberculosis treatment 
outcomes.18 Other necessary and informative literature on economic interventions did not meet inclusion 
criteria for this systematic review because it either related specifically to HIV/AIDS (such as the IMAGE 
study)151 or was limited by having no control group or impact assessment.80,152 
A consultation process was undertaken to inform the project and its scope: a total of 135 formative 
activities were conducted including multi-sectorial meetings, focus group discussion (FGDs), semi-
structured interviews, evidence reviews, and other expert consultations (Table 14, Page 92, and Figure 11, 
Page 96). Specifically, with regards to qualitative work with intervention patients and household contacts, 
an exit interview was conducted at 24 months that involved the patient and invited household members 
during a household visit. The interview detailed their evaluation of the socioeconomic intervention both 
qualitatively in free text comments and quantitatively through ranking the importance of the different 
elements of the intervention (e.g. cash transfers, household visits, TB Club, educational workshop, and 
interactions in the health post) for preventing and curing TB. In addition, at the end of each participatory 
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community meeting, feedback forms were completed by all participants about their favourite elements of 
the meetings and what could be improved (see Appendix 1). In addition to the TB-affected households, a 
civil-society of ex-TB patients was formed and registered as an independent body (“LUPORFAT” – Lucha Por 
Familias Afectadas por TBC / Advocates of families affected by TB). Members of the civil society were 
trained to assist in the running of day-to-day project activities and given responsibility for patients within 
their community. Civil society members also led the participatory community meetings. We conducted 
monthly meetings concerning the project and the intervention’s uptake and acceptance with round table 
discussions, brainstorming, and problem solving about how to refine and improve the intervention to be 
both more accessible and acceptable to TB-affected families in the locality.  
Table 15 (Page 93) summarises the critical review of the available evidence that occurred during the 
planning process, and the manner in which this review subsequently informed the main operational design 
and implementation decisions relating to some of the main aspects of the cash transfer intervention, 
including: existing cash transfer schemes, conditionality, and transfer size.  
Thus the planning process involving previous research, extensive expert consultation, and systematic 
reviews of cash transfer interventions led to the design of a novel social protection intervention that aimed 
to be locally-appropriate, feasible and sustainable, and consisted of:  
 economic support: conditional cash transfers to reduce TB vulnerability, incentivise and enable care; and 
 social support: household visits and participatory community meetings for information, mutual 
support, stigma reduction, and empowerment.  
The participatory community meetings, which are reported separately, consisted of an interactive 
educational workshop concerning issues surrounding TB and household finances, and a “TB Club” in which 
participants shared TB-related and other experiences in a support group format specifically adapted to the 
local setting.  
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Acceptability 
To characterise operational challenges and the participants’ perspectives, we performed an acceptability 
assessment using a mixed-methods approach. This involved the collection of quantitative and qualitative data 
from participants, a civil society group of ex-patient community representatives, CRESIPT project staff, and 
local and regional Peruvian TB Program staff and co-ordinators. 
Ethical Approval 
Approval was granted by the ethics committees of the Callao Ministry of Health, Peru; Asociación Benéfica 
PRISMA, Peru; and Imperial College London, UK. All interviewed participants gave written informed consent to 
participate in the study and for subsequent publication of anonymised data. 
Sample Size 
The main outcome of this preliminary work of the CRESIPT study (reported elsewhere) was completion of 
TB preventive therapy in household contacts of TB patients. TB patients had an average of five contacts and 
25% of those eligible for TB preventive therapy completed it.15 Therefore, a priori, we calculated that 312 
patients would give 80% statistical power to detect a 33% increase in the primary outcome comparing 
intervention versus control households with two-sided 5% significance. The 312 patients recruited were 
randomly assigned in a 1:1 ratio to the intervention arm (normal standard of care from the National TB 
Program plus socioeconomic intervention) and control arm (normal standard of care from the National TB 
Program). 
Designing and implementing the intervention 
Designing the conditional cash transfers 
Targeting: to provide evidence to assist national TB programs considering implementing TB-related 
socioeconomic interventions, our intervention exclusively targeted TB-affected households (i.e. was “TB-
specific”) rather than targeting all households living below the poverty line. The reasons for this decision were: 
encouraging results from the TB-specific ISIAT project;15 the urgent need for impact assessment and 
81 
 
operational evidence for TB-specific socioeconomic interventions; the lack of existing TB-specific or TB-
sensitive socioeconomic initiatives with which to feasibly collaborate in Peru; and the achievability of focusing 
on relatively small numbers of TB patients versus much larger, operationally unmanageable numbers of people 
at risk of TB in the wider community. In addition, it was expected that by working exclusively with TB-affected 
families we would generate evidence concerning those sections of the community most at risk of TB. 
Cash delivery strategy: Cash transfers directly into bank accounts were selected as the most locally-
appropriate way to deliver economic support because in the impoverished shantytown communities of the 
study site there were many: local bank agencies; food or material vouchers had poor accessibility and 
acceptability; direct cash transfers posed a security risk; and transfers using mobile-phone technology 
potentially overlooked the most vulnerable patients153 and were prone to handset loss/theft, damage, or 
faults. 
Cash transfer size: Deciding on the size and duration of cash transfers was difficult because this has varied 
considerably in past projects.154,155 Learning from similar regional projects,154 our local catastrophic costs 
findings,19 and ongoing liaison and site visits from key policy-makers from WHO, Pan-American Health 
Organisation, and the World Bank, we aimed to completely mitigate TB-related direct out-of-pocket 
expenses, which was expected to be equivalent to 10% of median TB-affected household annual income in 
the study site.19 This amount was: empirically believed to be too small to act as a perverse incentive;147,156 
affordable for a TB program in a resource-constrained country (expert opinion suggests that a 
socioeconomic intervention that adds less than 50% to the cost of biomedical treatment but reduces TB risk 
by 30-40% would be likely to justify policy change and widespread implementation);92,157 large enough so 
that poverty-related TB risk factors in TB-affected households may be reduced; and that incentivized and 
enabled TB-affected households to achieve the shared goals of the Peruvian National TB Program and 
CRESIPT project.  
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Cash transfer timing: We designed the intervention so that cash transfers would be provided throughout 
treatment but weighted towards the first two months, when TB-affected households incur the majority of 
hidden costs (Figure 13a, Page 98, and Figure 13b, Page 99).11,30,87  
Cash transfer conditions, levels, and responsiveness: We stratified cash transfer incentives into “double” 
and “simple” incentives. Double incentives were made for meeting the condition with “optimally” (i.e. 
monthly adherence missing less than two daily tablets). Simple incentives were made for meeting a 
condition “acceptably” (i.e. monthly adherence in which two or more tablets had been missed but the 
patient had not abandoned treatment). Figure 12 (Page 97) summarizes seven different potential scenarios 
of TB patients and the total amount of cash transfer incentives they would receive. Were a participant to 
receive all the double incentives available throughout treatment, they would receive a total of 230 US 
Dollars; for all simple incentives, they would receive a total of 115 US dollars (Figure 14a, Page 100, and 
Figure 14b, Page 101). In situations in which TB treatment routinely extended beyond 6 months, such as 
HIV-TB co-infection (9 months) or multi-drug resistant (MDR) TB (18 to 24 months), cash transfers 
continued throughout the duration of treatment. The decision to stratify simple and double incentives was 
taken in order to encourage a positive feedback loop of behaviour change through graded incentives whilst 
increasing the opportunity for vulnerable patient groups to receive cash transfers even when they could 
not achieve optimal behaviour.  
Implementation of the conditional cash transfers 
Banks: Of 10 banks visited, formal meetings were organised with four that aimed to: create a relationship with 
the bank to achieve sustainable cash transfers throughout the study; identify charge-free appropriate 
accounts; create a “virtual” way of opening accounts to minimize paperwork, time spent “in branch”, and 
travel-related patient costs; establish a mutually suitable day on which to accompany patients to open 
accounts; and to clarify the bank’s accessibility in our study sites (i.e. branches and agencies).  
Logistical concerns of the banks: The banks we consulted raised similar concerns about the proposed 
intervention, including: infection risk; cash transfer flow; and difficulties opening accounts with patients who 
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have no national identification, fixed abode, or are illiterate. We initially chose one bank that appeared to be 
more likely to overcome these issues because it had a social inclusion department with previous involvement 
in successful microfinance initiatives. 
Opening bank accounts: Recruited patients with a negative sputum smear microscopy test (indicating low 
infectiousness) were accompanied by our project staff to open a bank account. The account holder’s details 
were then relayed to our project office with a copy of the bank’s original documents. In the case that the 
patient was a minor, did not have legal capacity, wished for another household member to be the named bank 
account holder, or had prolonged sputum smear positivity, then a household member was selected by the 
patient or household to be the named bank account holder. Patient transport and time costs were reimbursed 
by our project.  
Cash transfer administration: The patient’s incentive card (Figure 13a, Page 98, and Figure 13b, Page 99) was 
updated by the field nurses when each condition was achieved. Confirmation of completion was made through 
liaison with the patient, review of CRESIPT project records (e.g. participatory community meeting attendance) 
and Peruvian National TB Program records and treatment cards (e.g. medication adherence verification). 
Signed incentives cards were returned to a project administrator who double digitized the data. Thus, a weekly 
list of patients, their bank account details, and required transfers was generated. The same day, this list was 
submitted electronically to a member of the social inclusion department of the bank, and the virtual transfers 
made. The transaction codes and receipts generated were double digitized in the CRESIPT project database 
and delivered to the patients in the health post by the CRESIPT field nurses. 
Recruitment 
From February to August 2014, we expanded project activities from 2 to 32 communities. As per the a priori 
sample size calculations and study protocol, 312 consecutive TB patients from the study site were invited to 
participate of whom 149 were randomized to receive the socioeconomic intervention. 12/149 (8%) patients 
declined to participate, 2/149 (1%) died prior to recruitment, and 2/149 (1%) were recruited and subsequently 
did not complete follow up. Thus, 133/149 (89%) were recruited and participated throughout the study period. 
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The number of patients declining to participate was higher in urban than in peri-urban communities (15% [95% 
CI 6-23] versus 5% [95% CI 1-10%] respectively, p=0.04). Of the 133 participants, 9/133 (7%) had MDR TB, 
5/133 (4%) were HIV positive, and 7/133 (5%) were diabetic. 
Cash transfers achieved up to 1st July 2015: Of 1299 potential cash transfers, 964 (74%) were achieved (of 
these, 885/964 [92%] were achieved optimally and 79/964 [8%] sub-optimally), 259 (19%) were not achieved, 
and 76 (7%) were yet to be achieved. Thus, 964 conditional cash transfers totalling 61,120 Peruvian Soles 
(20,373 US dollars) were made to TB-affected households for meeting the conditional goals of the Peruvian 
National TB Program and CRESIPT project (Figure 14a, Page 100, and Figure 14b, Page 101). The average cash 
transfer amount received by each TB-affected household over the course of the intervention was $173 USD. 
 
Lessons learnt and persisting knowledge gaps  
The implementation and acceptability assessment identified strengths and limitations of our theoretical 
approach during the design of CRESIPT. The lessons that emerged are grouped into successes, challenges and 
refinements in Table 16 (Page 94) and, ultimately, allowed us to identify persisting knowledge gaps in this 
field (Box 2, Page 102).  
Successes 
This project generated evidence that conditional cash transfers to TB patients were logistically achievable in 
impoverished shantytown communities of northern Lima/Callao, Peru. The intervention considerably 
supplemented small monthly food baskets given unconditionally to TB patients by the Peruvian National TB 
Program.  
Through regular steering meetings, focus group discussions, and contact in the health posts, strong 
collaboration was achieved between our team, banks and the Peruvian National TB Program:  
“The CRESIPT project and Peruvian National TB Program are complementary and should continue to 
support each other in a common goal.” [Peruvian National TB Program Regional Chief].  
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Such ongoing collaboration and adaptation to stakeholder and participant feedback helped the project to 
be more locally-appropriate, responsive, and patient-centred. 
The conditional cash transfers were facilitated by multi-sectorial collaboration including with the bank’s 
social inclusion department. Multiple, regular, simultaneous, virtual cash transfers were achieved through 
online banking with a digital record reduced the likelihood of fraud. Because field team staff were not 
directly carrying or giving cash or cash-equivalents (such as cash vouchers or cheques), cash transfers were 
a secure method of providing incentives. The majority of participants did not have bank accounts158 and 
some patients described the act of opening a bank account as empowering:  
“…especially for female patients, who are not normally the financial decision-makers of the 
households in these communities” [CRESIPT Project Nurse Technician] 
The social protection intervention was holistic and household-centred with the economic dimension of cash 
transfers being complemented by social activities including household visits and participatory community 
meetings.159 In addition to TB prevention and control messages, an educational component was an 
important element of the participatory community meetings, in which participants were involved in 
educational activities concerning: managing a household budget; spending and saving responsibly; and how 
to meet the conditions for cash transfers. This financial education was highly rated by participants and 
perceived as an ethically sound accompaniment to cash transfers by CRESIPT project staff and TB-affected 
households:  
“I understood and learnt more, and saw that I was not alone” [TB-Affected Household Member] 
“The meetings generated good solidarity and camaraderie” [TB-Affected Household Member] 
Our experience is consistent with reports that financial incentives should be complemented by education or 
“social marketing” if health objectives are to be achieved.124 Further research is needed to investigate the 
relative importance of health and financial education on the impact of cash transfer interventions aiming to 
improve health.  
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Challenges and refinements 
The lack of published evidence of similar studies was particularly challenging for the implementation of TB-
specific cash transfer incentives in resource-constrained communities. 
Cash transfer targeting: The significantly higher number of patients declining to participate seen in the 
urban rather than peri-urban communities may have been due to the fact that CRESIPT project activities 
were new in this area or reflect distinctions between these communities: 
“We don’t fully understand the demographic differences and challenges between the urban and 
peri-urban communities” [CRESIPT Project Investigator] 
The field staff reported that some patients were not willing to participate because: i) they thought that 
CRESIPT project staff were part of a governmental body; ii) they did not want to register their true address 
with either the TB program, a bank, or the CRESIPT project in order to keep “under the radar” [CRESIPT 
Project Nurse] especially those formerly-incarcerated or involved with “pandillas” (drugs gangs); iii) they 
did not wish our team to visit their home because their household was unaware of their diagnosis or they 
frequently moved location; or iv) the incentives were insufficient to match the money they lost for 
participating in project activities and, perhaps more importantly, for continuing on their treatment. In 
addition, patients with recognised “high-risk” factors for treatment default such as prolonged treatment 
courses (e.g. MDR-TB and/or HIV), mental illness, drug use, homelessness, or being formerly-incarcerated 
were difficult to recruit and retain. Because these patients did not consent to participate we could not 
formally characterise their reasons for declining. This lack of engagement and formal feedback is 
concerning given that such groups may have benefited most from the intervention.  
“Conditions are appropriate but you need to provide additional support to those people who find it 
harder to meet those conditions.” [Ex-TB Patient Civil Society Representative] 
“Some patients would never open a bank account because they don’t want to register their name.” 
[CRESIPT Project Nurse] 
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“[A negative aspect of the CRESIPT project intervention is] giving an economic incentive to a patient 
with drug-dependency and for that matter any other benefit/incentive such as food baskets (which 
some of these patients sell to buy drugs).” [Peruvian National TB Program Nurse] 
To combat some of these issues, extra care was taken during consent to reassure potential participants that 
the CRESIPT project team is a non-governmental research organisation with no connections to the justice 
system and that no project activity, especially household visits, was mandatory. In an attempt to address 
the needs of participants with HIV and/or MDR-TB, we explicitly specified that cash transfers for adherence 
were provided throughout treatment, regardless of treatment duration. This longevity meant that TB-
affected household support, staff-household relationship, and financial benefits of the cash transfers were 
refined to be more equitable and responsive to the ongoing needs of patients with HIV and MDR-TB.  
Hard-to-reach populations and/or difficult urban settings, such as those in which our intervention was 
implemented, may be characterised by violence, drug use and severe marginalisation that are also 
associated with TB. Future studies may further investigate the barriers, feasibility and impact of delivering 
TB-specific social protection interventions to challenging, vulnerable groups in such settings. 
Cash transfer delivery strategy: We changed bank-provider because the initial bank-provider: had limited 
geographical accessibility; provided inconsistent information “in branch” (resulting in some patients opening 
accounts with maintenance fees); was reported during feedback sessions to have been stigmatizing towards 
patients, not due to TB (the branch staff were unaware of patients’ diagnoses) but possibly due to other 
sociocultural factors such as poverty or appearance; and introduced account maintenance charges to 
previously charge-free accounts. 
 “Some patients lost faith in the project due to the hidden bank charges” [CRESIPT Project Nurse] 
The new bank-provider, while not having a specific social inclusion department, provided improved coverage 
and accessibility because of a greater density of agency micro-branches in local shops that facilitated 
participant transactions. While the new bank-provider overcame the challenges described above, these 
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experiences have led us to question whether banks are the most appropriate delivery strategy. Indeed, 
conditional cash transfer programs in Sub-Saharan Africa have predominantly used specified pay points to pay 
participants in cash rather than banks which may be less accessible to the poor and may have user fees.160 
However, banks have been the favoured partner agent in existing conditional cash transfer programs in Peru 
(JUNTOS), Brasil (Bolsa Familia), and Mexico (Progresa) with the co-ordination of national cash transfer 
programs being centralised through national banks in these countries.160 This level of coordination may only be 
suitable in countries with comparatively developed financial infrastructure, information and communications 
technologies, and accessibility to bank branches or micro-agencies.155 We have reviewed other modalities of 
conditional cash transfers in greater detail elsewhere.133 Future research into implementation of 
socioeconomic interventions may compare the effectiveness and cost-effectiveness of cash delivery 
mechanisms including mobile phone vouchers, mobile banking, automated or other pay points, or innovative 
strategies,155,161 for which rigorous evidence is currently lacking. To achieve optimal impact, implementers of 
conditional cash transfer programs may work more closely with the local communities and civil societies to 
establish how a program can be adapted to be appropriate and acceptable in that specific setting. 
Cash transfer size: During focus group discussions, the internal research committee debated what the most 
important objective of cash transfers is: mitigating TB-related costs; avoiding catastrophic costs; or reducing 
poverty-related TB risk factors. This confounded deciding the cash transfer amounts. To address this challenge, 
we analysed TB patients’ costs, which demonstrated that direct out-of-pocket expenditure was 10% of that 
household’s annual income.11 These results, together with additional data characterising annual household 
income for TB-affected households in the study site, informed the cash transfer amount necessary to match 
direct out-of-pocket expenditure and subsequently avoid catastrophic costs. The optimal cash transfer size is 
likely to depend on the intervention setting and proposed outcomes of the intervention. This will require 
baseline evaluation of local TB-related costs prior to planning for and implementing cash transfers of suitable 
amounts. Further research is required to evaluate how cash transfer size affects intervention impact and cost-
effectiveness.162 It is noteworthy that the strategy we adopted in this research was a “costs-mitigation” rather 
than a “poverty-reduction” strategy and involved a cash transfers amount that was appropriate and feasible 
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for the local setting. While long-term poverty reduction would be an appealing additional goal, this would 
likely require greater socioeconomic support than national TB programs could afford.  
Cash transfer timing: During focus group discussions, the delay from incentivized behaviour to cash transfer 
was noted as a barrier to achieving project conditions due to the lack of a tangible “reward” and 
accompanying positive reinforcement loop. For example, when a household attended a participatory 
community meeting, it could be one to two weeks before they received the corresponding cash transfer. 
“Patients want immediate and tangible gratification on the same day as they complete their 
condition” [Ex-TB Patient Civil Society Representative] 
Cash transfers were initially delayed due to the flow of information from the field, to the research office, to 
the bank-provider. While cash transfer flow improved during the project, patients and households stated 
that such delays made household budgeting difficult: 
“Due to the initial cash transfer delays, some patients didn’t get the money when they most 
needed it” [CRESIPT Project Nurse] 
Consequently, we increased the speed of the cash transfers and plan to instigate a system in which on the 
same day that a household attends a community meeting, they received a small high-protein food basket 
and a high-quality certificate-like voucher detailing the amount and date by which the cash transfer will be 
made. 
Participants reported that they would prefer to receive cash transfers at the beginning of the month for their 
adherence in the subsequent month rather than wait until the end of the month. As has been reported in 
other settings,163 the waiting was perceived as financially stressful and, on occasion, demoralising. Learning 
from this setting-specific qualitative feedback, in the planned CRESIPT study in these same communities, we 
will combine unconditional monthly cash transfer provided to all TB patients taking treatment with 
supplementary conditional cash transfers for meeting project and National TB Program conditions. 
Furthermore, we have self-imposed penalties on our project if incentives do not reach the patient’s bank 
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account within one week of confirmation that the condition has been met. Specifically, if a delay occurs, their 
cash transfer is doubled.  
Cash transfer conditions, levels, and responsiveness: Project conditions requiring involvement of “100%” of the 
TB-affected household in order to receive the cash transfer (e.g. attendance at participatory community 
meetings) were hard to achieve. In addition, the amount of these cash transfers was fixed and independent of 
household size (see Figure 12, Page 97) and thus felt to be inequitable because larger households received a 
lower cash transfer amount per household member. There was, therefore, a perceived challenge in balancing 
operational simplicity (e.g. fixed-amount incentives) while responding to patient household needs (e.g. 
variable incentive depending on household size). Consequently, on the basis of this qualitative evaluation of 
the implementation process, we suggest designing relevant incentives to be more equitable and responsive to 
household size: a fixed amount added to the patient’s cash transfer for each member of their household 
completing the condition. In this way, larger households will receive the same amount per household member 
as smaller households.  
 
Conclusions 
 
A novel TB-specific socioeconomic intervention was: designed through multi-sectoral collaboration coupled 
with evidence from a systematic review; refined during implementation through community participation, 
engagement and acceptability feedback to meet patient and household needs; and proved to be feasible in an 
impoverished, challenging environment. The intervention is now ready for impact assessment, including by the 
CRESIPT project. Further lessons from CRESIPT will aim to assist TB control programs to effectively implement 
the recent global policy change of including socioeconomic support as part of TB control activities.  
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Table 14: CRESIPT consultation process 
 
Formative 
Activities 
Attendees Events 
(n) 
Particip- 
ants (n) 
Notes / details 
A. Analysis of 
evidence 
 
CRESIPT project research team and international 
collaborators from Imperial College London,  
London School of Hygiene & Tropical Medicine,  
and John Hopkins School of Public Health 
3 28 Analysis and publication of ISIAT project results in 201115 
WHO-commissioned systematic review of conditional cash transfer  
schemes’ impact on TB control in 2011133 plus updated review in 2014 
B. Expert  
consultation 
Peruvian National TB program chiefs 
 
JUNTOS (www.juntos.gob.pe) 
(Peruvian conditional cash transfer program)** 
 
WHO Stop-TB partnership 
 
World Bank 
10 
 
1 
 
 
3 
 
2 
8 
 
5 
 
 
5 
 
3 
Steering meetings with regional and national TB Program coordinators 
 
Discussed logistics and minimal impact evaluation of conditional cash 
transfers for health/education to female heads of rural households164  
 
Ongoing meetings and site visits 
 
Ongoing meetings with senior World Bank economists especially  
relating to cost-effectiveness considerations  
C. Symposia 
and 
conferences 
International multi-sectoral researchers 
(including World and Pan-American Health  
Organisation members) 
3 30 “Social protection interventions for TB control”, UK, 2012132 
WHO led policy consultation on social protection for TB,Brazil, 201314  
TB Union World Lung Health conference in France, 2013 
D. Focus group 
discussions  
(FGDs) 
CRESIPT multidisciplinary team 
 
Ex-TB patient civil society “LUPORFAT” 
 
Key NGO Stakeholders 
 
CRESIPT project participants  
 
Peruvian National TB program health post staff 
 
Banks 
9 
 
4 
 
4 
 
19 
 
18 
 
6 
10 
 
13 
 
5 
 
20 
 
12 
 
5 
www.ifhad.org  FGDs with the CRESIPT field team research personnel  
 
Registered “Junta Directiva” (board of directors) of ex-TB patient 
community representatives “Lucha Por Familias Afectadas Por TBC” 
www.prisma.org Structured interviews and FGDs 
 
Including participatory community meetings and training of facilitators 
 
Multi-disciplinary teams: co-ordinators, doctors, nurses, and technicians 
 
Account executives and social inclusion department representatives 
E. Field team  
Meetings 
CRESIPT multidisciplinary team 34 
 
11 Covered operational field logistics and acceptance of the intervention 
F. Steering 
committee 
CRESIPT multidisciplinary team & international 
Collaborators 
19 6 Twice monthly committee review of published literature (including 
systematic review) and discussion of financial, methodological and 
statistical design issues and potential intervention improvements 
TOTAL NA 135 NA NA 
*mean average **We were unable to integrate our urban TB-specific intervention with JUNTOS’ existing rural cash transfer scheme. While JUNTOS may be TB-inclusive (i.e. 
some TB patients will receive incentives as they are below this poverty threshold), it is neither TB-sensitive nor TB-specific.133 Abbreviation: FGD = focus group discussion
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Table 15: Available evidence and CRESIPT project operational decisions relating to cash transfers 
 The available evidence - what do we know? Operational decisions for implementation of the CRESIPT project intervention 
Cash  
transfer 
schemes 
 Cash transfer schemes were implemented in Latin America in the 
1990s to tackle the socioeconomic consequences of financial 
crises.134 Schemes include: Bolsa Familia (Brasil, 1995); 
Oportunidades (Mexico, 1997); Red de Protección Social 
(Nicaragua, 2000-2005); Bono de Desarrollo Humano (BDH Ecuador, 
2004); Red Solidaria (El Salvador, 2005); and JUNTOS (Peru, 2005).  
 Our systematic review revealed only one controlled trial of TB-
specific cash transfers from South Africa that showed no significant 
increase in successful TB treatment outcome.18 During treatment, 
vouchers (15 US Dollars) that could be exchanged for foodstuffs 
were given to patients by local health post nursing staff. The 
authors opted for vouchers over cash due to: posing a lower 
security risk; not being able to be spent on unhealthy items such as 
alcohol or cigarettes; being easy to monitor; and “public health 
sector clinics would not have bank accounts, making electronic 
transfers difficult”.18 
 We investigated the use of food or other vouchers/cards but found very few 
existing systems in the study site. Those that were in place could only be 
redeemed in supermarkets (felt in FGDs to be inappropriate for the study 
population due to infrequent use, limited access, and higher costs of goods). 
 Based on our experiences and the limited published evidence, we opted for 
a bank cash transfer scheme. Bank transfers reduce the likelihood of fraud, 
robbery or security risk (a concern in impoverished shantytowns in Callao, 
Peru)18,148 and are reliable for maintaining accurate transfer records for cost-
effectiveness analysis. We also felt opening a bank account and having 
freedom of choice to decide how transfers were spent was empowering165   
 We decided not to impose conditions on how the cash transfers were spent. 
Successfully funded social protection interventions related to TB (especially 
MDR TB) have mainly focused on mitigating non-medical direct costs 
associated with having TB such as food or travel.80,165 There is some evidence 
that even when money rather than food vouchers is given as a form of social 
protection, it is commonly spent on food and travel costs anyway.163  
Condition- 
ality of  
cash 
transfers 
 Cash transfers can be unconditional, conditional (requiring specific 
behavioural, education or health actions) or combined.155,166  
 Unconditional cash transfer schemes include: Ecuador’s BDH 
targeting those below poverty threshold or by location;154,167 and 
village bankloans for TB-affected households in Cambodia.168  
 Conditions can be “hard” (if the condition is not met, the transfer is 
not made) or “soft” (less stringent conditions where transfers are 
made even when a condition is unmet). Soft conditionality may be 
preferable in settings with poor health infrastructure.134,166,169  
 Perú has an exemplary, well-established and organised National TB program. 
Learning from ongoing collaboration with regional heads of the TB program, 
we decided that our cash transfers conditions would relate to National TB 
Program treatment and prevention goals and selected project activities.  
 We chose to use conditional cash transfers that mixed both hard and soft 
conditions to be more inclusive: “hard” in that if participants met the 
condition with “perfect behaviour” then a double cash transfer was provided 
and “soft” in that if participants met the condition with adequate behaviour, 
then a simple cash transfer incentive was provided (Figures 13a and 13b).  
How much 
cash to 
give  
 Minimal evidence exists on the size of cash transfers. In Latin 
America, total amounts have varied widely in previous projects:  
6-10% of annual income in Ecuador;154 21.8% in Mexico; and 29.3% 
in Nicaragua.155   
 We aimed to establish a cash transfer amount that was too small to act as a 
perverse incentive,147 but large enough so that poverty-related TB risk factors 
in TB-affected households were reduced and the households were both 
incentivized and enabled to achieve National TB program and project goals. 
When to 
give cash 
 Most initiatives deal more with poverty than a finite illness such as 
TB, so evidence of duration and frequency of TB-specific cash 
transfers is scarce. Longer duration and more frequent cash 
transfers may have greater impact in TB-affected households.17 
 Our previous work in the study setting showed that hidden TB costs 
were mainly incurred pre-diagnosis or early in treatment.11 
 We decided to provide the majority of the cash transfer incentives in the 
intensive treatment phase (the first two months of treatment) and to continue 
monthly cash transfers specific for treatment adherence throughout 
treatment. This meant the intervention was designed to increase equity for 
people with TB-HIV co-infection and MDR TB whose treatment lasted longer 
than six months. 
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Table 16: Successes, challenges, and refinements of the cash transfer incentive dimension of the socioeconomic intervention. 
 Successes Challenges Refinements 
New 
evidence 
New experience and evidence was generated 
that TB-specific cash transfers for TB-patients 
were feasible in this study setting 
There was a lack of available evidence and thus 
clarity when prioritising the output of the cash 
transfers in these TB-affected households. Thus, 
deciding on the cash transfer amounts and timing 
was difficult 
Following previous and updated analysis of hidden 
costs and income of TB-affected households,11 cash 
transfer amounts were increased with the aim of 
reducing their poverty-related TB risk factors 
Collabo-
ration 
 
 
 
There was strong multi-sectorial collaboration 
with Peruvian National TB Program and bank 
staff, allowing multiple, virtual cash transfers to 
be made and recorded, reducing fraud and 
security risks 
Account maintenance charges were introduced 
by the bank during implementation of the 
intervention and delays in cash transfers eroded 
participants’ trust in the project 
We changed our bank service provider: the new 
bank had better accessibility and no charges. We 
self-imposed penalties on our project for late cash 
transfers (participants gained additional transfers) 
Cash 
Transfers 
Cash transfers lasted throughout treatment, 
increasing equity for people with TB and HIV co-
infection or MDR TB, whose treatment duration 
extended beyond six months 
 
Opening a bank account was a first-time 
experience for many of the participants and 
qualitative participant feedback suggested that 
this was perceived as an empowering action, 
especially for female members of the household 
who have previously been shown to be a 
vulnerable subpopulation in the study setting.5 
As a research team, we had limited experience of 
cash transfer interventions or working with new 
urban study communities 
 
Feedback suggested that patients would prefer 
immediate gratification for completion of 
conditions rather than delayed cash transfer 
bank payments 
 
Project conditions requiring all members of the 
TB-affected household to participate were poorly 
achieved and not equitable due to different 
household sizes 
Achieving a balance between operational simplicity 
and complex TB-affected household needs was 
challenging 
 
Immediate incentives were provided for attending 
participatory community meetings (including food 
baskets and high-quality vouchers documenting 
the date and amount owed to the participant)  
 
We combined conditional and unconditional cash 
transfers. Conditions requiring household 
participation were altered to be responsive to 
household size: incentives given were refined to be 
given per household member involved 
Inclusive-
ness and 
high risk 
groups 
The intervention was holistic and household-
centred because, in addition to cash transfers, it 
provided community meetings consisting of 
educational workshops (covering themes such as 
TB treatment, transmission, prevention and also 
financial themes such as responsible household 
budgeting in an interactive manner) and TB 
Clubs (mutual support to reduce stigma and 
increase empowerment, reported separately) 
“High risk” patients in more urban communities 
were difficult to engage with (especially the 
formerly-incarcerated, drug- or alcohol-
dependent, and gang members) 
Participatory community meetings for patients 
with MDR TB were established and increasing 
social support was provided to other high risk 
patients (including the homeless, drug or alcohol 
dependent, those with poor adherence and/or lack 
of engagement with our project) 
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Figure 10: Conceptual framework of the conditional cash transfer scheme within the CRESIPT project 
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Figure 11: Flow diagram of CRESIPT project activities during planning, implementation, and refinement of the social protection intervention. 
Abbreviations: MDT = multi-disciplinary team; NTP = National TB Program. *Includes documents of potential interest reviewed or used as references. **These weekly 
meetings have been an ongoing part of team activities for the past decade and are included here to illustrate when they focused solely on the CRESIPT project 
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Figure 12: Cash transfer received by participants in seven different potential scenarios during intervention implementation. Note: Typically in 
Peru, treatment of TB in people with non-MDR TB has a duration of 6 months, in people with HIV-TB co-infection treatment lasts 9 months, and in people with MDR 
TB treatment lasts 24 months. Key: = condition optimally achieved and double incentive cash transfer provided; X = condition not achieved thus no incentive 
cash transfer given/paid
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Figure 13a: Details of the operational conditions to be met in order to receive double 
incentives 
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Figure 13b: Details of the operational conditions to meet in order to receive simple 
incentives 
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Figure 14a: Proportion of patients optimally achieving (double incentive), adequately achieving (simple incentive), and not yet achieving 
project conditions. *This condition was achieved when the patient finished their treatment and 100% (double incentive) or ≥80% of the household contacts 
who were eligible for and started preventive therapy then finished preventive therapy. At the time of writing (July 2015), there remain some patients with 
prolonged treatment courses (predominantly those with HIV-TB co-infection or MDR TB) are still ongoing on treatment.  
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Figure 14b: Total amount provided to patients by conditional cash transfers in total and for each condition achieved. *This condition was 
achieved when the patient finished their treatment and 100% (double incentive) or ≥80% of the household contacts who were eligible for and started preventive 
therapy then finished preventive therapy. At the time of writing (July 2015), there remain some patients with prolonged treatment courses (predominantly those 
with HIV-TB co-infection or MDR TB) are still ongoing on treatment.
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Box 2: Lessons learnt and persisting research gaps 
Lessons learnt Research gaps 
Social protection interventions for TB 
control require inter-sectorial 
collaborations  
 What are the most effective and cost-effective partnership models for welfare and TB control bodies?  
 What are the best ways to integrate poverty reduction strategies and biomedical activities for TB 
control? 
  
TB-specific conditional cash transfers are 
feasible and safe, but logistically complex 
 What is the role of conditions in achieving the intervention objectives? 
 Are conditional, unconditional or combined cash transfers preferable and how does this depend on the 
settings in which the cash transfer program is implemented?161 
 What conditions are too hard to achieve for TB patients despite being well rewarded? 
 What is the best way to balance the conditions for the cash transfers in order that they reflect both the 
priorities of patients and their households, and the priorities of researchers and policy makers?162 
 What is the role of the size and timing of cash transfers on the impact of the intervention? 
 What is the effectiveness and cost-effectiveness of different delivery mechanisms? 
TB-specific conditional cash transfers can 
be challenging to deliver to difficult-to-
reach populations 
 What are the optimal ways to adapt conditional cash transfer settings targeted at hard-to-reach 
populations in challenging urban environments characterised by violence, drug-addiction and 
marginalisation?  
 Should social protection interventions only be offered to high-risk patients or is it more cost-
efficient to offer them to all patients plus an enhanced intervention to high-risk patients? 
 Is cash without social support sufficient to reach high-risk-patients or is social support necessary? 
 
 
Health and financial management 
education are necessary and ethically 
appropriate  
 Would cash transfers have the same impact even without an educational component? 
 What is the empowering factor of the cash transfers to TB patients: 1) receiving cash; or 2) being 
acknowledged and seen as individuals with rights and needs? 
 What is the aspect of the social protection intervention most likely to impact on TB prevention and cure: 
a) the economic dimension of cash transfers; b) the social dimension of home visits and community 
meetings; or c) both? 
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Chapter 5: The economic effects of a socioeconomic intervention for 
TB-affected households: the CRESIPT pilot study, Peru  
 
At the time of writing (February 2016), this chapter is under review as a manuscript for publication 
with the European Respiratory Journal. As described in Chapter 4, with the support of the multi-
disciplinary Innovation For Health And Development team and the team leader and PhD supervisor, 
Dr Carlton Evans, the candidate led this project’s conception, design, implementation, and 
refinement of the intervention. In addition, the candidate led the data analysis, manuscript write-up, 
and dissemination of results. 
Following the implementation and refinement of the socioeconomic intervention, the next step was 
to analyse the effect of the intervention on mitigation of TB-related and catastrophic costs (using the 
innovative, clinically-relevant catastrophic costs threshold created in Chapter 3). 
 
Introduction 
 
In order to enhance TB control, the World Health Organisation’s (WHO) End TB Strategy mandates 
complementing the existing biomedical response with approaches that combat the financial burden 
of TB. Specifically, the strategy recommends providing social protection for TB-affected households 
and includes a target of zero TB-affected households incurring catastrophic costs by 2035.  
Previously, catastrophic costs were defined financially as TB-related out-of-pocket expenses that 
led to worsening impoverishment of TB-affected households. In recent research, we defined a 
clinically-relevant catastrophic costs threshold, demonstrating that TB patients from households 
that incurred total TB-related household costs of ≥20% of their household annual income were 
more likely to die, abandon, or not be cured by TB treatment.19 Additionally, this research 
suggested that such catastrophic costs led to as many adverse outcomes as MDR TB.19 This 
catastrophic costs’ threshold has been included by the WHO within a tool to estimate country-
specific TB-related and catastrophic costs of TB patients and their TB-affected households. The tool, 
which builds on the published “Tool to estimate patients’ costs”79 and includes measurement of lost 
income in addition to direct out-of-pocket expenses, is being piloted and rolled-out in sentinel 
countries in 2015-6.  
However, collecting such costs data is complex, labour-intensive, and thus may be logistically 
difficult for national TB programs to perform. A potential solution may be to collect data on other 
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indicators of financial weakening or shock, called “dissaving”, as part of catastrophic costs 
surveillance. Examples of dissaving include households using savings, taking out a loan, taking a 
child out of education, and/or selling household items or assets. Evidence is needed concerning the 
accuracy of dissaving as a proxy measure for catastrophic costs and its validity in the WHO costs 
tool.  
Social protection, such as cash transfer interventions, aim to reduce or prevent further poverty and 
vulnerability by improving people’s capacity to manage social and/or economic risks.131–138 
Socioeconomic interventions include social protection and may additionally aim to defray TB-
related costs, incentivise and enable care and reduce TB vulnerability. Social risks of having TB 
disease include TB-related stigma whereas economic risks include incurring TB-related costs. TB-
related costs may be considered in terms of national economic costs, health-system costs, and 
human costs. In the setting of Peruvian shantytowns, the human costs associated with TB are 
generally experienced and shared by all the members of the household in which someone receives 
TB treatment.15 In this manuscript we focus on costs experienced by TB-affected households that 
are henceforth referred to as TB-related costs.132–134,142 There is minimal operational research 
assessing the impact of socioeconomic interventions on mitigation of the effects of TB-related 
costs. Such interventions may be a cost-effective investment from a societal perspective170 through 
their potential ability to enhance TB control as part of the post-2015 End TB Strategy. 
Building on the findings of the Innovative Socioeconomic Interventions Against TB “ISIAT” study,15 
we designed a new more focused, clearly defined socioeconomic intervention aiming to support 
TB-affected households (i.e. be “TB-specific”) in order to better achieve TB prevention and cure.121 
During a household-randomized controlled study, we piloted this intervention in order to optimise 
its impact for the larger Community Randomized Evaluation of a Socioeconomic Intervention to 
Prevent TB (CRESIPT). Here we report the economic effects of this new intervention during the 
CRESIPT pilot study, including an evaluation of dissaving as a possible proxy marker for catastrophic 
costs and an assessment of the intervention’s impact on defraying TB-related costs and 
catastrophic costs.  
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Methods 
Participants, study setting, and description of the socioeconomic intervention are provided in 
greater detail in Box 3. 
Box 3: The CRESIPT Pilot study: Socioeconomic intervention methods, participant 
recruitment, and impact of the intervention  
 
  
Study methods15 
Study setting  
The study took place in 32 shantytown communities in Callao, Peru, with an estimated population of one million 
people.33 The annual TB notification rate across these communities was 206 new cases per 100,000 people between 
2011 and 2013,33,34 greater than the national rate of 95 per 100,000 people.27,35,36 
Intervention  
The intervention aimed to increase: i. screening for TB in household contacts and MDR-TB testing in TB patients;   
ii. adherence to TB treatment and preventive therapy; and iii. engagement with socioeconomic support activities. 
This integrated intervention consisted of:  
 Economic support component: conditional cash transfers throughout treatment to mitigate TB-related 
costs and thereby reduce TB vulnerability, incentivise, empower, and enable equitable access to care; and 
 Social support component: household visits and participatory community meetings for information, mutual 
support, stigma reduction and empowerment.  
The cash transfers of the economic component of the intervention were designed so that if a patient achieved all 
possible conditions and thereby received all possible cash transfers throughout treatment, this would largely defray 
their direct out-of-pocket expenses for their entire illness that were previously found to be 10% of annual 
household income in this study site.19,121 
Participants  
Inclusion criteria: any patient initiating treatment with the Peruvian national TB program for TB disease in health 
posts in the study setting was invited to participate between 10th February and 14th August 2014.  
Exclusion criteria: inability or unwillingness to give informed, written consent. For patients who were minors, a 
parent or guardian was asked to give informed, written consent and patients who were old enough were also 
invited to provide their assent to participate.  
After informed written consent, patient households were randomised to the intervention or control arm: 
 Control TB-affected households: TB-affected households in which a TB patient received the Peruvian 
national TB program standard of care only; and 
 
 Intervention TB-affected households: TB-affected households in which a TB patient received the Peruvian 
national TB program standard of care plus the socioeconomic intervention. 
Healthy control households: were randomly-recruited households not known to have TB-affected household members 
and recruited concurrently with TB patients. Potential healthy control households were randomly selected from maps 
of the 32 study site communities. Either this household or the nearest inhabited household to this location was invited 
to participate during a household visit. All available household members, regardless of age, were invited to participate 
in the study. Healthy controls were not matched to patients because the study aimed to characterise risk factors for TB 
outcomes including sex, age, and poverty.  
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General analysis of costs. Continuous data were summarized by their arithmetic means and their 
95% confidence intervals (CI) and compared with the Student’s t-test whether the data was Gaussian 
or non-Gaussian because this approach is considered to be robust for health economics data analysis 
(and facilitates comparison with previous studies).11 Furthermore, because of the skewed nature of 
some expenditure data, most median values were zero or close to zero limiting the descriptive 
usefulness of presenting median values. As described previously,19 any direct expenses, lost income, 
or annual income recorded as “zero” or missing was replaced with 0.5 Peruvian Soles per day i.e. the 
midpoint of zero and the lowest unit of measurement, 1 Peruvian Sol. Categorical data were 
summarised as proportions with 95% CI and were compared with the z-test of proportions. We 
Operational definitions of the key study variables (TB disease, TB treatment phases, TB costs, and 
dissaving) were used from our group’s published research19 as reported in Chapter 3. However, in 
addition to the existing study definitions, new definitions of novel study variables such as “dissaving” 
were also created (Box 4).  
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Box 4: Operational definitions 
  
TB Treatment Phases*  
Pre-treatment: the time from self-reported onset of TB-related symptoms until treatment initiation 
Intensive treatment phase: the initial phase of daily (or 6 days per week) TB therapy, usually the first two 
consecutive months of TB treatment 
Continuation treatment phase: the months following intensive treatment phase in which treatment is given 
three times per week, usually for four consecutive months 
During treatment: the intensive treatment phase plus the continuation treatment phase 
Entire illness: the time from TB-related symptom onset to the end of the continuation treatment phase 
TB Costsⱡ 
Direct medical expenses: costs of medical examinations and medicines  
Direct non-medical expenses: costs of natural non-prescribed remedies, TB-care related transport, extra food, 
and other miscellaneous expenses caused by the TB illness 
Direct (“out of pocket”) expenses: the sum of direct medical and non-medical expenses 25,79,96  
Lost income (indirect expenses): the income the patient estimated that the household lost due to TB illness or 
tuberculosis-related time off work since symptom onset and during treatment 25,79,96  
 
Total costs: direct expenses plus lost income 
TB-related costs: refers collectively to direct expenses, lost income, and total costs 
Income: the money earned by the household, stated monthly or annually 
Catastrophic costs: a threshold of total costs of the entire TB illness ≥20% of that household’s annual income, 
which were associated with a higher likelihood of TB patient death, abandonment, or TB recurrence in a cohort 
of TB-affected households from impoverished Peruvian shantytowns.19  
 
TB-related costs cohort impact: To estimate the impact of TB-related costs at a cohort level, TB-related costs 
are expressed as a proportion of average annual income of the entire study cohort of TB-affected households 
TB-related costs impact: To estimate the impact of TB-related costs at an individual household level, TB-related 
household costs are expressed as a proportion of the same household’s annual income 
 
Poverty and Dissaving 
Socioeconomic variables: relatively stable proxy poverty markers including: home ownership, highest patient 
education level, material that walls were composed of, material that floors were composed of, toilet services, 
electricity use, water facilities, phone ownership (landline and/or cell), fuel used to cook at home, TV 
ownership, radio ownership, cooker/stove ownership, and refrigerator ownership.  
Poverty score: a composite score using arbitrary units derived by principal component analysis (PCA) of all the 
socioeconomic variables15  
Dissaving variables: proxy markers of household financial weakening and shock that included household 
members having: taken loans (informal and formal); left education (e.g. to care for or accompany patient); sold 
or pawned household items; used savings; started a new or second job; been asked to eat elsewhere; been 
asked to move out or find other lodgings; and performed fund-raising events (e.g. buying and cooking food to 
sell to friends, family, colleagues, and others for a small profit) 
Dissaving score: a composite score using arbitrary units derived by PCA of all the dissaving variables  
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*These treatment definitions apply to all TB patients, irrespective of whether they had MDR TB or non-MDR 
TB. Peruvian National TB Program guidance recommends at least 18 months of treatment for MDR TB patients. 
Treatment is tailored to patients with MDR TB by a multi-disciplinary team according to their resistance profile 
and may not correspond to a specific “intensive” and “continuation” treatment phase. 
ⱡ Income, expenses, and costs are all measured in Peruvian Soles (average 1 US dollar equivalent to 2.9 
Peruvian Soles during the study period) at the household level unless otherwise stated.   
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Costs and poverty. A locally-validated questionnaire 15,19 was updated and used to interview patients 
and collect socio-demographic data concerning household income and expenses throughout TB 
illness. Interviews were conducted at baseline with TB patients in intervention and control arms, as 
well as healthy controls. For all patients, this baseline interview occurred prior to or at the time at 
which treatment commenced. All patients (but not healthy controls) were subsequently interviewed 
after 2, 4, 8, 12, 16, and 20 weeks. At all baseline and subsequent interviews, data was collected 
characterizing earnings, income, expenses, employment (paid or unpaid), days unable to work due to 
illness, additional household food expenditure due to TB illness (e.g. over and above normal food 
expenditure), and crowding since the previous interview. As per previous research,11 crowding was 
defined as both a continuous variable (number of people per room) and a dichotomous variable 
(percentage of households with greater than cohort median people per room). A final “exit” 
interview took place at 24 weeks or, in those who continued TB treatment beyond 24 weeks, at 28 
weeks of treatment. The baseline and exit interviews (but no other interview) included 
anthropometric measurement of height and weight, calculation of body mass index (BMI), and a 
detailed assessment of 13 key stable variables associated with socioeconomic position (Box 2). These 
variables were used to create a composite household poverty index score in arbitrary units using 
principal component analysis (PCA), as described previously.19 The Eigenvector loading values derived 
by PCA analysis were analysed in order to assess which of the socioeconomic variables contributed 
the most to - and thus had the highest discriminatory power to explain - the poverty score in this 
setting. The proportion of intervention patient households’ TB-related costs that were defrayed by 
the conditional cash transfers was calculated. Additionally, changes in poverty score and body mass 
index (BMI) from recruitment to the exit interview was analysed in order to evaluate the impact of 
the intervention on nutritional and other poverty-related TB risk factors. 
Dissaving. Elements of “dissaving” specifically related to the patient’s TB illness were also recorded 
at each interview (Box 4, Page 107), cumulative dissaving episodes (i.e. each separate occasion on 
which an element of dissaving occurred) were measured, and a composite dissaving score was 
derived by PCA from all of the dissaving variables.19 The dissaving score was measured as a 
continuous variable in arbitrary units with the mean dissaving score of the patient cohort being 0 
units. A higher score implied greater dissaving and thus implied that the TB illness was causing a 
greater financial challenge. The Eigenvector loading values derived by PCA analysis were analysed in 
order to assess which of the dissaving variables had the highest discriminatory power to explain the 
dissaving score in the setting (variables with higher Eigenvector loading values being more 
discriminatory). Univariate and multiple logistic regression analyses with stepwise exclusion of non-
contributory variables were used to assess the association between dissaving and socioeconomic 
variables including catastrophic costs. For these analyses the dissaving score was considered as a 
binary variable of higher than versus lower than average dissaving. This dissaving analysis tested 
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whether dissaving may be a possible proxy indicator of catastrophic costs (see Introduction to this 
chapter).29  
Data shown: Data concerning TB-related costs, catastrophic costs, and dissaving is shown for both 
intervention TB-affected households and control TB-affected households. Data concerning the effect 
of the socioeconomic intervention on defraying costs are only shown for the intervention TB-affected 
households. This is because control TB-affected households did not receive the socioeconomic 
intervention and thus their TB-related costs were not defrayed. 
Ethical approval: The project had ethical committee approval and all participants gave informed 
written consent prior to participation. 
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Results 
 
Participants. The recruitment period was from 10th February 2014 to 14th August 2014 when the a 
priori study sample size was reached and data collection on TB-affected household costs continued 
until 1st June 2015. Figure 15 (Page 121) shows TB-affected household recruitment and 
participation: 312 TB patients from separate households were invited to participate, of whom 90% 
(282/312) were recruited. Of these, 147 were randomized to the control arm and received normal 
standard of care only (“control TB-affected households”) and 135 were randomized to the 
intervention arm and additionally received the socioeconomic intervention (“intervention TB-
affected households”). Of the intervention TB-affected households, 98% (132/135) completed final 
follow-up. Nevertheless, all 135 intervention TB-affected households had TB-related costs data 
available for analysis. Healthy control households were randomly recruited from the same 32 study 
site communities concurrently with the TB-affected households. 98% (262/266) of healthy control 
household members gave informed consent and participated.  
Descriptive data. Baseline demographic data are summarised in Table 17 (Page 118), which 
compares all patients with healthy controls, and their households. There were no significant 
demographic differences between intervention and control patients or their households. TB 
patients’ household income in Peruvian Soles was lower during the intensive phase (1109 [95% CI 
1011-1206], p<0.0001) and maintenance phase (1155 [95% CI 1050-1261], p=0.004) than pre-
treatment (1316 [95% CI 1210-1421], Table 17, Page 118). Multiple logistic regression analysis 
revealed that being a TB patient versus healthy control was independently associated with being 
poorer (OR 1.7 [95% CI 1.2-2.4], p=0.002, Table 18, Page 119). 
Costs: direct expenses and lost income. Constituent direct expenses and lost income are summarized 
in Figure 16 (Page 122). Throughout the entire illness, non-medical expenses were greater than 
medical (67% [95% CI 65-68] versus 33% [95% CI 32-35] of total direct costs, p<0.0001), predominantly 
due to additional food and transport expenses during treatment. Direct expenses and lost income 
were higher during treatment than pre-treatment (direct expenses 7.1% [95% CI 6.2-8.1] versus 2.3% 
[95% CI 1.9-2.8] of average TB-affected household annual income, p<0.0001; and lost income 8.0% 
[95% CI 6.5-9.2] versus 2.2% [95% CI 1.8-2.6], p<0.0001). As a proportion of total costs during the 
entire illness, lost income was similar to direct expenses (48% [95% CI 48–52% versus 52% [95% CI 50-
54], p=0.3, Figure 16, Page 122). 
Total costs are summarized in Figure 16 (Page 122). Total costs were significantly lower pre-treatment 
(4.5% [95% CI 3.8-5.3] of average TB-affected household annual income) than during treatment (15% 
[95% CI 13-18], p<0.0001), intensive phase (6.3% [95% CI 5.6-7.1], p<0.02), or maintenance phase 
(9.2% [95% CI 6.8-10.8], p<0.0001). While total costs were higher during maintenance phase than 
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intensive phase (9.2% [95% CI 6.8-10.8] versus 6.3% [95% CI 5.6-7.1], p=0.0005). This was because 
maintenance phase was twice as long as intensive phase. In fact, costs per month during intensive 
phase costs were approximately one and a half times greater than costs per month during 
maintenance phase (p=0.001).  
Poverty and TB-related costs: In poorer versus less poor households, direct expenses in Peruvian Soles 
throughout the entire illness were lower (mean direct expenses 1267 [95% CI 1070-1464] versus 1470 
[95% CI 1001-1938], Figure 17, Page 123). However, total costs made up a greater proportion of poorer 
household’s annual income (poorest households 29% [95% CI 23-34] versus least poor households 
19% [95% CI 14-23], p<0.001, Figure 17, Page 123). The socioeconomic variables with the highest 
discriminatory power to explain the poverty score in this setting were: not having a refrigerator; 
quality of wall material (e.g. a wall made of mud/straw rather than bricks); quality of floor material 
(e.g. a floor made of mud/rubble rather than concrete); type of toilet (e.g. no toilet facility or 
rudimentary outdoor latrine rather than a flushing toilet in a specific separate bathroom of the house; 
and not having a television (Figure 18, Page 124).  
Dissaving and the association of dissaving with catastrophic costs: Patient households 
experienced an average of 1.3 episodes (95% CI 1.1-1.5) of dissaving pre-treatment, 3.4 episodes 
(95% CI 3.0-3.8) in the intensive phase of treatment, and 3.7 episodes (95% CI 3.2-4.2) in the 
maintenance phase of treatment. Thus, cumulatively, patient households experienced an average 
of 8.4 (95% CI 7.5-9.2) episodes of dissaving during the entire TB illness. Multiple regression analysis 
of the dissaving score demonstrated that patients who belonged to households with more than 
average dissaving were independently more likely to: incur catastrophic costs (OR 1.8 [95% CI 1.1-
3.1], p=0.02), be poorer (OR 1.8 [95% CI 1.1-3.0], p<0.03), and have more food insecurity (OR 2.2 
[95% CI 1.2-3.8], p=0.008, Table 19, Page 120). The variables with the highest discriminatory power 
to explain the dissaving score in this setting were: missing scheduled payments; starting a new job; 
selling or pawning household items; undertaking small scale fundraising activities; and being asked 
to eat elsewhere to conserve household food (Figure 18, Page 124).  
Conditional cash transfers and mitigation of direct costs, total costs, and catastrophic costs: 
122/135 (90%) of intervention TB-affected households received at least one conditional cash 
transfer. These 122 intervention TB-affected households received a total of 890 conditional cash 
transfers (80% of potential conditional cash transfers), receiving on average a total of 520 Peruvian 
Soles (173 US Dollars), which is equivalent to 3.5% of average TB-affected household annual income 
or 42% of average TB-affected household monthly income).121,159 The conditional cash transfers 
defrayed 20% (95% CI 15-25) of total costs, 39% (95% CI 37-43) of direct costs (Figure 19, Page 125), 
and hence 19% of lost income. Overall, 36% of patient households incurred catastrophic costs. 
Compared to control households, intervention households were less likely to incur catastrophic 
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costs (30% [22-38] of intervention households versus 42% [34-50] of control households, p=0.002, 
Figure 19, Page 125). 
Equity: The data in three pairs of columns at the left of Figure 20 (Page 126) suggest that the 
conditional cash transfers were equitable in their TB-related costs mitigation in terms of poverty, 
gender, and food insecurity. Conditional cash transfers defrayed total costs to a greater extent in 
poorer households (22% [95% CI 19-25] versus 18% [95% CI 14-22], p=0.08) and female patients 
(23% [95% CI 19-27] versus 18% [95% CI 15-21], p=0.06, Figure 20, Page 126).  
Conditional cash transfers and poverty-related TB risk factor reduction: Figure 21a (Page 127) 
shows the change in poverty score from baseline to final follow-up for control versus intervention 
patients. There was no significant difference in poverty score or change in poverty score in control 
patients, intervention patients, or control versus intervention patients. BMI increased significantly 
from baseline to final follow-up in the intervention patients (2.2 kg/m2 increase from 22 kg/m2 [95% 
CI 21-23] to 24.2 kg/m2 [95% CI 23-25], p=0.0003) and also the control patients (1.6 kg/m2 increase 
from 21.6 kg/m2 [95% CI 21-22] to 23.2 kg/m2 [95% CI 22-24], p<0.004, Figure 21b, Page 128). There 
was a non-significant trend towards intervention patients’ BMI increasing to a greater extent than 
control patients (Figure 21c, Page 129). Post hoc subgroup analyses of the poorest third of patients 
or on the subset of patients who experienced catastrophic costs also showed no statistically 
significant effect of the intervention on BMI, savings, income, or poverty score (data not shown). 
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Discussion 
 
We evaluated the effect of a TB-specific socioeconomic intervention121 including cash transfers on 
mitigation of the effects of TB-related costs in impoverished Peruvian shantytowns. The financial 
burden of TB was high, especially amongst poorer TB-affected households. Over one-third of the 
TB-affected households experienced catastrophic costs and thus were at increased risk of adverse 
treatment outcome.19 Households with greater dissaving were nearly two-times as likely to incur 
catastrophic costs, suggesting that dissaving may be a useful and simple proxy indicator of 
catastrophic costs risk. The intervention defrayed only a fifth of patient households’ TB-related 
costs but, despite this, households that were randomized to receive the intervention were less 
likely to incur catastrophic costs. The intervention was equitable to vulnerable groups within the 
cohort including poorer households and patients who were female. This evidence suggests a 
socioeconomic intervention including a social protection component can contribute to defraying 
TB-related costs, reduce the likelihood of incurring catastrophic costs, and will inform future 
implementation of such interventions in line with the End TB Strategy. 
 
Impact of the socioeconomic intervention on defraying TB-related costs and mitigating 
catastrophic costs 
The findings of this current research are important because they indicate that a socioeconomic 
intervention reduced the likelihood of incurring catastrophic costs – an encouraging finding that 
contributes to WHO’s goal of eliminating catastrophic costs by 2035. However, despite reducing the 
likelihood of incurring catastrophic costs, the impact of the socioeconomic intervention may have 
been limited by the fact that the conditional cash transfers defrayed only 20% of patient 
households’ total costs. During planning of the intervention, it had been estimated that if 
implemented nationally this conditional cash transfer program would increase the Peruvian TB 
program budget by between 5 and 26% per patient.22 Focus group discussions with key 
stakeholders including local staff of the Peruvian TB program and a civil society of TB-affected 
people suggested that such an increase in program expenditure was locally appropriate, affordable, 
and potentially sustainable.13,15 Therefore, to enhance the impact of the intervention, it will likely 
be necessary to increase the proportion of costs defrayed by conditional cash transfers in order to 
further incentivize TB-affected households, eliminate catastrophic costs, reduce TB vulnerability, 
and enable improved access to TB treatment and care. This could be achieved by a combination of: 
reducing system costs (e.g. through rapid diagnosis, improved access to treatment and preventive 
therapy); increasing the value of the cash transfers; and increasing access to and uptake of the 
conditional cash transfers (e.g. stratifying the intervention so that high-risk groups receive greater 
and more frequent socioeconomic support).  
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Equity of the socioeconomic intervention on TB-related costs mitigation  
There was evidence that the intervention was equitable because the proportion of direct expenses, 
lost income, and total costs defrayed by conditional cash transfers was higher in poorer households 
and female patients. These findings are encouraging because such vulnerable and marginalised 
patient groups have previously been found to have reduced access to TB care and prevention in the 
study setting, and thus are more likely to experience adverse TB treatment outcome.11,69,171 In order 
to reach these underserved groups in the future, national TB-specific socioeconomic interventions 
may benefit from a broader approach than simply money and education, including cross-sector 
provision of improved access to health insurance, social housing, housing improvements (e.g. 
optimizing ventilation), employment services (nearly half of total TB-related costs were due to lost 
income), and multi-disciplinary drug and alcohol addiction clinics (services not widely available 
during the study period in the study setting. In addition, alternative forms of DOT may be beneficial 
to reduce TB-related financial burden and allow an early return to work, such as VOT (video-
observed therapy) or peer-observation of therapy. 
 
The association of poverty and TB 
Patients were poorer than healthy controls whether assessed by factors acutely affected by having 
TB disease (such as employment status and income) or stable, long-term measures of 
socioeconomic position that constituted the poverty score (including household ownership, 
household assets, and education level). These findings reinforce Virchow’s 150 year-old assertion 
that TB is a social disease1,9,11 and imply that poverty scores may be useful tools with which to 
assess TB risk, especially in vulnerable groups. The relationship between poverty and TB is complex 
and requires further descriptive and particularly interventional research, especially in the light of 
the End TB Strategy’s renewed call to combat the social determinants of TB.16   
 
Dissaving and the association of dissaving with catastrophic costs 
Dissaving is a simple, proxy measure of financial shock.172 A key research question to be answered 
by the current research is how well the prevalence of certain dissaving measures correlates with 
likelihood of incurring catastrophic costs. In the current study setting, dissaving was associated with 
being a vulnerable, underserved individual or household. Patients from households with more than 
average dissaving were: poorer; more likely to incur catastrophic costs; and have greater food 
insecurity. In addition to a recently published study demonstrating the correlation of dissaving with 
TB-related costs in different settings,173 our current results provide evidence to inform the potential 
role of dissaving and provide provisional support for dissaving as a proxy marker of catastrophic 
costs.172 This is important because our previous work showed that catastrophic costs were 
associated with adverse TB treatment outcome and may be assumed to have a negative effect on 
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TB control. Thus, the same may be the case for dissaving. Were dissaving to be adopted as a proxy 
indicator of catastrophic costs, it is probable that local adaptation of dissaving measures will be 
necessary: in specific settings, certain dissaving variables may be more relevant to, and correspond 
more closely with, likelihood of incurring catastrophic costs. For example, in rural sub-Saharan 
Africa where formal loans or payments may be less frequent, other dissaving variables such as 
selling livestock may be more important contributors to dissaving.10 Piloting of the WHO TB costs 
tool including dissaving measures may soon shed new light on this under-researched area. 
 
Limitations. Firstly, the study sample size was determined by TB outcomes (see linked BMC 
Medicine article on the impact of the intervention on TB prevention and cure) so no a priori power 
calculations were made to evaluate the impact of the intervention on financial outcomes. Secondly, 
despite the encouraging findings concerning equity of the intervention, research nurses reported 
their subjective impression that patients who declined to participate in the study were much more 
commonly from groups associated with high-risk of adverse treatment outcome (including the 
formerly incarcerated, homeless, and/or those with drug addictions). However, this qualitative 
observation cannot be quantitatively verified because these patients chose not to give informed 
consent and so we were unable to formally collect data on their specific risk factors. Thirdly, costs 
of accessing treatment for concurrent comorbidities (including HIV and diabetes) throughout TB 
illness were not specifically examined during this study. However, only 6% of the cohort had 
diabetes and 5% HIV respectively and these comorbidities were equally distributed in the 
intervention TB-affected households and control TB-affected households, so it is unlikely that this 
would have influenced our results. Fourthly, we only studied the financial effects of MDR TB for six 
to seven months, whereas patients with MDR TB are usually treated for 18 months or more. We 
decided a priori to analyse the catastrophic costs of both MDR and non-MDR patients together for 
six to seven months, given the small number of MDR TB patients, and in order to be consistent with 
our previous published research into catastrophic costs of TB-affected households.19 Finally, there 
is currently no standardized, accepted method by which to measure mitigation of the effects of 
catastrophic costs and defraying TB-related costs.  
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Conclusions 
 
Accessing even free TB care was associated with higher dissaving, high TB-related costs, and 
frequent catastrophic costs in Peruvian shantytowns, especially for poorer households. This 
research provides evidence supporting the use of dissaving as a proxy indicator of catastrophic 
costs. A novel, complex, socioeconomic intervention was feasible, equitable, defrayed a substantial 
proportion of TB-related costs, and reduced the likelihood of incurring catastrophic costs. Informed 
by these findings, the socioeconomic intervention has been increased in value and its impact on TB 
health outcomes is ready to be evaluated during the Community-Randomized Evaluation of a 
Socioeconomic Intervention to Prevent TB (CRESIPT) study. 
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Table 17: Baseline demographic characteristics of patient and healthy-control study 
populations. P values are the difference between all healthy-controls and all patients by univariate 
logistic regression adjusted for age and sex.  
 
*Pre-treatment versus intensive phase **Pre-treatment versus maintenance phase. Note: there was 
no significant difference between household incomes during intensive versus maintenance phase 
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Table 18: Univariate and multiple logistic regression of specific poverty indicators associated with TB disease (comparing patient versus 
healthy-control study populations).  After univariate logistic regression adjusting for age and sex, contributory variables (p≤0.1) were entered into a multiple 
logistic regression analysis. The variables that have blank data cell rows in the multiple logistic regression column were those non-contributory variables excluded 
from the final model. The variables “Not in paid employment” and “Lower monthly household income” were not included in the multiple regression model 
because these variables were strongly collinear with the variable “Poor”. “NA” refers to these variables. Body mass index was not included in the analysis because 
this variable is strongly and acutely influenced by having TB disease. 
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Table 19: Patient household (n=282) dissaving score associations with health and socioeconomic variables.  The patient cohort had a median 
average dissaving score of 0. Higher (more positive) scores indicate greater dissaving and hence greater financial shock. Lower (more negative) scores indicate 
lower dissaving and hence less financial shock. Health and socioeconomic variables were analysed for association with dissaving score by univariate logistic 
regression. Multiple logistic regression was then performed with stepwise exclusion of non-contributory (p>0.1) variables. The variables that have blank data 
cell rows in the multiple logistic regression column were those non-contributory variables excluded from the final model. 
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Figure 15: Participant recruitment and randomisation. Recruitment constituted completing informed consent and a recruitment questionnaire. Dashed 
arrows refer to participants who were not included in the final analysis.  
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Figure 16: TB-affected household direct expenses, lost income, and total costs by treatment phase. P values are differences of total costs between 
treatment phases by T-test
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Figure 17: Total direct household expenses during the entire illness and total costs during the entire illness as a proportion of 
annual income by poverty tercile (n=282). This analysis is comparable with previous research.19   
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Figure 18: Variables with the highest Eigenvector loading values derived by principal component analysis. Higher eigenvector values 
represent a higher discriminatory power of that specific variable to explain the poverty score and dissaving scores (see Box 2).   
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Figure 19: Catastrophic costs incurred by intervention (n=132) and control (n=140) households. The top p value is regression analysis 
adjusted for confounders including food insecurity, poverty level, household crowding, highest level of education of head of household, resistance 
profile of patient, and employment of patient. 
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Figure 20: Intervention incentives as a proportion of direct expenses and total costs of that household. Incentives refer to conditional cash 
transfers received by the intervention patient households. P values are univariate logistic regression of each binary variable against total costs mitigated by 
the incentives. 
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Figure 21a: Relative poverty score and changes in relative poverty score between all patients and healthy-controls at 
baseline, and intervention patients and control patients at baseline and follow-up. P values are the difference of poverty score 
between all patients and healthy-controls, and the change in poverty score from baseline to follow-up in and between intervention and 
control patients. 
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Figure 21b: BMI at baseline and final follow-up in all patients, supported arm patients, and control arm patients. P values 
represent the difference in BMI between baseline and follow-up on univariate logistic regression. 
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Figure 21c: Change in BMI from baseline to follow-up in supported arm patients and 
control arm patients. P values represent the difference in change in BMI from baseline to final 
follow-up between patient and control arms on univariate logistic regression. 
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Chapter 6: A randomized controlled evaluation of a socioeconomic 
intervention to improve tuberculosis prevention and cure in 
impoverished shantytowns of Callao, Peru 
 
At the time of writing (February 2016), this chapter is under review as a manuscript for publication 
with the Bulletin of the World Health Organisation. The findings reported in this chapter form the 
crux of this PhD thesis: the impact of the socioeconomic intervention on TB preventive therapy 
uptake in household contacts and TB cure in patients from impoverished Peruvian shantytowns. 
 
Introduction 
 
One third of the world’s population is estimated to have latent tuberculosis (TB) infection, mostly in 
resource-constrained settings.174 Those at highest risk of progressing from latent TB infection to TB 
disease include: household contacts of TB patients and people living in poverty.175 It has previously 
been shown that HIV-negative people with latent TB infection who took TB preventive therapy had a 
60%175 decreased risk of progressing to active TB disease. Despite this proven benefit, the global 
utilisation and impact of preventive therapy on TB control are severely limited because latent TB 
infection is infrequently tested6 and people with latent TB infection are infrequently prescribed, 
start, adhere to, or complete TB preventive therapy.15,176–178 Such people are more likely to develop 
TB disease, hampering global TB control.179–181  
Difficulty adhering to medicines including TB preventive therapy is common and reduces the 
intended benefits.176,177,179,182 However, it is not only TB contacts who are at increased risk due to 
non-adherence: TB patients who do not start, adhere to, or finish TB treatment are more likely to 
have adverse treatment outcomes (including death, treatment failure, and TB recurrence)183 and 
transmit TB to other people including households contacts.184 In addition, such patients are more 
likely to develop multi-drug resistant TB (MDR-TB);185 an increasingly prevalent, global public health 
threat.6 
Enhancing access to TB preventive therapy and treatment is likely to improve TB prevention and 
cure. The current slow decline in TB incidence is associated with a predominantly biomedical 
approach, which is proving insufficient to meet the reductions recommended in the End TB Strategy. 
To meet these goals, complementary strategies including socioeconomic support are required.156,186–
202  
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Social protection interventions include conditional cash transfers and aim to reduce poverty and 
vulnerability by improving people’s capacity to manage social and/or economic risks.131–138 Although 
these and other socioeconomic interventions are already relatively common tools in the response 
to HIV/AIDS and maternal health,139,140 there is extremely limited evidence on the impact of these 
interventions on access to TB preventive therapy in household contacts or cure in TB patients.132–
134,142  
Our research group (www.ifhad.org) was funded to undertake the Community Randomized 
Evaluation of a Socioeconomic Intervention to Prevent TB (CRESIPT) project. Prior to initiating 
CRESIPT, we report here the household-randomized controlled pilot evaluation of the complex TB-
specific socioeconomic intervention that is proposed for the CRESIPT study 159,171. The aims of the 
current pilot project were to evaluate the impact of this intervention on TB prevention and TB cure, 
and refine the intervention for the CRESIPT study.  
Methods 
 
Setting. 32 contiguous shantytown communities in Callao, Peru, with a population of approximately 
one million people203 and an annual TB notification rate of 109 new cases/100,000 people/year in 
2014,203,204 higher than nationally.26,158 
Design. This household-randomized controlled study evaluated the impact of a socioeconomic 
intervention on TB preventive therapy uptake by household contacts (henceforth termed 
“contacts”) and TB cure in patients.  
Intervention. The intervention is detailed in Chapters 4 and 5 and Box 5. 
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Box 5: Description of the socioeconomic intervention  
Background: The project was informed by the findings of our group’s Innovative Socioeconomic 
Interventions Against TB (ISIAT) study,15 two systematic reviews of cash transfer interventions, 
133,159,171 expert consultations,132 and feedback from civil society and local and regional heads of the 
Peruvian TB Program.171  
Outputs: The intervention targeted defined outcomes along the TB causal pathway and promoted 
equitable access to TB program activities205 including: 
i. screening for TB in contacts and MDR-TB in TB patients;  
ii. adherence to TB treatment and preventive therapy; and  
iii. engagement with social support activities.  
The socioeconomic intervention has previously been described in Chapters 4 and 5.171 Briefly, it 
constituted economic and social support: 
- Economic support consisted of conditional cash transfers throughout treatment to defray 
average household TB-related costs thereby reducing TB risk factors whilst also incentivizing, and 
enabling care. Economic support was designed so that direct out-of-pocket expenses (previously 
found to be 10% of annual household income in the study setting)171 would be mitigated in patients 
who achieved all conditional cash transfers. During planning of the intervention, it had been 
estimated that if implemented nationally this conditional cash transfer program would increase the 
Peruvian TB Program budget by approximately 15% per patient.206 Focus group discussions with key 
stakeholders including local and regional staff of the Peruvian TB Program suggested that such an 
increase in program expenditure was locally appropriate, affordable, and potentially 
sustainable.19,79,171.  
- Social support consisted of household visits and participatory community meetings that aimed 
to provide information, mutual support and empowerment, and stigma reduction. The household 
visits were made shortly after patients were started on treatment and focused on education 
concerning TB transmission, treatment, preventive therapy, and domestic finances. The community 
meetings took place monthly in each study site community.171 The meetings re-emphasized the 
educational themes of the household visit, and developed an event entitled “TB Club” in which 
participants shared TB-related and other life experiences within a mutually supportive group 
setting (to be reported elsewhere).207 All household members were invited and encouraged to 
participate in both the household visits and community meetings. 
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Participants. Inclusion criteria were patients commencing treatment for TB disease administered by 
the Peruvian TB Program in the study communities. These patients were invited to participate with 
a consent form that explained the randomization process. For patients who were minors, a parent 
or guardian was invited to give informed written consent and the patient to assent to participate. 
Contacts were defined as individuals who reported being in the same house as the recruited TB 
patient for over 6 hours/week. Exclusion criteria were inability or unwillingness to consent. 
Randomization was performed by TW and DH using random number tables to generate an 
individual household randomization sequence for each health post that was restricted to blocks of 
30. The randomization assigned a patient household at a ratio of 1:1 to either the control arm, in 
which households received Peruvian TB Program standard of care, or the intervention arm in which 
households additionally received the socioeconomic intervention. The mechanism for allocation 
concealment consisted of cards placed in pre-numbered sealed envelopes detailing allocation to 
the intervention or control arm. Once patients gave informed consent to participate, a project 
nurse opened the envelope in front of the patient and informed them of their allocation.  
Data collection. A locally-validated questionnaire 11,15 was used to collect health, wellbeing, and 
socio-demographic data, at baseline as treatment commenced and 24 weeks later (28 weeks if 
treatment was prolonged, usually because of MDR-TB and/or HIV-TB co-infection). Both interviews 
included measurement of height and weight to calculate body mass index (BMI), and assessment of 
13 stable socioeconomic position indicators including assets, access to services, and education 
level.159,171 The final interview also included a mixed-methods qualitative and quantitative 
questionnaire concerning feedback, in which participants were asked to rank the importance of 
each activity constituting the intervention (time spent with our project’s research nurses and 
technicians in the health post, home visits, educational workshops, TB Clubs, and the conditional 
cash transfers).  
Preventive therapy. The most recent Peruvian TB Program guidelines that applied throughout this 
study recommended that preventive therapy be provided to all contacts under 5 years old of a 
patient with non-MDR pulmonary TB (unless the contact had had previous TB disease), and 
preventive therapy should also be considered for contacts aged 5 to 19 years of a patient who have 
a tuberculin positive skin test indicating latent TB infection and were a contact of a patient with 
non-MDR pulmonary TB.205 However, tuberculin was generally unavailable throughout this study. 
Preventive therapy consisted of a six-month course of daily isoniazid that was collected weekly 
from health posts by patients and taken unsupervised at their home.205 Data concerning preventive 
therapy uptake were collected collaboratively and prospectively from Peruvian TB Program records. 
Of note, control households did receive information concerning household contacts of the TB 
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patien being tested and treated for latent TB infection in the form of face-to-face clinic contact 
(most commonly with Peruvian TB Program nurses) and also Peruvian TB Program educational 
leaflets, posters, and booklets (all available to download in Spanish from 
www.tuberculosis.mins.gob.pe). However, the extent to which this information was communicated 
was highly variable between health posts in the different study site communities. 
Treatment. The Peruvian National TB Program offered free TB diagnostic testing to all suspected TB 
patients who, once diagnosed, received free anti-TB directly observed therapy (DOT) administered 
at health posts.205 As an incentive and benefit for participation, all patients, regardless of their 
randomisation, were offered an additional sputum test with Xpert MTB/rif™ performed by our 
research laboratory for rapid rifampicin susceptibility testing, which was not otherwise routinely 
available. TB treatment outcome data were collected collaboratively with the Peruvian TB Program 
from their treatment cards at the time of final follow-up and were not influenced by this research.  
Treatment outcomes. Peruvian TB program outcomes were consistent with those defined by the 
World Health Organisation.174 The Peruvian TB Program defined cure of drug-susceptible TB as a 
patient with bacteriologically confirmed TB at diagnosis who completes treatment and has a 
negative sputum smear during the final month of treatment.205 This involved confirmation during 
clinical assessment by a National TB program physician to evaluate symptoms, examination, weight 
trend, and, when necessary, investigation such as chest radiographs and blood tests. Patients who 
completed their TB treatment course but did not complete the required sputum testing and/or 
physician review were classified as having completed treatment. Other programmatic outcomes 
were death (all-cause mortality during TB treatment); failure of treatment (as determined by the 
physician and/or demonstrated by positive sputum microscopy/culture after 4 months of 
treatment); abandonment of treatment; and unknown outcome (patient relocated to another 
region or was lost to follow-up with inability to determine outcome). The Peruvian TB Program 
defined treatment success as patients who completed treatment or were cured, as per WHO 
guidance. An additional project definition was continuing on treatment after our 28-week follow-up 
interview. MDR-TB patients, whose treatment duration commonly extends to 24 months, were 
defined as continuing treatment if still taking TB treatment at this 28-week follow-up interview. 
Primary study outcome. The primary study outcome compared intervention households with 
control households and was uptake of TB preventive therapy in contacts aged less than 20 years. A 
priori subgroup analysis of uptake, adherence to, and completion of TB preventive therapy for 
household contacts aged under 5 years old and household contacts aged from 5 to 19 years old was 
also performed. Completion of TB preventive therapy was operationally defined in line with 
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Peruvian national guidance: contacts who started and took 6 months (24 weeks) of preventive 
therapy (as documented in their preventive therapy treatment cards).205  
The secondary study outcome was National TB Program confirmed TB cure in patients as described 
above. This analysis evaluated patients with cure versus patients without cure without any 
exclusions (intention-to-treat). Further sub-analyses were also performed evaluating patients with 
cure versus patients in whom it was not known whether they had been cured or not, such as 
patients: with unknown outcome; who were still on treatment; or who completed treatment 
without assessment. Finally, a sub-analysis of patients who had WHO-defined treatment success 
versus patients who did not have treatment success was performed.208 
Sample size. Recent evidence from the study site showed that TB patients had an average of five 
contacts, three contacts aged <20 years and so potentially eligible for TB preventive therapy, and 
25% of them completed it.15 Therefore, a priori, we calculated that 312 patients would give 80% 
statistical power to detect a 33% increase in the primary outcome comparing intervention versus 
control households with two-sided 5% significance.  
Blinding. It was not feasible for the patients or the research team to be blinded to patient 
allocation. TB Program staff were not informed of and were generally unaware of patient allocation 
but were not confirmed to be blinded. 
Analysis. Socioeconomic variables were combined into a composite index of household 
socioeconomic position using principal component analysis, as previously described.11 Data at the 
household and individual (patient or contact) level were used for intention to treat and 
supplementary analyses with adjustments for household clustering using robust standard errors 
because there was more than one household contact per patient in most households. The primary 
and secondary outcome were analysed by univariate logistic regression and multiple logistic 
regression adjusted for household clustering and known confounders measured at baseline 
(including household-level factors such as poverty, household crowding, head of household’s 
highest education level, monthly income, and food insecurity; and patient-level factors such as age, 
gender, employment status, and TB resistance profile) that generated adjusted odds ratios (aOR) 
for relevant, contributory socioeconomic and health factors. Time-to-event analysis was performed 
in order to generate a crude, unadjusted log-rank value for difference between number of weeks of 
preventive therapy taken by household contacts from intervention versus supported households. 
Approval. The project had ethical committee approval and all participants gave informed written 
consent prior to participation.
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Results 
 
Participants. Recruitment commenced 10th February 2014 and the intended sample size was 
reached 14th August 2014 and follow-up was completed 1st June 2015. 312 TB patients were invited 
to participate, 90% (282/312) were recruited and randomized to the intervention (n=135) and 
control (n=147) arms. Three recruited patients had their TB diagnosis revoked and two died during 
the study; and seven recruited patients did not complete follow-up. Thus 96% (272/282) recruited 
patients had complete follow-up (Figure 22, Page 147). 68% of patients had sputum smear-
microscopy positive TB. 9% (24/282) of patients had MDR-TB, none of whom had been cured or 
completed treatment during the study because MDR-TB treatment generally requires at least two 
years of continuous antibiotic therapy in Peru. No substantive baseline imbalances were found 
between intervention and control patients in the baseline characteristics shown in Table 20 (Page 
141). Patients had an average of five contacts, 97% (1290/1331) of whom were recruited. 40% 
(518/1290) of recruited contacts were aged under 20 years old of whom 410 completed follow-up 
(Figure 22, Page 147).  
Intervention. 122/135 (90%) of patient households that were randomized to the intervention arm 
of the intervention received at least one conditional cash transfer. A total of 890 conditional cash 
transfers were made (80% of potential conditional cash transfers) with an average total of 520 
Peruvian Soles (173 US Dollars) per household received a maximum of 640 Peruvian Soles (230 
dollars) per household.159,171  
Primary outcome. Contacts aged less than 20 years old from intervention households were more 
likely than those from control households to start preventive therapy (44% versus 26%, aOR 2.2 
[95% CI 1.1-4.2], p=0.022, Table 21, Page 142 and Figure 23, Page 148). Time-to-event analysis 
showed that household contacts from intervention households took a greater number of weeks of 
preventive therapy than those from control households (log-rank test p=0.005, Figure 24, Page 
149). Although crude analysis showed that household contacts were more likely to complete three 
and six months of preventive therapy (Figure 23, Page 148), these increases were not significant 
after adjusting for household clustering (completion of three months 33% versus 22%, aOR 1.8 
[95% CI 0.90-3.7], p=0.095 and completion of six months 20% versus 12%, aOR 1.9 [95% CI 0.79-
4.6], p=0.15, Figure 23, Page 148). Subanalysis of contacts aged 5 to 19 years old (Table 22, Page 
143 and Figure 25, Page 150) and less than 5 years old (Table 23, Page 144 and Figure 26, Page 151) 
showed a similar pattern, with those less than 5 years old tending to be more likely to start, adhere 
to, and complete preventive therapy than 5 to 19 year olds.   
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Secondary outcome. The intention-to-treat-analysis showed that patients from intervention 
households were more likely than those from control households to have cure (51% [95% CI 43-
60%] versus 37% [95% CI 30-45], aOR 1.8 [95% CI 1.1-2.9], p=0.02, Table 24, Page 145, Table 25, 
Page 146, and Figure 27, Page 152). This pattern was maintained after excluding patients with 
unknown outcome, and/or those still on treatment, and/or those who completed treatment (Figure 
27, Page 152). However, using the National TB Program definition patients from intervention 
households only tended to be more likely to have a successful treatment outcome than patients 
from control households (76% versus 70%, aOR 1.6 [95% CI 0.87-3.0], p=0.13).  
Feedback: 74% (100/135) patients from supported households completed a feedback 
questionnaire. They rated social support (a composite average of home visits, health post project 
interactions and community meeting educational workshop and TB Club rankings, 3.1 [95% CI 3.0-
3.2]) as more important than the economic support (conditional cash transfer ranking 1.9 [95% CI 
1.5-4.3], p<0.0001, Figure 28, Page 153). In poorer households, cash transfers tended to be rated 
more highly (2.2 [95% CI 1.7-2.7] poorest versus 2.0 [95% CI 1.4-2.6] poor versus 1.5 [95% CI 0.8-
2.0] least poor, p=0.06) and social support activities less highly (composite social support activities 
ranking 2.9 [95% CI 2.8-3.1] poorest versus 3.1 [95% CI 2.9-3.3] poor versus 3.2 [95% CI 3.0-3.3], 
p=0.02). 
 
Discussion 
 
During the CRESIPT pilot study, we designed, implemented, refined,121 and evaluated a novel TB-
specific socioeconomic intervention including cash transfers in a resource-constrained setting. The 
intervention proved to be feasible171 and improved rates of TB preventive therapy uptake in 
contacts and TB cure in patients.  
The findings of this paper generate new knowledge suggesting that socioeconomic interventions 
including conditional cash transfers can modify behaviour and improve TB prevention and cure in a 
challenging environment. Prior to this study, evidence assessing interventions to improve TB 
preventive therapy or treatment adherence has been hampered by lack of randomization, limited 
sample size, and/or being conducted in high-resource countries with restricted patient groups (e.g. 
HIV-infected people,209 homeless people,186,187 migrants,193 or injecting drug users156,175,188,198). 
Recent systematic reviews concluded that there was currently no evidence that incentives including 
cash transfers increased TB preventive therapy completion17 and minimal evidence to guide World 
Health Organization recommendations concerning implementation and scale-up of TB-specific 
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socioeconomic interventions in resource-constrained settings.210 Since the publication of these 
reviews, there have been very few controlled studies to further knowledge in this area.15,18 This 
current research from a resource-constrained setting contributes new knowledge to fill this evidence 
gap and inform global TB policy.  
The finding that this intervention increased TB preventive therapy uptake and number of weeks of 
preventive therapy taken is important because non-adherence to TB preventive therapy is 
frequent156,178–181,196,211–214 and leads to higher rates of secondary TB. Nevertheless, even in the 
household contacts from intervention households, the uptake of preventive therapy was low with 
less than half of the household contacts even starting preventive therapy. However, the aim of the 
study was not to achieve 100% preventive therapy coverage in household contacts because only a 
subset of household contacts is eligible to receive preventive therapy. Instead, we approximately 
doubled uptake of TB preventive therapy in household contacts under 20 years old. This increase in 
preventive therapy uptake was greatest in household contacts under 5 years, the great majority of 
whom are eligible for TB preventive therapy, at highest risk of death from TB disease, and in whom 
the impact of preventive therapy will therefore have the greatest health benefits. By contrast, in 
Peru, household contacts aged 5-19 years are not all eligible for preventive therapy: they generally 
require a clinical assessment including a tuberculin skin test that confirms TB infection before a 
decision may be taken to offer TB preventive therapy. Current shortages in the worldwide supply of 
tuberculin have made such screening difficult to achieve.215 Despite this logistical challenge, 
intervention household contacts aged 5-19 years approximately doubled their preventive therapy 
uptake, highlighting the strength of the effect of the socioeconomic support they received.  
While these CRESIPT pilot study findings are encouraging, it must be noted that despite a trend 
towards increased TB preventive therapy completion in the intervention contacts, there was not 
statistically significant evidence for this increase and many contacts who were probably eligible for 
TB preventive therapy did not complete it despite being offered our socioeconomic intervention. A 
potential reason for this may be that conditional cash transfers for preventive therapy were not 
given monthly like they were for TB treatment. In addition, the conditional cash transfer for 
completion of preventive therapy was only made if all (rather than for each of the) eligible contacts 
in the household completed it. The conditional cash transfer design was informed by our previous 
analyses of TB-related costs11 and aimed to temporarily reduce poverty,11,216 mitigate direct costs,11 
and thereby enable and improve healthcare access.217 However, results from the economic analysis 
(see Chapter 5) demonstrate that the transfers did not completely mitigate direct out-of-pocket 
expenses, suggesting that the financial burden of TB was still high for many of the intervention 
households. On the basis of the current results of this CRESIPT pilot study, we have since optimised 
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the design of the economic component of the intervention to completely mitigate direct expenses 
and to offer monthly conditional cash transfers to individual household contacts to further enhance 
uptake and completion of preventive therapy and thus prevent incident TB. This new design has 
been incorporated into the larger, five-year, well-powered community-randomized CRESIPT study, 
which is currently commencing and will evaluate the cost-effectiveness and impact of the refined 
socioeconomic intervention on health outcomes, access to TB care, and community TB notification 
rates.  
This research provides preliminary evidence in support of WHO’s End TB Strategy, which calls for 
expansion of the existing biomedical paradigm for TB control by incorporating socioeconomic 
interventions and Universal Health Coverage initiatives that address poverty and social 
determinants, the main drivers of the global TB epidemic.16 This CRESIPT pilot study highlights the 
potential importance of investing not only in diagnosing and treating TB disease but also in 
supporting TB-affected people and households. While these findings suggest that conditional cash 
transfers may contribute to improved patient outcomes (perhaps through diminishing food 
insecurity during TB treatment as well as improved access to medical care), it must be noted that the 
intervention went beyond cash transfers by offering education informing and promoting stigma 
reduction, inclusiveness, and empowerment during household visits and participatory community 
meetings. This social support focused on risk factors for non-adherence to preventive therapy such 
as: being female and/or belonging to a marginalized group,193,218–220 age,220,221 illegal drug use,196, 
homelessness,197 alcohol misuse,222 and TB-affected families’ and individuals’ own knowledge, 
attitudes and perceptions.214,223 The design of this CRESIPT pilot study did not allow analysis of the 
differential impact of the social support component and the economic support component of cash 
transfers on access to TB cure and access to prevention. Nevertheless, in the field of HIV, conditional 
cash transfers interventions have often been complemented with health education for beneficiaries, 
and it has been suggested that, without education or social support, conditional cash transfers are 
unlikely to have an impact on health outcomes.140 Thus, optimising social support and addressing 
specific aspects of poverty such as food insecurity are likely to be key issues on which to focus in 
order to strengthen the impact of future interventions.  
This study had several limitations. Firstly, we used TB cure as an outcome measure rather than TB 
treatment success, which combines TB cure and TB treatment completion. We took this approach 
because previous data from the study site demonstrated that patients who complete treatment 
(rather than being confirmed as cured) are more likely to have early subsequent TB recurrence and 
so not truly be cured.5 Thus better characterisation of TB treatment outcomes will be a priority for 
future research. Secondly, this CRESIPT pilot (as opposed to the forthcoming CRESIPT project) did 
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not aim to evaluate the impact of the intervention on rates of secondary TB disease in household 
contacts and thus the intervention’s potential influence on TB control.  
 
Conclusions 
 
This CRESIPT pilot study has demonstrated that a novel socioeconomic intervention was feasible, 
acceptable, enhanced access to TB prevention, and improved TB cure rates in an impoverished 
setting. These findings support the new global End TB Strategy and highlight the need for larger-
scale evaluations, such as CRESIPT, to determine the impact of socioeconomic interventions on TB 
care and prevention, potentially towards TB elimination.  
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Table 20: Baseline demographic characteristics of all patients, intervention patients, 
and control patients 
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Table 21: The association of health, socioeconomic position, and receiving the socioeconomic intervention with uptake of TB 
preventive therapy in household contacts under 20 years old (n=410). Univariate and multiple logistic regression show odds ratios of likelihood 
of preventive therapy uptake.  
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Table 22: The association of health, socioeconomic position, and being randomized to receive the socioeconomic intervention with 
uptake of TB preventive therapy in household contacts aged 5 to 19 years old (n=287). Univariate and multiple logistic regression analyses 
show odds ratios of likelihood of preventive therapy completion.  
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Table 23: The association of health, socioeconomic position, and receiving the socioeconomic intervention with uptake of TB 
preventive therapy in household contacts aged under 5 years old (n=125).  Univariate and multiple logistic regression analyses show odds ratios 
of likelihood of preventive therapy completion.  
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Table 24: The association of health, socioeconomic position, and being randomized to receive the socioeconomic intervention with 
TB cure (n=282). TB cure was defined by the treatment outcome defined by the Peruvian TB Program in their national protocol, consistent with WHO 
guidance174 (see Methods).  
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Table 25: Patient (n=282) outcomes according to Peruvian national TB Program definitions. 
“Cured” refers to those patients who had confirmed TB cure as defined by the treatment outcome defined by 
the Peruvian TB Program consistent with WHO guidance174 (see Methods) 
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Figure 22: Participant recruitment and randomisation. Recruitment constituted completing informed 
consent and a recruitment questionnaire. Dashed arrows refer to participants who were not included in the final 
analysis and not to their household contacts  
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Figure 23: Uptake, completion of three months, and completion of six months of TB preventive therapy in intervention (n=260) and 
control (n=258) contacts under 20 years old. Error bars are 95% confidence intervals. P values are derived by logistic regression. P values on the lower 
lines are crude, unadjusted derived by univariate logistic regression. P values on the middle lines are derived by univariate logistic regression adjusting for 
household clustering. P values on the upper lines are derived by multiple logistic regression adjusting for household clustering and potential confounders (see 
Methods)   
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Figure 24: Number of weeks of TB preventive therapy taken by intervention (n=260) and control (n=258) contacts under 20 years old. 
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Figure 25: Uptake, completion of three months, and completion of six months of TB preventive therapy in household contacts aged 5 to 19 
years old (n=300). Error bars are 95% confidence intervals. P values are derived by logistic regression. P values on the lower lines are crude, unadjusted derived 
by univariate logistic regression. P values on the middle lines are derived by univariate logistic regression adjusting for household clustering. P values on the upper 
lines are derived by multiple logistic regression adjusting for household clustering and potential confounders (see Methods)  
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Figure 26: Uptake, adherence to at two and four months, and completion of six months of TB preventive therapy in household contacts 
aged under 5 years old (n=125). Error bars are 95% confidence intervals. P values are derived by logistic regression. P values on the lower lines are crude, 
unadjusted derived by univariate logistic regression. P values on the middle lines are derived by univariate logistic regression adjusting for household clustering. P 
values on the upper lines are derived by multiple logistic regression adjusting for household clustering and potential confounders (see Methods) 
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Figure 27: Cure and treatment success in TB patients. Error bars are 95% confidence intervals. P values are derived by logistic regression. P values on the 
lower lines are derived by univariate logistic regression analysis. P values on the upper lines are derived by multiple logistic regression adjusting for potential 
confounders (see Methods section of this chapter) 
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Figure 28: Supported patient feedback ranking of the importance of the social and economic support activities of the social protection 
intervention.  The P value shows the difference between the composite ranking of all the social support activities and the economic support. 
 Chapter 7: Final Conclusions 
 
In impoverished shantytowns of Callao, Peru, having TB disease was associated with being poor; 
thus, TB remains a social disease. Quantifying the independent social determinants that constitute 
poverty and contribute most strongly to acquiring TB infection and progressing to TB disease remains 
complex. The associations identified between season, crowding, and vitamin D emphasise the 
potential for improving nutrition, correcting vitamin D deficiency, and reducing poverty to contribute 
to TB prevention. Thus in order to control TB, the global response may benefit from a socioeconomic 
as well as biomedical approach.  
The association between TB and poverty is bidirectional: despite TB treatment being ostensibly free, 
having TB disease was expensive for impoverished TB patients in Peru to afford. The new definition 
of catastrophic costs created by this research demonstrates that such costs are clinically relevant 
because they are associated with greater likelihood of adverse TB outcome. Indeed, catastrophic 
costs explained as many adverse outcomes as MDR TB. The novel catastrophic costs threshold 
defined by this research has since been endorsed by the World Health Organisation and become part 
of global TB control policy. This research also generated new knowledge concerning the association 
of dissaving with TB-related costs and catastrophic costs, and the role of dissaving as a practical, 
logistically-simple, proxy marker of catastrophic costs. These findings have already informed the 
implementation of the World Health Organisations TB Patient Costs tool, which is being piloted in 
sentinel sites for potential scale-up from 2015 onwards.  
One potential method of broadening the biomedical response to TB disease to be more holistic is by 
defraying catastrophic costs through targeted socioeconomic interventions. Therefore, through 
multi-sectoral collaboration and supported by evidence from a systematic review, we designed a 
novel TB-specific socioeconomic intervention to prevent TB and cure TB disease. The intervention 
was refined to better meet patient and household needs during implementation through community 
participation, engagement and acceptability feedback and subsequently proved to be feasible, 
equitable, acceptable, reduced TB-affected households’ catastrophic costs and improved TB care and 
prevention in a challenging, impoverished setting. This research emphasizes the need for larger-scale 
integrated socioeconomic interventions to improve TB control and also other health outcomes. In 
the light of our findings, in conjunction with key stakeholders from the World Health Organisation 
and World Bank, we have developed the protocol of the larger-scale, adequately-powered, 
Community Randomized Evaluation of a Social Protection Intervention to Prevent TB study, 
“CRESIPT”, which will evaluate the impact of the intervention on TB prevalence and control in the 
study setting.  
 Despite the positive findings of this research, the impact of the socioeconomic intervention may 
have been limited by the modest defraying of TB-related and catastrophic costs achieved through 
conditional cash transfers. Such a modest yet significant impact, means that, in its current form, the 
intervention would be unlikely to show an impact on community rates of incident and prevalent TB 
during the larger-scale CRESIPT project. Therefore, through liaison with international policy-makers 
in the World Health Organisation’s Task Force on Catastrophic Costs and Task Force on Social 
Protection, the intervention has been refined for implementation during the CRESIPT study. 
Refinements include: increased frequency and amounts of conditional cash transfers in order to fully 
mitigate catastrophic costs; providing conditional cash transfers for individual members of the TB-
affected household (including monthly transfers to individual households contacts for adherence to 
preventive therapy); and strengthening the highly-valued social support provided by the intervention 
- especially for high-risk patients such as the homeless, those with drug addiction, and those with 
MDR TB. In this way, the IFHAD team hopes to optimize the CRESIPT project’s impact on TB-related 
costs mitigation, to enhance social support, and hence improve TB control.  
This PhD research characterised the social determinants of TB, including TB-related catastrophic 
costs, in Peruvian shantytowns and subsequently created, implemented, and refined an innovative 
TB-specific socioeconomic intervention to mitigate catastrophic costs and support TB-affected 
families. The intervention is now ready for further impact assessment at a community level. The 
findings of CRESIPT, an extension of this PhD research, will aim to assist TB control programs to 
effectively implement the recent - yet 150-years overdue - global policy change of providing 
socioeconomic support to control TB.  
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Appendix 1: An operational toolkit detailing how to implement a 
socioeconomic intervention for households affected by TB (English 
version) 
 
The Spanish version of this toolkit is available on request. 
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Background  
TB kills more people each year than any other single infection, so there’s an 
urgent need to evaluate new TB-control interventions. Almost all TB control resources 
are spent on healthcare, labs and medicines. These save millions of lives, but it is 
poverty and development not healthcare that principally determine TB rates. For 
example, despite an acclaimed biomedical TB control program Peru has frequent TB 
and over the past decade multidrug-resistant TB rates have doubled to the highest 
levels in the Americas. These problems are concentrated in impoverished "hotspots", 
such as peri-urban and urban shantytown ‘slums’ around northern Lima/Callao, 
where our IFHAD team has been working for more than a decade. 
 
A new approach: fighting poverty to control TB 
Poverty increases TB risk through factors such as crowding and malnutrition. 
Conversely, TB worsens poverty through TB-related expenses and lost income. Poor 
people are more likely to get TB and less likely to be cured by TB treatment. However, 
it is the poor who have least access to TB care. This mismatch between need for TB 
care versus access to TB care undermines TB control. To try to address these issues, 
we are evaluating supplementing traditional TB healthcare with socioeconomic (social 
and economic) support for TB-affected households. We aim to improve access to TB 
care and mitigate TB-related costs in order to improve TB patients cure rates and 
subsequently prevent TB in those patients’ household contacts and the wider 
community. 
 
Progress so far  
Since 2007, our IFHAD team’s "Innovative Socio-economic Interventions Against 
TB (ISIAT)" project evaluated socioeconomic interventions to fight poverty and 
increase equitable access to TB care. The results of this project showed that 
socioeconomic support increased: testing for TB and HIV;, successful treatment 
completion; and also equitable access to TB prevention. Put into context, these exciting 
results showed that a simple and inexpensive socioeconomic intervention could 
achieve results even better than some news tests and pills. But can socioeconomic 
interventions help to control TB? 
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New project: CRESIPT 
Thanks to the encouraging results of ISIAT, the Joint Global Health Trials 
consortium of the Wellcome Trust, the Medical Research Council and the Department 
For International Development of the British Government (UK-AID) together with the 
World Bank have funded our IFHAD research team to undertake a new 6-year project. 
This project is rigorously assessing the impact of the most effective elements of the 
socioeconomic support from the previous ISIAT trial. Importantly, not only are we 
assessing impact on costs-mitigation and access to TB care but also on actual TB 
control for whole communities. Specifically, in 16 communities, our multi-disciplinary 
team are offering TB-affected households an integrated program of: 
(1)    social support for enhancing equitable access to TB-related healthcare and also  
(2) economic support to help them to afford TB care and to reduce their   
vulnerability to TB.  
Meanwhile in 16 other ‘control’ communities, people living with TB receive the 
standard healthcare provided by Peru’s excellent TB control program, without our 
socioeconomic intervention. Two years later we will compare TB rates in the 16 
communities that received our socioeconomic intervention versus the 16 communities 
that did not, to assess the cost-effectiveness and impact of our intervention and 
whether this socioeconomic intervention helped to control TB.  
 
Conclusion 
A socioeconomic intervention is being assessed for its capacity to reduce poverty-
related TB risk factors, improve access to TB care and prevent TB treatment failure, 
TB recurrence, and TB transmission. The intervention is targeted at those in greatest 
need in order to transform TB cure and care into TB control. 
 
The goal of this toolkit 
The goal of this toolkit is to act as a manual for other groups (including research 
teams, non-governmental organisations (NGOs), governmental organisations, and 
others) who aim to implement socio-economic support for individuals, households, or 
communities affected by TB. Within this manual, we offer simple, practical advice, 
methods, and document all the tools and materials that we used so that other people 
may be able to repeat our intervention in other settings. 
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Preparation 
 The preparation that is necessary prior to implementation of a socioeconomic 
support intervention depends on the circumstances in which the intervention is to be 
undertaken. For example, the requisites of a research team may be different to those 
of a charity, care provider, or NGO. The following are relevant examples of 
preparatory exercises that we undertook prior to implementing our socioeconomic 
support intervention. 
Community feedback from the relevant community in which 
you will be working 
 It is informative to find out the knowledge, attitudes, and practices of 
different groups within the community itself in order to tailor your 
socioeconomic support intervention to local circumstances 
 Focus groups can be performed with community leaders, civil society, 
healthcare personnel, patient groups, and other interested parties 
Find out which other related projects already exist in the 
community in which you will be working 
 It is important to make contact with other organisations, groups or teams 
working in the same community in order to understand their role 
 Other projects may exist that are performing a similar role or socioeconomic  
support intervention and it would be preferable not to overlap work 
 Share information with other organisations, groups and teams working in the 
same community to inform them of the proposed project, get their feedback, 
and potentially collaborate  
Presentations to local healthcare providers 
 When a research team works alongside the local, regional or national health 
system, or the research project takes place to some extent within health 
posts and/or hospitals, it is essential to inform the directors of such health 
directorates and their healthcare staff of the proposed project: who your 
team members are; what your objectives are; and how those objectives will 
be achieved. In addition, showing any relevant project approvals obtained is 
important (see below) 
 Apart from informative presentations, it would also be advisable to invite 
members of the health post / centre or other relevant staff members to 
parts of the project or intervention being undertaken 
Approval by relevant organisations 
 It is essential to obtain the relevant permissions / approval depending for 
any intervention in the community within which you are working 
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 If you are undertaking a study, accredited local, national, and/or 
international ethical committee approval will be necessary in accordance 
with the current revision of the Declaration of Helsinki 
 If you are working as part of a project rather than a study, relevant legal, 
community or governmental approval will still be required to implement a 
socioeconomic support intervention 
Perform pilots and practice sessions 
 An easy way to involve all the organisations mentioned above is to 
undertake practice sessions or pilots of the intervention (for example, an 
educational workshop or interview) 
Building an efficient and productive team 
 Working in a team can have mixed results. Teams that work well together can 
produce outputs and results far greater than each individual in the team could ever 
have produced. Conversely, teams that do not work well together may struggle to 
complete projects successfully. Below are some points to consider when setting up and 
managing project teams. 
Defining goals 
 A team or project without clearly defined goals or objectives will struggle to 
stay on course 
 Goals can be short-term (e.g. weekly) or long-term (e.g. over the course of the 
project) and, ideally, should be accessible for any team member to review (i.e. 
in a project handbook or manual) 
 Goals may be for individual team members (e.g. number of patients recruited 
per week) or of the project as a whole (e.g. all data double digitized and 
project recruitment and follow-up completed within a certain time-frame) 
  
Multidisciplinary team work and roles 
 Each team member has their own personal strengths or areas of expertise. A 
team that is able to recognise and cultivate these personal abilities is likely to 
have more success in achieving their goals. In addition, members of such a 
team are likely to feel more highly valued and useful  
 While many roles may overlap, develop and evolve, it is important that each 
team member understands their own role, the role of other team members, 
and how the two may affect each other and interact 
 
Communication, communication, communication 
 Regular team meetings attended by as many of the team as possible may be a 
good way to keep everyone informed of developments and progress 
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 Continuous feedback and evaluation of progress is useful to avoid 
misunderstanding, overlap of work, and to overcome difficulties 
Our project field team 
 Our active IFHAD project field team consists of: 4 principal physician 
investigators, 1 research nurse co-ordinator, 7 research nurses, 6 research nurse 
technicians, and 2 data managers. In addition, as will be discussed in further detail, we 
also provided TB patients and ex-TB patients the opportunity to be trained by our team 
to become “facilitators” (sometimes known as health promoters or health champions). 
Such facilitators were not only essential in the design of the socioeconomic support 
but also its subsequent implementation. 
 We hope that this toolkit provides useful materials and examples for any team 
wishing to implement a socioeconomic support intervention, specifically with TB-
affected families. Clearly, the size and skills of a team that are required will depend on 
the scale of the intervention to be implemented and its goals. The essential 
requirement for the success of a project such as this is motivated people who have 
sufficient time available and a vocation to work with TB affected families
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Project Team Activities 
 
 Before starting to implement any activities of a socioeconomic intervention 
with TB-affected families, you will need to answer certain questions:  
 What is the intervention that we are aiming to implement?  
 Where are we going to implement the intervention?  
 How are we going to implement the intervention? 
 Which members of the team will be involved in which activities? 
It’s possible that a socioeconomic intervention concerning TB patients will be 
undertaken in health posts and/or hospitals as much as in the community. It may be 
that team activities not only involve salaried members of the team but also that they 
rely on the assistance of volunteers from the community itself (for example, ex-
patients or patients approaching the end of treatment who may act as facilitators as 
mentioned above). Therefore, good team communication and coordination 
concerning project activities and project timescales is essential. 
We designed checklists detailing the activities of our team from patient 
recruitment, throughout each step of patient treatment and screening of contacts for 
preventive therapy, and until the final follow up of our project two years after 
treatment initiation. Examples of these checklists can be found in Document 1a-e.  
Apart from using the checklist to regulate and document the team activities, 
we also created a timesheet that each member of the team filled in daily. This 
timesheet can be found in Document 2. By using this timesheet, we generated a 
register of not only the different activities performed by each member of the team 
but also the time invested and money spent on each activity. For any team 
performing “field work” that involves undertaking a socioeconomic intervention, the 
timesheet also gives an idea of the project’s direct costs (in money and materials) and 
indirect costs (time invested by members of the team be they voluntary or salaried). 
These data are essential for analysing the cost-benefit of the project and offer a useful 
estimation of the true economic project resource costs for other teams that want to 
implement a similar intervention and need to predict budgetary requirements. 
Activities in the healthpost 
 Invitation and explanation – During the two year recruitment period, we 
are inviting all patients diagnosed with TB (non-MDR or MDR TB, children or 
adults, pulmonary or extrapulmonary TB) in the communities in which we 
work to participate. In order to fully explain our project, its goals, its 
conditions, its advantages and potential disadvantages to patients (including 
those who are unable to read), we used a compact, portable flipchart with 
colourful slides (Document 3). This flipchart details all the steps of the project 
in a way that is simple and easy to understand for all ages and reading abilities. 
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 Informed consent – Given that our intervention is part of a study and the 
decision to participate is completely voluntary in nature, we take informed 
consent from each participant (Document 4) signed by the patient or, in the 
case that the patient is a minor or person mentally incapable of giving 
informed consent, their guardian. Patients that do not give informed consent to 
participate are not included in the project and their treatment by the health 
post continues as normal. We also reassure all consenting participants that 
their ongoing participation is completely voluntarily and that they can 
withdraw from the study at any time they may wish to. 
 Questionnaire – We complete detailed questionnaires with all consenting 
participants to collect socioeconomic, health, TB risk factor (social capital, 
hidden costs, and Beck score), and stigma data. This questionnaire is too long 
to be included in this document and can be reviewed online at our charity 
website www.ifhad.org. If you or your team is planning to apply a 
questionnaire or data-collection tool during your intervention, you should aim 
to ensure that you can find (or create) a place in the health post which is 
private, quiet, and has sufficient space in which the patient can feel 
comfortable, not under pressure, and can respond to the questions posed in 
the best way possible. 
Activities in the community 
 Initial home visit – We ask all the recruited patients randomized to receive 
the intervention for permission to visit their home in order to perform a home 
visit that: reiterates the key educational messages covered in the flipchart; 
completes any remaining parts of the questionnaire; confirms household 
contacts (and register their identity cards etc.); performs anthropomorphic 
measurements of the contacts (height and weight for example); verifies the 
questionnaire responses concerning the materials from which the house is 
constructed and number of rooms; and responds to any further questions or 
concerns that the family may have. These programmed home visits are 
undertaken by the research nurses or assistants of our team. It is essential to 
remember that it is of utmost importance to maintain the confidentiality of the 
patient and their contacts at any time including when conducting household 
visits. Therefore, bear this in mind with respect to team uniform worn (for 
example, uniforms that mention “TB”) and do not divulge the patient’s 
diagnosis to any person (be it family, a neighbour or other) against the wishes 
of the patient. 
 Additional home visits – There are some families amongst those 
affected by TB, who will require more support than others in order to be able 
to complete the TB program requirements (such as adhering to treatment, 
keeping medical clinic appointments etc.). Patients and their families only 
receive an additional programmed household visit by research nurse or 
assistant of our team if they are classified by our team as being at “high risk”. 
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This includes patients with MDR TB, patients who have poor early adherence 
and families in which the contacts fail to attend their screening for TB. The 
flow chart detailing all the household visits (including initial and additional) 
and high risk factors can be found in Document 5.   
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The socioeconomic intervention 
Since 2007, ISIAT1 evaluated socioeconomic support to fight against poverty 
and increase equitable access to TB care. This socioeconomic support increased 
testing for HIV and TB, successful completion of treatment, and equitable access to 
TB prevention measures. These exciting results showed that a simple and 
inexpensive socioeconomic support package can improve TB care. Our new 
socioeconomic intervention consists of two integrated elements: 
(1) Social support constituted household visits and community meetings 
(including group-events entitled “TB Clubs”) and aimed to inform and 
empower, reduce stigma, and facilitate mutual support; and 
(2) Economic support to mitigate TB-related costs, incentivise and enable more 
equitable care, and reduce TB vulnerability.  
Social support: interactive community meetings 
In addition to the home visits described above, which form a valuable part of 
the social support of the intervention, we also designed interactive community 
meetings. From the feedback obtained during the ISIAT pilot project1 workshops and 
from focus groups with ex-TB patient civil society and regional TB program staff, we 
analysed various methods of giving socioeconomic support to TB-affected families. In 
this way, we were able to learn from the community in which we work. Thus, we 
focused and improved the previous design of the ISIAT workshops to provide the 
social support necessary within the new CRESIPT project. The new form of social 
support, “participatory community meetings”, consists of two parts: 1) an 
“Educational Workshop”, in which we develop key TB themes (including treatment, 
preventive therapy, transmission and risk factors); and 2) a “TB Club”, in which the 
patients and their contacts share experiences, reduce stigma, and are empowered. 
Economic support: Conditional bank transfers 
 Learning from a systematic review that our group was commissioned to 
perform by the WHO,2 we designed a conditional cash transfer program in which 
patients who completed national TB program goals (including adherence, contact 
screening) and our project goals (e.g. attendance at interactive community meetings) 
received cash incentives in the form of bank transfers. The aim of such bank transfers 
                                                          
1 Rocha et al. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational 
assessment. Int J Tuberc Lung Dis. 2011 Jun;15 Suppl 2:S50-7. doi: 10.5588/ijtld.10.0447. 
2 Boccia et al. Cash transfer and microfinance interventions for tuberculosis control: review of the impact evidence 
and policy implications.Int J Tuberc Lung Dis. 2011 Jun;15 Suppl 2:S37-49. doi: 10.5588/ijtld.10.0438. 
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is to reduce the potential for TB-affected families to incur catastrophic costs, incurred 
by 39% of our patients in the communities in which we work3  
                                                          
3 Wingfield et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcomes 
with multi-drug resistance: A prospective cohort study, Peru. In press PLOS Medicine 2014. 
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The Interactive Community Meetings 
Our interactive community meetings take place each month in each 
community in which we work. Were the implementing group to have the resources 
or was only working with a smaller number of communities, it would be 
recommendable to host the meetings more often. Although the educational workshop 
and TB Club form two distinct parts of the interactive community meeting, many of 
the elements that they contain overlap and complement each other. 
The aims of an interactive community meeting are to: 
1) Educate TB-affected families and patients (and healthcare personnel who attend) 
2) Reiterate the CRESIPT conditions (including facilitator selection) 
3) Decrease stigma (especially self-stigma) 
4) Create community mutual support networks of TB-affected families 
5) Learn skills through doing / gain useful knowledge for daily life 
6) Mobilize the community of TB-affected families in order to improve active case 
finding of new TB patients 
 
The above aims will be realised throughout the interactive community meetings. The 
educational workshop section focus mainly on aims 1 and 2 but aim 3 will also be 
included when the theme of TB Clubs is introduced. The TB Club itself focuses mainly 
on aims 3 to 5. Aim 6 is a recurrent theme throughout the interactive community 
meeting.  
Things to consider when organising a community meeting 
The key things to be decided prior to the community meeting are: 
 Which members of the team will lead the community meeting? 
 How many team members are going to participate? 
 Where is the community meeting going to take place? Is this place 
adequate or appropriate (with respect to price, security, lack of 
interruptions, size and facilities)? 
 What materials will be necessary and how much will it cost (making an 
estimated budget may be valuable)? Will there be travel cost 
reimbursement or refreshments?  
 How are participants going to be invited and registered and will there be 
a certificate of attendance provided? 
 How is feedback from participants going to be collected? 
In this manual, we have provided examples of the methodological guide (Document 6), 
program (Document 7), participant registration form (Document 8), example of list of 
necessary costs (Document 9) and materials (Document 10), and the certificate of 
attendance (Document 11).  
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Specific aims of the educational workshop 
1) Educate TB-affected families about: 
a. TB (types, treatment, adherence, risk factors, and importance of active 
case finding) 
b. Responsible saving and spending 
c. Human rights and the responsibilities of the national TB program 
 
2) Reiterate the conditions of the CRESIPT project: 
a. What are they? 
b. How can they be achieved? 
c. What benefits to you and your family might there be by completing 
these conditions? 
d. How to become a facilitator? 
 
3) Reduce self-stigma and internalized stigma (introduction to TB Club)  
a. Introduce the themes of stigma and empowerment 
b. Explain the aim behind and the logistics of the TB Club 
 
Exploration of these themes can be found in Document 6. Also in the Document, we 
include some ideas on how to develop the key learning themes of the educational 
workshop section of the interactive community meeting (Document 12). 
Specific aims of the TB Clubs 
1) Decrease anticipated and self-stigma through: 
a. Belonging 
b. Learning 
c. Challenging norms 
2) Create networks of mutual support: 
a. Sharing experiences 
b. Getting to know other TB-affected families 
c. Encouraging mutual support outside of the limits of the interactive 
community meetings 
3) Learning through doing – empowerment for everyday life: 
a. Working in a team to resolve problems 
b. Empowerment through reduction of self-stigma 
c. Advocacy, activism and finding a voice 
 
In Document 13, we include a more detailed guide on how to set up and run a TB 
Club. Within this guide, you will find information on the importance and history of 
self-help groups, how to divide the TB Club, what materials will be needed, and 
strategies for using the drawings concerning stigma and empowerment.   
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Community feedback and observations 
 The interactive community meetings aim to support families affected by TB. It 
might be that there are parts of the meetings that are more successful than others but 
it is important to have a flexible approach that allows the sessions to be adapted to 
suit the needs and requirements of the individuals, families, and communities in 
which they are taking place, while keeping in mind the goals listed above. In order to 
achieve this, it is important to obtain the opinions of the participants throughout the 
process. This can be difficult to do - especially in an objective manner – if the 
participants believe that they may lose an incentive from the intervention if they 
report that part of the meeting was not received well or performed poorly.  
 It is worth remembering that in the interactive community meetings, we want 
to involve and affect as many of the participants as possible and both the educational 
workshop and TB Club sections of the meeting to function well. Well planned 
feedback sessions or forms can inform: 
 If there is a specific subgroup amongst the participants that key messages do not 
reach (for example women, people who are illiterate, adolescents) 
 If there is a part of the meeting not working very well (for example, the 
educational workshop receives a high feedback score whilst TB Club does not) 
 The optimal way to manage and maintain consistency in the quality of the 
intervention and its concurrence with project goals across all members of the 
team and communities involved in the intervention 
It is recommendable that all the members of the team, including the facilitators sit 
down together immediately following the meeting to discuss: Which things went 
well? Why / How? What things can we improve? How can we improve them? 
The named member of the team responsible for each interactive community 
meeting can be in charge of this task and record the team’s collective responses. 
Apart from this feedback between the team, there are other ways of obtaining 
feedback during the interactive community meetings: 
 A team member or facilitator in training participates in the meeting purely as an 
observer, noting things that went well and things to improve 
 At the end of the meeting (for example, when a snack is provided), all of the 
participants can be asked informally which things they enjoyed and which not 
(Note: it must be explained clearly to the participants that they can give negative 
comments and that we only aim to improve the process) 
 We also designed an anonymous feedback form (Document 14) to be filled out 
by participants and deposited in a box or envelope prior to receiving their 
attendance certificates (Note: additional support will need to be given to those 
who are illiterate, who have poor sight, and those who have rarely filled out 
such forms)  
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Certificates of Attendance 
 
 Through community feedback with ex-patients and discussions within the 
team and project steering committee, we decided to award certificates of attendance 
to those families participating in the interactive community meetings. This decision 
was taken in order to formalise the interactive community meeting, to provide 
another instant gratification apart from the incentive offered, and for the personal 
(and potentially professional) development of the individual. Attendance at such 
educational events could be considered a part of continuing education and be 
provided in a curriculum vitae as evidence of participation in a community activity at 
a later date. 
 Certificates were only given to those who attended for the whole duration of 
the interactive community meeting and had completed their feedback forms. This 
was explained to participants prior to the meeting. An example of the certificate of 
attendance that we gave participants can be found in Document 11. 
 Other ideas relating to the certificates of attendance include: 
 Providing different coloured / quality certificates to differentiate people who 
have attended for example 1/2/3/4/5 interactive community meetings 
 Encouraging participants to build a portfolio of these certificates (especially 
those who wish to become facilitators) 
 With each individual and the group’s permission, take a photo at the end of the 
interactive community meeting with all the participants together and give this 
photo out at the next meeting. 
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MDR TB and Infection Control 
 
Clearly, while implementing any intervention which involves TB patients, it is vital 
to maintain infection control measures and to avoid transmission of TB. Specifically, 
an intervention such as this should aim to: 
 Decrease TB transmission in patient households through education concerning 
how TB is spread; 
 Avoid TB transmission or acquisition between TB patients and contacts; and 
 Avoid unnecessary exposure to TB for the members of the intervention team or 
facilitators. 
In order to adhere to the above, we made some ground rules for our project: 
 Patients with non-MDR TB who had been on uninterrupted appropriate anti-TB 
treatment for at least 2 weeks and/or had laboratory evidence of sputum smear 
negativity were allowed to participate in the interactive community meetings 
 Patients with MDR or rifampicin resistant TB who had 2 negative cultures were 
allowed to participate in community meetings as any other patient or contact 
 Patients with MDR or rifampicin resistant TB and sputum or culture positive were 
invited to interactive community meetings specifically for these patients 
conducted by the team whilst both team and patient wore masks (see below) 
Patients with MDR TB are at higher risk of treatment failure and incurring catastrophic 
costs than patients with non-MDR TB.2 In addition, patients with MDR TB are more likely 
to have comorbidities such as HIV and drug addiction. Patients with MDR TB may take 
some months for their sputum smear to become negative, remaining infectious for 
longer than those with non-MDR TB. Putting these factors together, for a socioeconomic 
intervention in patients with MDR to have most effect, it seems likely that it must begin 
early in the treatment of MDR TB patients whilst they are still sputum smear positive and 
therefore infective. Due to this we decided for patients with MDR TB: 
 We would create a separate interactive community meetings to be performed 
with only MDR TB patients on a monthly basis with both staff and patients 
wearing protective N95 masks (for methodological guide see Document 13) 
 That once their sputum had become negative, patients with MDR TB could join 
the interactive community meetings like any other patient and would receive 
an additional incentive for doing so (see Incentives in Document 15) 
 Screened contacts of patients with MDR TB who had no evidence of active TB 
disease (including symptoms) could attend the interactive community meetings  
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Economic Support: Conditional Cash Transfers 
 
We detailed the social aspect (interactive community meetings and home 
visits) of the socioeconomic intervention above. In addition to those activities, 
economic support is offered to all members of consenting TB-affected households in 
supported communities. This constitutes (bank account) cash transfers conditional 
upon completing the TB treatment and prevention activities that are offered free of 
charge by the national TB control program. A further conditional cash transfer is 
provided for attendance of all members of the TB-affected household at at least one 
interactive community meetings. 
The bank accounts into which transfers are made have been set up, preferably 
in the patient’s name. Other cash transfer programs such as JUNTOS in Perú elected 
the female head of the household as the recipient of a bank account and cash 
transfers. In our intervention, we decided that the patient would be the recipient 
with the aim to empower them to make their own financial decisions and be 
incentivized to complete their treatment. In the case that the patient is a minor, the 
bank account is opened in the name of their guardian. In a few other cases, the 
patient and family may also decide that another household member would manage 
the bank account.  
The Conditions 
Cash transfers were designed to have the same value as the combined food and 
cash transfers in our previous ISIAT pilot study,1 equivalent in value to US$230 per 
household (56% of average TB-affected household monthly income, 10% of TB-
affected household median income). Conditions for the cash transfers are the 
following and can be reviewed in more detail in Document 15: 
 TB prevention in contacts 
o All relevant household contacts are screened for TB 
o After screening, those that require it, start TB preventive therapy 
 TB treatment in patients 
o Good adherence to anti-TB therapy, throughout treatment 
 Joint goals for TB-affected households 
o Allow home visits from our team and attend interactive community 
meetings 
o The TB patient and all contacts who started preventive therapy, finish 
their treatment 
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Soft conditionality 
The conditional cash transfers adopted a form of conditionality called “soft” 
conditionality.44Perfect completion of the condition results in a “double incentive” 
whereas adequate completion of the condition results in a “simple incentive”. For 
example, patients with near perfect adherence (i.e. missed <2 doses in the first month 
of treatment) will receive a double incentive each month whereas those whose 
adherence was only adequate (i.e. missed ≥2 doses in the first month of treatment 
without abandoning treatment) receive a simple incentive (Document 15). Combined 
with the assessment of “high risk” and additional home visits, this type of soft 
conditionality has been put in place to ensure that the most vulnerable, unwell, 
stigmatized and highest-risk TB-affected households can still receive economic 
support, to reduce costs (e.g. conditionality was associated with 18% of the costs of 
Mexico’s poverty-reducing conditional cash transfer program PROGRESA, between 
1997 and 2000).  
Previous work in other settings has shown that when cash transfers are 
provided without supportive education, behavioural changes are not sustained and 
the intervention can have little impact.5 For this reason, during initial recruitment, 
home visits and interactive community meetings, we provide education (both verbal, 
written and participatory) on responsible domestic economics, spending and saving 
(Document 6 and Document 7). Also, we give reading material (Document 15a) and 
accompany all supported TB patients who require assistance to open their bank 
accounts. 
Support from banks and other forms of economic support 
 We visited many banks to discuss the ways in which we would be able to 
deliver conditional cash transfers in a timely manner. The main relevant issues and 
talking points between the bank and our group were: 
 What was legally required to open a bank account (i.e. documents, presence of 
potential account holder in a specific branch) 
 The bank’s concerns regarding exposure of their clients and staff to TB infection 
 Explanations of infection control measures that our group would take to 
maintain both patient and bank staff safety (including non-MDR TB patients 
having to have been on treatment for at least 2 weeks prior to opening their 
account) 
                                                          
4 Adato et al. Social protection to support vulnerable children and families: the potential of cash transfers to protect education, health and 
nutrition. AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV. Volume 21, Supplement 1, 2009 
 
5 London et al. for the Ethics Working Group of the HIV Prevention TrialsNetwork (2012) Improving Ethical Review of Research Involving 
Incentives for Health Promotion. PLoS Med 9(3):e1001193 
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 The potential for a streamlined or adjusted system for TB patients to open 
their accounts that would reduce the time spent in the bank  
 Establishing if the bank had a social inclusion department that could be 
involved and/or provide education on responsible spending and saving 
 Choosing an appropriate account so that the patient was not charged for 
withdrawing cash, could not get into debt, and was not open to inappropriate 
sources of credit, all of which could serve to worsen their socioeconomic position 
 
There are many other methods available to provide economic support (food 
packages, food vouchers, cards that can be used to buy products in a list of specific 
establishments, and cash).36 The method a project decides to use to economically 
support their participants will depend on the community and area in which they live 
and existing schemes.   
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Facilitators and intervention sustainability 
 TB predominantly affects impoverished people in resource-constrained 
settings. A project implementing a TB intervention will have a specific duration and 
will be working within a predefined budget. Therefore, it is essential when planning 
an intervention with TB-affected families, that sustainability is considered – ideally 
the positive effects of an intervention will continue within the community after the 
project itself is finished. In addition, as previously touched upon, in order for an 
intervention to be both acceptable and relevant to the local population, involving TB 
patients and their families in the activities of the intervention is necessary. 
 We decided to invite TB patients and ex-patients to become trained as 
“facilitators” for our project: people with personal experience of TB who are able to 
carry out project activities such as home visits, leading interactive community 
meetings, supporting patients to complete their treatment and receive their cash 
transfers, and performing active case finding. The role, selection and training of 
facilitators can be found in more detail in Document 16. We aimed to make the 
training practical and involving various steps so that quality of training and quality of 
facilitators completing such training would be high (Document 17). 
Criteria to become a facilitator 
 No longer an infection risk 
 Being a patient or contact who is completing their own conditions for cash 
transfer (good adherence, all contacts screened, attends community meetings) 
 Interested in and available to support other TB-affected families 
 Ideally, live in the same community as the patients which they support 
 Attend: a half-day training session, two home visits, and two interactive 
community meetings (initially observing then leading under supervision) 
Roles of the facilitator 
 Assist the project team: logistics and leading interactive community meetings 
 Support TB patients to adhere to and complete treatment 
 Support TB-affected families to ensure that all relevant contacts are screened 
for TB and start, adhere to, and complete preventive therapy 
 Undertake additional home visits for high-risk families 
 Educate TB-affected families, reduce stigma and increase empowerment 
Benefits for the facilitator 
 General training in education, leadership, working in a team, and 
professionalism – broadening of experience for the future (Examples of the 
facilitator training can be found in Document 17 and the presentations on our 
website www.ifhad.org) 
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 Economic benefit of receiving an incentive each time a patient that they 
support achieves a condition and receives an incentive (Document 15) 
 Incentive to complete their own treatment, a positive feedback loop 
Feedback and assessment 
 Just as is the case for the interactive community meetings, we created a 
feedback form for the training sessions for facilitators (Document 18). The 
form is anonymous and it was explained that its sole purpose is to make sure 
that we are able to respond and improve the training we offer.  
 Clearly, it is important that the contents taught during the training day are 
understandable and that the facilitators are able to use this information to 
support TB-affected families. We created a pre and post training session 
“exam” that is a multiple-choice test that covers the key messages of the 
session (Document 19). The purpose of this test is not so much to test the 
knowledge of the participants but to review the difference between pre and 
post session responses and assess the effectiveness of our teaching. 
  
 192 
 
Measuring the impact of the intervention 
 
Prior to initiating the implementation of your intervention (or even prior to 
planning the design of your intervention), it is important to think about the impact of 
that the intervention might have. Some useful questions to start exploring the theme 
could include: 
 What are the primary, secondary, and additional objectives of your 
intervention? 
 Which results / outcome measures are you going to use as indicators 
to measure the impact of your intervention? 
 Will you collect and analyse qualitative data (for example, feedback 
through interviews with the participants or other community 
members), quantitative data (for example, concrete data such as 
health or socioeconomic position indicators), or both? 
 If the intervention is part of a scientific study: What is the hypothesis? 
What is the desired measure of effect for your intervention? What is 
the sample size necessary to give the study sufficient power to detect a 
difference between intervention and control groups in the outcome 
measured? 
 
With respect to our specific project, the socioeconomic intervention forms part 
of a study in which, through randomization, half of the TB-affected families receive 
the support of the intervention and half do not. With relation to our specific 
objectives of mitigating TB-related costs, improving TB prevention, and improving 
TB cure, some of the indicators that we measure include: 
 Initiation, adherence to, and completion of preventive therapy 
 Direct costs (e.g. medicines and transport), indirect costs (e.g. lost 
income) and catastrophic costs of having TB 
 Proportion of patients with prolonged cure confirmed by a prevalence 
study two years following treatment initiation (a TB prevalence study 
involves obtaining a sputum sample from all members of TB-affected 
households participating in the study and testing it for TB whether the 
participant is symptomatic for TB or not) 
 Rate of secondary TB in household contacts  
 Rate of incident TB in the community 
  
In addition to the above, it is also advisable to lead focus groups, obtain objective 
participant testimonies or use a feedback questionnaire in the communities in which 
the intervention was realised. In this way, you can check the acceptability to the 
community of the intervention and to listen and take note of their opinions on the 
intervention and perhaps how it could be improved or locally adapted.  
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Document 1a: Checklist of all activities with supported TB patients during the first month of treatment  
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Document 1b: Checklist of all activities with supported TB patients during the first month of treatment (cont.) 
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Document 1c: Checklist of activities with supported TB patients during first and second months of treatment 
 
CHECKLIST OF ALL ACTIVITIES OF IPSYD TEAM WITH SUPPORTED PATIENTS TW;v15;20140711
Z Code:____________________________________Date of diagnosis:_________________________________Date of recruitment:____________________________
Treatment start date:___________________________Healthpost:_____________________________________Key: Outcome : -9 = impossible; -1 = pending; E = complete;  P = in process 
Types of TB: P = pulmonary; EP = extrapulmonary
Resistance profile: S = fully sensitive; M =  MDR; R = resistant not MDR
Approx Mth Outcome Initials Date Notes / Comments
NOTE: If the condition is complete, write in the 
incentives card aswell
NOTE: If the condition is complete, write in the 
incentives card aswell
25 doses in total (NOTE: If the condition is 
complete, write in the incentives card aswell)
50 doses in total (NOTE: If the condition is 
complete, write in the incentives card aswell)
47. CONDITION OF CASH TRANSFER COMPLETED: If between 80 and 100% of listed household 
contacts have had their medical appointment to rule our TB and that those who need to take 
chemoprophylaxis or be treated for TB have started their treatment, sign and deliver the 
"incentives card" of the patient to the IPSYD team administrator to make the respective 
payment
48. CONDITION OF CASH TRANSFER COMPLETED: In the first month - confirm that the patient 
has completed 25 doses, sign and deliver the incentives card to the IPSYD team administrator 
to make the corresponding payment
49. In the first month: if the patient has not completed 25 doses coordinate with their 
facilitator 
50. CONDITION OF CASH TRANSFER COMPLETED: In the second month - confirm that the 
patient has completed 25 doses, sign and deliver the incentives card to the IPSYD team 
administrator to make the corresponding payment
51. In the second month: if the patient has not completed 25 doses coordinate with their 
facilitator 
52. Ask about the relationship of the family with the facilitator (good/normal/bad)
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39. CONDITION OF CASH TRANSFER COMPLETED: If we have visited the housed, completed 
the questionnaire, and listed all households contacts in the first week or first month, sign 
and deliver the "incentives card" of the patient to the administrator of teh IPSYD team to 
make the corresponding transfer 
40. Verify patient adherence
41. (Before AHV1) Verify adherence of contacts to chemoprophylaxis
38. Verify that the patient has received their bank card (where necessary)
35. Confirm with the bank the hour and data organised (where necessary)
42. (Before AHV1) Verify that >50% of the family have attended ≥1 interactive community 
meeting and if not, it is a "high risk" household and will need a AHV1
37. Verify the patient opened their account successfully and obtain new account number
44. Confirm that the contacts were assessed to rule out TB disease and for prophylaxis
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33. Obtain the second sputum sample (in the healthpost, at 15 days of treatment)
34. Deliver the result of the second sputum sample to healthpost (as early as possible)
46. Confirm that the contacts subsequently diagnosed with TB have started their TB 
treatment
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43. (Before AHV1) Speak with a) facilitator b) staff of healthpost to find out if there are any 
surmountable family problems
36. Accompany the patient to the bank (or confirm their attendance)
45. Confirm that the appopriate contacts have started chemoprophylaxis
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Document 1d: Checklist of activities with supported TB patients during third to six months of treatment 
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Document 1e: Checklist of activities with supported TB patients from six months to end of treatment
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Document 2: Daily attendance and project costs form 
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Document 3: Introductory educational flipchart for recruitment 
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Document 4: Flowchart for household visits 
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Document 5: Example Interactive Community Workshop Guide 
 
INTERACTIVE COMMUNITY MEETING: EDUCATIONAL WORKSHOP AND TB CLUB Nº 1 
HEALTH POST CIUDAD PACHACUTEC 
 
“WORKING TOGETHER WITH COMMUNITIES TOWARDS GOOD HEALTH FOR ALL” 
Friday 7th March2014 
 
 
General Objective:  
o Improve the cure, prevention and control of TB (both non-MDR and MDR) in households and communities affected by TB.  
 
Specific Objectives: 
 
o Ensure that patients and their household contacts understand in general terms simple methods for the prevention and control of TB  
o Create a culture of responsible saving and spending to promote social and economic development. 
o Educate about the conditional cash transfers and how they relate to completing the objective of the Peruvian National TB Program. 
o Reduce stigma, combat depression and increase empowerment. 
o Achieve that all participants recognise and value their own personal characteristics and reinforce positive feelings about themselves 
 
Outputs:  
o The participants define, in their own words, the questions and answers from the roulette wheel relating to TB. 
o The participants recognise and put into practice the messages about domestic economy (household spending and saving). 
o The participants recognise their treatment objectives and learn how to exercise their rights as people affected by TB. 
o The participants, of their own volition, comply with the health post personnel requests with respect to treatment of TB patients and prevention of TB 
in household contacts.  
o The participants actively participate in the community activities of the IPSYD team and CRESIPT project. 
o The participants are able to improve their outlook on how they approach having TB and feelings relating to stigma. 
 
 
IPSYD team members responsible: Tom Wingfield, Marco Tovar, Rosario Montoya, equipo CRESIPT 
 
Location:   Auditorium of the Health Post Ciudad Pachacutec. 
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PROCESS AND 
THEME 
OBJETIVE CONTENT METHOD / TECHNIQUE TIME MATERIALS LEAD 
PERSONNEL 
OUTPUT 
 
PRIOR 
ACTIVITIES 
 
 
 
Preparation of space in 
which the interactive 
community meeting will 
occur.  
 
 
 
 
Group the seating in a circle with all 
seats facing the “Prize-giving 
Roulette.”  
 
 
Participatory 
 
 
60 min. 
(13:30-
14:30) 
 
 
Chairs, table, 
projector, laptop, 
plugs and 
extension cables, 
White board or 
similar pens, 
paper, flip chart, 
balloons, etc. 
 
 
Whole CRESIPT 
team 
 
 
 
 
Space prepared and ready to receive 
the participants. 
 
The attendance list will have been 
previously generated by the Project 
administrator and must be updated and 
finalised by the end of the meeting 
 
 
 
Reception of the 
participants 
 
Register all participants 
attending 
 
 
Previously generated register 
 
Participatory 
 
 
30  min. 
(14:30 -
15:00) 
 
 
Register 
Pens 
Relevant list of 
those who need to 
receive cash 
transfer after 
attending 
 
Namebadges 
 
 
Carlos (PAC) 
Rosario Sosa 
 
 
 
Pilar Tapia 
 
 
The register will be completed which 
includes the participants reimbursement 
for travel expenses (must sign). In 
addition, the document listing those 
requiring cash transfer must also be 
completed 
 
Participants will be identified by name 
badge which will have an additional 
number “1” or “2” assigned 
 
Welcome and 
introductory 
presentation 
 
 
Presentation of the 
outline of the session’s 
program 
 
 
Themes visited, personnel, timing 
 
 
Presentation 
 
 
7 min 
 
 
Copies of the 
community 
meeting program 
Projector & laptop 
 
Dr. Marco Tovar and 
Dr Tom Wingfield 
 
The participants are orientated to the 
central themes of the community 
meeting. 
 
Group activitiy 
 
 
Generate trust and 
remove inhibitions 
 
The participants are grouped 
according to the number assigned 
previously to them on their 
namebadge 
 
Participatory, interactive 
 
8-10  min 
 
Clear space in 
order to split 
group into two 
 
Charo Montoya 
Pilar Tapia 
 
 
The participants get to know each other 
in order for further communication to be 
facilitated 
The ABC of 
Tuberculosis 
(First hour) 
 
Orientate the 
participants about TB 
 
 
 
 
 
Make sure that the 
participants have 
relevant supporting 
Reading materials that 
they can review in their 
own time 
 
 
Definition of TB 
Transmission of TB 
Types of TB 
Diagnosis of TB 
Treatment  
Adherence 
Prevention of TB 
Risk factors 
Importance of active case-finding in 
TB 
 
Information leaflets 
 
 
 
Participatory 
 
 
 
 
 
 
Key ideas 
 
 
 
 
 
 
 
10 min. 
 
 
 
 
 
 
 
 
Roulette with 
questions and 
responses to the 
key themes.  
 
Projector and 
Laptop 
 
 
Community 
meeting materials 
(Booklets, slides, 
flip chart) 
 
Reading material 
 
  
 
Carlos Pozo 
Dr. Tom Wingfield 
 
Dr. Tovar 
Charo Montoya 
 
 
Rosario Sosa 
 
 
 
 
 
 
Frank Fernandez 
 
 
 
 
The participants respond in teams to the 
roulette questions and respond with the 
asistance of written posters to the 
questions 
The image and key message are 
displayed on the projector screen 
 
Those participants taking part in the 
game receive useful materials at the 
end (notebook, writing materials etc) 
 
The participants are encouraged to 
show the Reading material provided to 
their household members unable to 
attend the community meeting 
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PROCESS AND 
THEME 
OBJETIVE CONTENT METHOD / TECHNIQUE TIME MATERIALS LEAD 
PERSONNEL 
OUTPUT 
 
Domestic 
economy 
 
Motivate the participants 
concerning the 
importance of 
responsible spending 
and saving. 
 
 
 
 
 
Examine how money is spent within 
households 
 
Expound the importance of a budget 
 
Saving for future expenses (forward 
thinking) 
 
Participatory 
 
 
Key Ideas  
 
 
 
 
10 min. 
 
 
 
 
 
 
 
Roulette with 
questions and 
responses to the 
key themes.  
Community 
meeting materials 
(Booklets, slides, 
flip chart) 
Reading material 
concerning saving 
 
Carlos Pozo 
Dr. Tom Wingfield 
 
 
Pilar Tapia 
 
 
The participants describe how money is 
spent in the home and recognise the 
main sources of income. The 
participants consider the importance of 
making a household budget. They show 
and make an example of a household 
budget. The participants recognise how 
to plan for unexpected spending/events. 
     
      Conditional 
cash transfers 
into a bank 
account 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The participants are 
informed about the 
essential requisites for 
receiving the conditional 
cash transfers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Encourage and inform 
the patients and their 
family of the importance 
of agreeing to and 
committing to the 
programmed activities 
 
 
 
 
 
 
1. WHAT ARE THE CONDITIONS 
FOR RECEIVING THE CASH 
TRANSFERS? 
 
Sputum simple (preferentially prior to 
treatment - will receive doublé 
incentive). Home visit in the first 
week following treatment start 
Interactive community meetings: 
Workshops. TB Club 
 
Evaluation by the National TB 
Program: medical consultation, 
preventive therapy, treatment of TB 
including treatment of new 
household cases.  
Adherence to treatment for cure 
 
Household contacts complete 
preventive therapy (6 mths isoniazid) 
 
2.  HOW DO YOU ACHIEVE THE 
CONDITIONS? 
 
Active participation at interactive 
community meetings by all 
household members at at least one 
session. Complete treatment in a 
timely manner with good adherence 
as detailed in the incentives card. 
Become facilitator: On completing 
project and program early 
conditions, actively participating in 
interactive community meetings, 
having a vocation and time available 
 
 
Participatory 
 
 
Key ideas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participatory 
 
 
Key ideas 
 
 
 
 
 
 
 
 
10 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 min. 
 
 
 
 
 
 
 
 
 
Roulette with 
questions and 
responses to the 
key themes.  
 
 
 
Community 
meeting materials 
(Booklets, slides, 
flip chart) 
 
 
 
 
 
Reading material 
including 
incentives card 
 
 
 
 
 
 
 
Incentives card 
 
 
Carlos Pozo 
Dr. Tom Wingfield 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carlos Pozo 
Dr. Tom Wingfield 
 
 
 
 
 
 
 
 
 
 
 
 
The participants participate actively in 
the roulette game 
 
All the patients provide a sputum simple 
at the appropriate time 
 
The participants collaborate by 
providing suitable times for a household 
visit. 
 
The participants agree to participate in 
the interactive community meetings and 
invite other members of their household. 
 
The participants attend their TB clinic 
visits for treatment or ruling out TB in a 
timely manner. 
 
All participants that have relevant 
household contacts (especially children 
<5) have started preventive therapy or 
treatment for TB as indicated by the 
healthpost. 
All the patients are adherent to their TB 
treatment. 
All children and other relevant contacts 
on preventive therapy are adhering and 
ensure that any contacts who still have 
not had their TB screening appointment, 
arrange it  
All participants have a copy of the 
incentives card. 
Keep an eye out for candidates (self-
elected or elected by the team) who 
meet criteria for and are keen to 
become facilitators 
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PROCESS AND 
THEME 
OBJETIVE CONTENT METHOD / TECHNIQUE TIME MATERIALS LEAD 
PERSONNEL 
OUTPUT 
      Conditional 
cash transfers 
into a bank 
account 
Reinforce the potential 
positive outcomes of 
adherence etc 
3. IF YOU MANAGE TO 
COMPLETE THE CONDITIONS 
WHAT HAPPENS? 
o There should be  less risk of 
treatment failure and more chance 
of cure with good adherence and 
completion of treatment 
o Screening for TB and giving 
preventive therapy in contacts.may 
prevent them getting TB disease 
o This applies especially to children. 
With respect to the IPSYD Project 
benefits: 
o You’ll gain a DOUBLE incentive 
o You will have the opportunity to 
join us as a facilitator  
o By participating in the 
community meetings you’ll 
receive education about TB. 
o You will be able to take part in 
the TB Club’s to reduce stigma 
 
Participatory 
 
Key ideas 
 
 
 
5 min. 
 
 
Roulette with key 
questions.  
 
 
Carlos Pozo 
Dr. Tom Wingfield 
 
 
Motivate the patients to adhere to 
treatment and follow National TB 
Program guidance 
 
 
 
Ensure that 100% of household 
contacts attend their screening medical 
consultation and receive and complete 
preventive therapy as necessary 
 
 
100% of <5 year olds start their 
preventive therapy 
 
The participants complete each 
condition of the IPSYD Project and 
receive all the relevant benefits 
 
Stigma (Part 1) 
What are 
stigma, 
empowerment, 
and TB clubs? 
 
 
1. Educate patients 
and their contacts 
about self-stigma 
and empowerment 
2. Introduce the theme 
of TB clubs – their 
aim, background and 
effectiveness 
3. Motivate 
participation  
 
  
What is stigma? What causes 
stigma? What are the effects of 
stigma? What are the different types 
of stigma? Enacted, anticipated, elf-
stigma 
What is being empowered? What is 
a TB Cub? Proven to be successful, 
the clubs are a safe and 
compassionate place in which we 
can share feelings and experiences 
 
Participatory 
10 mins Drawings of 
Becerra in 
powerpoint that 
reflect the 
patient’s doubts 
and worries at the 
beginning of 
treatment 
contrasted with 
their hope and 
positivity at the 
end of successful 
treatment 
Dr Tom Wingfield  
The participants increase their sense of 
self-esteem 
 
To feel better about ourselves as TB-
affected people 
Fight for our rights 
Understand why we feel as we do  
Understand why others treat us the way 
they do  
To make living with TB easier To 
complete TB treatment and get cured 
 
Part 2: Stigma 
 
 
 
 
 
 
 
 
Part 3: 
Empowerment - 
“¿How can we 
beat stigma?” 
 
Help the participants to 
identify the different 
ways in which TB-
related stigmas has 
affected their lives and 
explore how this made 
them feel. 
 
Help participants to 
identify how they can 
confront stigma through 
their own actions 
  
Relaxing music / welcome / review of 
the agreements of the TB club (see 
guide) 
Motivational ice breaker. This could 
be Hot (see document 1), Las 
Balsas (see Document 2) o Head to 
head (Document 3) 
TB Club (see guide) Facilitator 
prepares flipchart with 3 columns to 
fill: “Empowerment”, “Rights”, 
“Responsibilities”   
 
Participatory 
Active (learn through 
doing) 
 
 
 
 
 
 
Participatory 
Active (learn through 
doing) 
 
 
30 mins 
 
 
 
 
 
 
 
30 mins 
 
 
Necessary 
Becerra stigma 
and 
empowerment 
drawings (there 
are 18 in total) 
Power point 
(possibly) 
TB Club 
agreements 
Flip chart with 
marker pens 
 
 
Frank Fernandez 
Mari Haro 
Doug Huff 
 
 
 
 
 
Tom Wingfield 
Frank Fernandez 
Doug Huff 
 
 
“Exercise our rights” 
“Take responsibility for our health and 
lives” 
“Educate and train ourselves”  
“Be self-sufficient” 
“Have self-confidence and self-esteem” 
“Earn money” 
“Work together and support each other 
to improve” 
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Document 6: Example of program of interactive community meeting
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Document 7: Key learning themes of educational workshops 
and activities 
 
      Rather than have educational workshops that developed one specific theme 
concerning TB each time over months, we decided that we would make the workshops 
into activities involving core themes that would always be touched upon. This meant 
that a patient or household contact who attended just one workshop and did not 
attend further would learn the important points about TB. In addition, for patients or 
contacts who attended multiple workshops the content although repeated would not 
be tiresome as it would be presented in a different way every time. Some related 
presentations are available from our website, www.ifhad.org. We aimed to keep 
language simple and not overload participants with technical or extensive detail, 
therefore the themes and responses are not exhaustive. The key themes we covered 
were as follows (numbers indicate what we felt to be the most important aspects of 
each theme). 
TB infection, disease and control 
1. What are some ways in which TB disease can be prevented? 
 Including how TB is transmitted 
 Cough hygiene; Ventilation; Nutrition; Reduce avoiding overcrowding 
2. What are risk factors for getting TB disease? 
 Extremes of age; Overcrowding; Poverty; Malnutrition; Specific 
illnesses: Diabetes, HIV, Alcoholism 
3. TB, TB diagnosis and TB treatment 
 Different types of TB (MDR/sensitive, 
pulmonary/extrapulmonary) 
 Diagnosis of TB (including simple explanations of smear, culture, 
and molecular tests) 
 Phases of treatment, duration of treatment and differing 
treatments depending on resistance or other factors (e.g. HIV) 
 Free treatment provided by government 
 Integral medical attention (e.g. with maternal health, psychology 
etc) and patients’ rights 
 Healthcare workers’ and the TB program’s responsibility 
4. Adherence to treatment 
 Education and reminders necessary 
 Increase likelihood of cure 
 Decrease likelihood of developing resistance or failing treatment 
 Support from the IPSYD project and family members 
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 Reducing the hidden economic burden of treatment with cash 
transfers 
 
Household spending and saving 
1. What do we need to do to make a household budget and spend/save 
responsibly? 
 List of all household income 
 List of all household spending (including travel, education, and 
food) 
 Sources of unexpected expenditure (including illness and loss of 
work) 
 Payment of debts 
 Saving with anticipation 
 Avoid spending more than one earns 
 Money-generating ideas 
 
2. What are our sources of household income? 
 Income of husband/wife/head of household 
 Income of other household member or relative 
 Small own business or other work (e.g. caring for children, washing 
clothes) 
 Family business 
 Cooperative (e.g. making artesanía, canteen) 
 Non-cash income (e.g. in return for food or board) 
The IPSYD project and conditional cash transfers 
1. With regards to the IPSYD project, what do I have to do to receive my 
conditional bank transfers? 
 Open a bank account (with our assistance) 
 Give us a sputum sample to perform a molecular test and give you 
a rapid resistance test result 
 Allow us to visit your home, finish the questionnaire if necessary 
and list your household contacts 
 Adhere to TB treatment until completion 
 Screen household contacts for TB disease 
 Contacts needing preventive therapy (medicine to prevent TB) and 
those requiring treatment, start, adhere to, and finish treatment 
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Activities for interactive learning concerning the above themes 
(pictures and plans available from www.ifhad.org) 
 
1. Prize-giving roulette – Participants are split into two teams and take turns 
spinning a roulette detailing the main themes. Questions concerning the theme 
landed on are asked of each team and they have to find the appropriate answer 
from posters hanging around the area in which the meeting is taking place. 
Correct answers get a point, the answers are discussed and both teams receive 
individual small gifts at the end. 
 
2. Advance and win! – the participants are split into two teams and a team 
representative stands at the start of a short path made of different coloured 
tiles. Each tile represents a theme. The teams roll a dice with colours on each 
side to see which questions they answer. The questions are presented on 
posters with writing and representative pictures for those who can’t read and 
the team whose turn it is decide on an answer. A correct answer means the team 
can move forward one tile but if incorrect the questions passes to the other side. 
 
3. Word play – the participants are split into two teams. They are given a 
number of large cards that each contain a separate word. The separate words 
when ordered correctly form a sentence related to TB knowledge (e.g. TB can be 
transmitted through the air), or household economics (e.g. Making a household 
budget is a good way to save money). Each round corresponds to a different 
theme. The team that makes the sentence first and reads it out together the to 
the arbitrator wins a point. The team with the most points by the end are the 
winners. 
 
4. Snap TB with Memory! - participants are split into three teams. A pre-
prepared board contains a number of black squares. Behind each square is a 
picture relating to an aspect of TB (e.g. transmission, TB treatment) or 
household finances (e.g. opening a bank account). The teams approach the 
board and, taking it in turns, choose two black squares to reveal the picture 
behind. If the pictures match then they get asked a related question by the 
arbitrator. If they answer the question correctly, they collect the two cards (1 
point) and the go passes to the next team. If they answer the question 
incorrectly, the two remaining teams have the opportunity to answer the 
question for bonus points. 
 
5. Making fun of TB - The participants are split into two teams. Prior to the 
game, 54 large playing cards have been designed with 3 “suits assigned to 17 
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each of the cards. The logos cover ABC of TB, domestic finances, and the 
conditional cash transfer incentives of the socioeconomic intervention. There 
are also 3 jokers. Each group is dealt 6 cards and elects a person to play for 
them. The players from two of the teams sit down at a table visible to everyone. 
The aim is to get three cards of the same suit. Once the player does this they put 
the three cards on the table and will answer two questions about that subject. 
The first question is worth two points with a bonus question worth one point. 
Once one round of questions has been played the players switch over. 
 
6. This is war….against TB! – This game follows the outline of a popular TV 
show in Peru. Candidates are split into two teams and a member from each team 
approaches a buzzer with a hand behind their back. A question is shown on the 
slide show (if projector available) or on a poster. The question is a “starter 
question” concerning wither ABC of TB, domestic finances, and the conditional 
cash transfers. The player that buzzes soon gets to answer the question 
(without conferring with their team). If they get the starter question right then 
they get two points and rejoin their team and answer two further related bonus 
questions for a point each. If they get the starter question wrong then the 
opportunity to answer goes to the other player (without conferring). If they 
answer the question right then they reget two points, rejoin their team and their 
team gets the chance to answer the two bonus questions for a point each. The 
winner is the team with the most points when the questions are exhausted 
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Document 8: technical guide on setting 
up a TB Club 
 
 
 
Developed by Doug Huff, Psych. Frank Fernandez, and Tom Wingfield 
 
Summary for facilitators 
Contents of TB Club Theme 1: Explaining the clubs and stigma (10 minutes at the 
end of the educational workshop) 
Contents of TB Club Theme 2: Personal experience (first 30 minutes of the club)  
Contents of TB Club Theme 3: Empowerment  
(Second 30 minutes of the club) 
Support Materials 1-4 for activity 
Becerra Drawings and Explanations
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TB Clubs: a reference for the facilitators 
A BRIEF SUMMARY 
Each interactive community meeting will consist of 2 parts which will each last 
about an hour: 
1) Educational workshop:  
    a) 50 minutes concerning TB and the Project goals, plus  
    b) 10 minutes of an introduction to stigma (Contents TB Club) 
2) TB Club  
    a) 30 minutes: Stigma (Contents of TB Club Theme 2) 
    b) 30 minutes: Empowerment (Contents of TB Club Theme 3)  
Why do we need TB Clubs? 
 TB Clubs are a way to share experiences and therefore reduce feelings of 
isolation and stigma 
 Many countries of the world (from Nicaragua in Latina America to Ethiopia in 
Africa) already have TB Clubs with success: these Clubs work!  
 Given that the TB Clubs are “for TB-affected people and by TB-affected 
people” they will deal with the key themes in the lives of TB-affected families 
How do TB Clubs work? 
 With the support of a facilitator, the groups will talk about the themes 
surrounding TB including stigma and empowerment 
 The materials that we are going to use in the TB Clubs such as drawings and 
interactive jigsaws are guiding talking points 
 To facilitate communication networks between our TB Club members and to 
be more in keeping with their personal experiences we will separate groups in 
to patients (two groups, one male and one female) and contacts 
 The TB Clubs will last for approximately one hour 
 We want to improve the TB Clubs and therefore will continuously be asking 
for both TB Club Member and facilitator feedback of what we did well and 
what we could do better  
 
What is a TB Club and what are a TB Club’s goals? 
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 TB Clubs are a space free of prejudice in which we can: 
o Share experiences 
o Express ourselves 
o Explore the theme of stigma 
o Learn to empower ourselves as TB-affected people 
 TB Clubs are facilitated by facilitators and IPSYD team members but directed 
by the Club itself 
What are the agreements of the TB Club? 
 All of us in the TB Club have the right to speak 
 All of us in the TB Club should have the opportunity to speak 
 Nobody needs to speak if they do not wish to, it is not a requirement 
 We must respect the opinions of all members of the TB Club (even if we were 
to have a difference of opinion) 
 We must listen to all TB Club members when they speak and not interrupt 
 What is said in the TB Club stays in the TB Club: it is completely confidential 
(of course, it would be great if the messages from the TB Club concerning 
stigma and empowerment were spread by TB Club members in the 
community but without revealing any personal details of other TB Club 
members) 
Open questions about the Becerra drawings (pages 64-70) to start conversations 
and sharing of points of view: 
 What can you see in the drawing? (describe) 
 What do you think the people in the drawing (patient / family / health 
personnel) are feeling and or thinking? 
 How do you feel when you see this drawing? Why do you feel like that? 
 Is there anyone here who has had a similar experience or has known 
somebody who has had a similar experience? Would you share that 
experience with the group? 
 Does anyone who was listening have any comments about what they’ve just 
heard from their friends in the TB Club or any other comments? 
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Content of TB Club Theme 1: 
Introduction to stigma, empowerment and the TB Clubs at the end of 
the educational workshop 
 Title: “What is Stigma, Empowerment, and TB Clubs?” 
 Time: 10-15 minutes at the end of the first hour of the interactive community 
meetings before starting the hour of the TB Clubs 
 Goals:  3 
1. Educate TB patients and their contacts to TB Self-Stigma & Empowerment 
2. Introduce TB Clubs – their purpose, history, effectiveness  
3. Motivate participation  
 Materials:  
 Becerra drawings on powerpoint and copy in hand: #2, 13  
 Facilitator Presentation:  
 “What is Stigma?”:  
 Stigma is: 
 the negative thoughts, behaviors, and judgments some people have 
towards others they think they are somehow “different” and 
therefore less valuable or less worthy human beings 
 in our case the “difference” is a health problem -- TB  
 stigma can cause feelings of exclusion, rejection, blame, shame, or 
worthlessness  
 Stigma can have many layers and affect each person in varied ways for 
many different reasons e.g. 
 being poor or unemployed, being a woman, not having much 
education, belonging to a certain group of people or being from a 
certain part of the country, or having an illness or disability 
 Stigma is a process 
 everyone learns how to stigmatize, from the time they are children  
 it is how we recognize the differences between people 
 it is considered a normal part of life and is not bad in itself 
 but when we say a person that is different is a bad person because 
of the difference then the process becomes harmful, damaging, and 
painful to others 
 “What Causes Stigma?”: 
 stigma is caused by fear, misunderstanding, and misinformation 
 the most common cause is fear e.g. 
 fear of getting TB and it’s harmful health effects  
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 fear of missing work or being fired 
 fear of being rejected by family members and friends 
 fear of being isolated and excluded from social events 
 fear of being discovered to have TB and being stigmatized 
 “What are the Effects of Stigma?”: 
 stigma can affect each person in different ways for different reasons  
 it can cause feelings of sadness, loneliness, worthlessness, shame, guilt, 
and fear 
 these feelings cause stress, which causes more harmful health effects in 
addition to the TB 
 when people are afraid others will discover they have TB they often hide 
or conceal their TB to avoid stigma and the painful feelings that come with 
it 
 Concealing prevents them for getting diagnosed, receiving treatment, and 
becoming cured 
  “What are the different types of Stigma?”: 
 there are 3 types of stigma: 
1. enacted stigma 
2. anticipated stigma 
3. self-stigma 
 Enacted Stigma:  
 is the physical or verbal expression of stigma 
 in our case it is the comments or behaviors people make towards us 
because we have TB 
 it is a form of discrimination 
 it occurs in our homes, neighborhoods, markets, churches, at work, 
on TV, in the government, in the health care system 
 because so many people practice this form of stigma in so many 
ways and in so many places it is very hard to change – it can take 
many years to change people’s attitudes and believes, and then not 
everyone will change  
 Anticipated Stigma: 
 is the type of stigma we think others will have towards us if they 
suspect or discover we have TB 
 sometimes we don’t have to actually experience stigma – we just 
assume other people will have these stigma thoughts and feelings 
about us 
 we become fearful that others will discover we have TB and 
stigmatize or discriminate against us 
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 to avoid these fears and painful feelings we Conceal our symptoms 
of TB and avoid getting diagnosed or receiving or completing 
treatment  
 Self-Stigma: 
 is the type of stigma we apply to ourselves 
 the influence of stigma can be so strong we may begin to believe the 
negative thoughts and attitudes we think others have about us are 
true  
 we may begin to think it is our own fault we have TB, or that we 
have done something wrong or bad to deserve TB 
 we may begin to believe we are less valuable human beings than 
others and not deserving of respect, dignity and rights like other 
people  
 when we accept and believe these untrue judgments about us this is 
called Self-Stigma 
 self-stigma occurs when we believe and accept the stigma & 
discrimination other people have toward us is true  
 because stigma is painful we may try to avoid the pain by isolating 
ourselves from other people, avoiding our friends and relatives, not 
participating in social events    
 this can make us feel more sad, lonely, depressed, and hopeless 
 we may feel abandoned by our family and friends, at the time we 
most need their help and support 
 self-stigma this is the most harmful of the 3 types of stigma  
 but self-stigma is also the type of stigma we ourselves can do 
something about, we can control, we can resist 
 when we learn to resist self-stigma we can resist all 3 types of 
stigma and become empowered 
 “What is being Empowered?”:  
 Empowerment is participating in activities that increase our ability to make 
changes in our lives 
 it is having the ability to recognize and solve problems that affect our lives 
 it is having a say in decisions that affect our lives and being listened to 
 it is being recognized and respected as human beings of worth and value, 
as equal citizens with equal rights  
 and being able to use our rights to improve our lives and the lives of our 
family, friends, and community 
 we can learn to become empowered and resist TB stigma by participating 
in TB Clubs 
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 “What are TB Clubs?”: 
o TB Clubs are special support groups for men and women with TB  
o they have been used successfully to resist TB stigma and help empower 
people with TB in other countries around the world for 20 years 
o they are a safe, supportive place where we can share our thoughts, 
feelings, experiences, and concerns without fear and without being judged 
o a place where we can learn more about self-stigma and empowerment, 
and practice the skills to resist stigma 
o a place where we can learn to: 
 feel better about ourselves 
 stand-up for ourselves 
 understand why we feel the way we do  
 understand why people behave the way they do towards us  
 make living with TB easier 
 complete TB treatment and become cured 
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Contents of the TB Club Theme 2: Personal experience of stigma 
 
 Title: “How has TB Stigma affected our lives?” 
 Time: 30 minutes 
 Goal: Help people identify the different ways they have been affected by TB stigma and 
how TB stigma makes them feel  
 Materials:  
 Becerra drawings: #1, 2, 3, 4, 11, 12, 13 
 may use HC staff and children drawings if theme arises spontaneously 
from group 
 flipchart/stand/markers  
 TB Club Agreement  
 Process:  
 Facilitator: Reiterates the welcome and opening of the TB Club 
 Facilitator: reviews TB Club Agreement 
 Facilitator: can decide to put relaxing instrumental music on in the background 
as a relaxation technique 
 Facilitator: to break the ice and get people interacting, the facilitator may want 
to do an activity with the group (Activity Materials 1-3) 
 Club members choose a drawing that shows a past or current event that they or 
a family member or a friend may have experienced 
 Club members think quietly to themselves for several minutes about how this 
event made or makes them or a family member or a friend feel 
 Facilitator acknowledges how hard it may be to share painful experiences and  
feelings, that it requires trust in ourselves and each other, and that through this 
process we can learn how to overcome stigma 
 Questions/Discussion:  
 Facilitator asks if any Club member would like to share their drawing and how 
their own experience is similar in some way to the drawing  
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 if there are no volunteers Facilitator may lead by selecting a drawing and 
sharing their personal experience and feelings associated with that 
drawing 
 Facilitator should be certain Club members talk about their feelings associated 
with their experience, not just the facts of the experience, by asking when 
necessary: “how did this make you feel”? 
 Facilitator gives every Club member an opportunity to share 
 Closing Messages:  
 Facilitator asks group “what important things have we learned from our 
experiences and feelings?” 
 Facilitator writes key summary words on flipchart 
 Facilitator says: 
 “these stories help us understand how some people may judge and 
condemn people with TB” or blame people for having TB as if it were their 
own fault” 
 “these stories also shows us how it feels to be stigmatized -- it can be 
painful and make us feel like outcasts, strangers, unwanted, unnoticed, as 
if we are not human anymore” 
 “feeling stigmatized can hurt our health in addition to what the illness 
causes” 
 “but we can learn to overcome self-stigma with Empowerment which we 
will talk about in the second half hour” 
 Facilitator offers to speak with anyone who would like to talk more during, the sign-
out session  
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Contents of TB Club Theme 3: Empowerment 
 
 Title: “How can we overcome Stigma?” 
 Time: 30 minutes  
 Goal: Help people identify how to respond to stigma though individual action  
 Materials:  
o Becerra drawings: #1, 2, 3, 4, 5, 11, 12, 13  
 may use HC staff and children drawings if theme arises spontaneously 
from group 
o flipchart/stand/markers  
o TB Club Agreement  
 Process:  
o There are many different ways to facilitate a TB club, the following listed are 
certain examples 
o The facilitator can decide to perform an activity to break the ice and get people 
moving (Document 1-3)  
o The facilitator can put some relaxing instrumental music in the background to 
relax the participants 
o Facilitator reviews TB Club Agreement 
o Facilitator prepares flipchart page divided into 3 columns labeled 
“Empowerment”, “Rights”, “Responsibilities/Duties” 
 Questions/Discussion: 
o Facilitator gives every Club member an opportunity to share  
o Facilitator asks Club members to think about and share their ideas about   
“Empowerment” and writes them on flipchart e.g. 
 “standing up for your rights” 
 “taking responsibility for your health and/or life” 
 “getting training or education”  
 “being self-reliant -- standing on your own 2 feet” 
 “being self-confident” 
 “earning money” 
 “working together to support each other/change things” 
o Facilitator asks Club members to think about and share their ideas about 
“Rights” and writes them on flipchart e.g.  
 the right to be treated with respect and dignity  
 the right to participate (have a say) in decisions that affect our lives 
 the right to not be discriminated against in any form because we have TB 
 at home:  
o the right to be with our family and friends  
o the right not to be evicted from our house by our family or 
landlord because we have TB 
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 at work: the right to work and not to lose our job because we have 
TB 
 in the community:  
o the right to buy and sell food or goods  
o the right to attend school, church, or social events 
o the right to organize and attend support groups  
o right to the same quality health care and information as 
others receive 
o the right to participate (have a say) in decisions about our 
health care and TB treatment, ask questions,  get answers 
o Facilitator asks Club members to think of and share their ideas about 
“Responsibilities/Duties” and writes them on flipchart e.g.  
 the duty to protect our families, friends, and the community from getting 
TB 
 the duty to take all our medicines, complete TB treatment, become cured 
 the duty to help other people who may have TB become diagnosed, 
receive and complete treatment, become cured 
 the duty not to stigmatize/discriminate against others 
o Facilitator asks Club members to think about and share their ideas about what 
kind of actions they might take to “Empower themselves” and writes them on 
flipchart e.g. 
 do not self-stigmatize e.g. 
 resist accepting and believing the negative stigma thoughts others 
have towards us because we have TB e.g. 
o it is not our fault we have TB, we did not want to get TB, we 
have done nothing wrong to deserve having TB 
 believe that we are good, valuable people, worthy of love and 
deserving of the same rights others have  
 remember -- “we are good people with a bad illness, not bad 
people because we have TB” 
 talk with and educate other people about TB stigma/discrimination e.g. 
 family members, friends, neighbors, co-workers, health care 
workers 
 explain to others what stigma is, how it hurts people, how it 
prevents people from receiving treatment and becoming cured, 
how it is a form of discrimination 
 correct myths & misinformation about TB when you hear people 
repeating it 
 talk openly to others about your knowledge, experience, and 
feelings about TB 
 support our fellow Club members and any TB patient in fighting against 
TB stigma, completing TB treatment, and becoming cured e.g. 
 visit TB patients in their homes  
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 help TB patients get to healthpost visits and take their medicines 
daily 
 encourage to speak openly with healthpost doctors, nurses, and TB 
Facilitators about questions they have about their TB, their 
treatment or medicines, and any bad side effects they are having 
from the medicines  
 speak out against TB stigma/discrimination when we see or feel we or 
others are being stigmatized/discriminated against because of TB e.g. 
 stand up for our rights when we think they are being denied or not 
being considered 
 be a role model: watch our own thoughts and words and don’t 
stigmatize others 
 Closing Messages: 
o Facilitator asks group “what important things have we learned from our 
experiences and feelings?” 
o Facilitator writes key summary words on flipchart e.g. 
 do not self-stigmatize: resist, believe, remember 
 educate: explain, correct, talk openly 
 support: visit, help, encourage 
 speak-out, stand-up, be a role model  
o To finish: The facilitator can decide to finish with handshakes or “abrazotherapy” 
(essentially, shaking hands or hugging each member as comfortable / 
appropriate) 
o Facilitator: can reinforce the session asking the Club to update or exchange 
numbers for people who wish to continue their conversations. The facilitator 
offers to speak with anyone who would like to talk more during, the sign-out 
session  
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SUPPORT MATERIAL 1 
 
ACTIVITY: HOP (3-4 minutes) 
 
OBJECTIVE:  
Integrate and motivate the members to improve communication and maintain the attention of all 
the members participating, creating a favourable and friendly environment.  
 
GROUP SIZE:  
The number of members participating is not specific. This activity can be performed with all 
types of groups (children, adolescents, and adults).  
 
TIME REQUIRED:  
3 minutes approximately although this depends on the number participating in the activity  
 
MATERIAL:  
None specific.  
 
PLACE:  
This activity can be performed as much in open as in closed spaces, without requiring a large 
space.  
 
DEVELOPING THE ACTIVITY:  
The participants are asked to listen to objects that belong to a certain group (number, fruit, 
colours, country or group). People raise their hands if they hear an object that belongs to the 
group and say “hop”. If they get it right then they will accumulate points and if they get it wrong 
then they will accumulate negative points and the facilitator can make a pretend “punishment” 
for the losers or round of applause for the winners. 
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SUPPORT MATERIAL 2 
 
ACTIVITY: THE RAFTS (3-4 minutes) 
 
OBJECTIVE:  
Integrate and motivate the members to improve communication and maintain the attention of all 
the members participating, looking for leaders and creating a favourable and friendly 
environment.  
 
GROUP SIZE:  
The number of members participating is not specific. This activity can be performed with all 
types of groups (children, adolescents, and adults).  
 
TIME REQUIRED:  
3 minutes approximately although this depends on the number participating in the activity  
 
MATERIAL:  
None specific.  
 
PLACE:  
This activity can be performed as much in open as in closed spaces, without requiring a large 
space.  
 
 
DEVELOPMENT OF ACTIVITY:  
The participants are informed: Let’s imagine that we’re in the sea and only those castaways that 
are in boats of 2 are going to be saved…followed by 3, then 4, 5, 6 and so on successively (or 
backwards, mixed etc). 
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SUPPORT MATERIAL 3 
 
ACTIVITY: HEAD TO HEAD (3-4 minutes) 
 
OBJECTIVE:  
Integrate and motivate the members to facilitate interaction and work in groups 
 
GROUP SIZE:  
The number of members participating is not specific. This activity can be performed with all 
types of groups (children, adolescents, and adults).  
 
TIME REQUIRED:  
3 minutes approximately although this depends on the number participating in the activity  
 
MATERIAL:  
None specific.  
 
PLACE:  
This activity can be performed as much in open as in closed spaces, without requiring a large 
space.  
 
DEVELOPMENT OF ACTIVITY: The facilitator will ask the participants to form pairs and then 
motivating them by joining body parts. Instructions: Nose to nose, eye to eye, elbow to elbow, 
cheek to cheek, foot to foot, head to toe, hand to hand, arm to arm, belly to belly, back to back, 
hand to ear etc 
¡Make your own connections! You can make variations on a theme.  
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SUPPORT  
MATERIAL 4 
 
Psychological concept: 
Stages and levels of life 
 
 
 
Let’s consider 3 ways in which people deal with the issues facing them: 
 
1) Think responds to the question What?  
What thoughts do I have (as a person), what do my family and those close to me think (family), 
what do others around me at work, in the street, in church, think (community), what is the 
general feeling “out there” (wider environment) 
2) Feel responds to the question How? 
What we feel about ourselves, personal and internalized emotions (person), what feelings and 
emotions arise at home that may help or hinder the fight against stigma (family) how do people 
in the community around me manage their emotions and feelings (community), what is the 
general feeling “out there” (wider environment) 
 3) Act responds to the question When? Where?  
When and where can I act against stigma (person), when and where would my family and 
household challenge stigma (family) where and when in the community and in the general 
population (community and wider environment) 
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The Becerra drawings - explanation & points for conversation 
DRAWINGS 1-12: STIGMA (FIRST PART OF THE TB CLUB) 
Drawing 1: 
Usefulness: This drawing shows a lady that has her own business, 
an eatery. She is or was a TB patient. The drawing illustrates both 
stigma and loss of household income. 
¿What can we see? The lady is trying to sell her food to a pair of 
young men who appear to be rejecting her offer and laughing at 
her. We may presume that this maltreatment relates to ignorance 
and enacted stigma by the men against the lady regarding her 
diagnosis.  
Points for conversation: Has anyone in the Club experienced a 
similar situation such as loss of work, reduction of income? This 
may lead to conversations concerning human rights, and how to 
combat TB costs (including cash transfers). 
Drawing 2:  
Usefulness: This drawing encompasses stigma in its various forms 
and is great to start conversation and to introduce the theme of 
stigma. The drawing is the opposite of drawing 13 that shows 
empowerment, like a “before/after” TB.  
¿What can we see? A young man with TB who appears sad with 
many current issues passing through his mind: loss of work and 
family, disapproval from a respected figure, and feelings of 
isolation.  
Points for conversation: What can people see in the picture? Why 
have people treated the young man like this? Is there anyone in 
the Club who can relate to any one of the thoughts passing 
through this man’s head? 
Drawing 3: Usefulness: This drawing is highly important and has a high 
educational value because it can be interpreted in various ways: TB 
transmission on public transport and beyond, active case-finding, 
and stigma against or logical avoidance of people with a chronic 
cough 
¿What can we see? A man coughing on public transport. The coaster 
/ bus is overfull with many people of different ages and with all 
Windows closed that increases the risk of TB transmission. The 
young man has noticed the other gentleman’s cough and seems 
surprise and scared.  
Points for conversation: How is TB transmitted? What can we do to 
decrease the risk of transmission seen in the drawing? What advice 
would you give to the coughing chap?  
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Drawing 4: 
Usefulness: The value of this drawing is to focus on the stigma 
that exists in the home. It concerns relationships within the 
family, TB transmission and nutrition. In this way, it is similar to 
drawing 2. 
What can we see? A TB patient is sat apart from his family at 
home during dinner. He still has a cough.  
Points for conversation: Is there anyone in the Club who can 
identify with what is happening in the drawing? What can we do 
at home to reduce the risk of TB transmission? At home, how 
can we avoid our relative with TB feeling stigmatized? Does TB 
transmission risk stay the same throughout treatment? 
 
Drawing 5: 
Usefulness: This drawing is meant to identify with younger 
people in school or college. With respect to adolescents, it also 
refers to the stigma that relates to being a TB contact. What can 
we see? A pupil is sitting apart in the corner of his class. The other 
students are laughing at him and even the teacher appears 
annoyed by his presence. The pupil is isolated from class and may 
be a TB patient or contact. 
Points for conversation: (Try to ensure that the younger people 
of the group have a chance to talk) Is there anyone who identifies 
with what they see? Is what’s going on in the picture fair? How 
can we prevent this type of maltreatment in schools and 
colleges? 
Drawing 6: 
Usefulness: This drawing is centred more around females. It 
describes distinct fears: risk of transmission to children, relatives 
and partners, and opinions of friends/community 
¿What can we see? A lady is considering all her fears about TB: 
infecting her children, rejection by her husband, gossiping of 
friends. From her point of view, having TB means that she is 
going to ruin other people’s lives. 
Points for conversation: (Try to ensure that the women of the 
group speak) How can we reduce the risk of infecting children 
and how are we going to check that they don’t have TB? Should 
we explain about TB to children? How does TB affect 
relationships between a couple? 
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Drawing 7: 
Usefulness: This drawing is about the stigma that we come 
across even in healthposts. So, it’s important that no TB 
program health personnel are present in the Clubs so patients 
can freely express themselves. 
¿What can we see? The healthcare professional is signalling 
(without looking) that the patient should keep away from her 
and leave his sample. The patient appears shamefaced and 
upset. Ironically, in the background a poster can be seen that 
talks of the rights of TB patients: perhaps the healthcare 
professional should take note! 
Points for Conversation: Can someone share their experience of 
the healthpost (good/bad)? ¿What are the healthposts’ 
responsibilities and the patient’s rights? 
Drawing 8: 
Usefulness: This drawing deals with active case finding and how 
couples’ relationships may be affected by TB. 
¿What can we see? A man that probably has TB who has a severe 
cough. His partner seems to realise that perhaps he has TB. Due 
to that, she asks him to keep away from her. He covers his mouth 
and looks ashamed. It seems unclear whether she suggests to 
him to go and get checked to rule out TB or not. 
Points for conversation: How are relationships between couples 
affected by TB? What are the different ways in which someone 
can react to finding out that their partner has TB? How can we 
face and resolve such problems like TB as a couple? 
Drawing 9: 
Usefulness: This drawing deals with the way in which TB can 
affect young people in school or college. It goes together well 
with Drawing 5, especially in a group consisting mainly of young 
people / adolescents. 
¿What can we see? In the foreground, a group of boys is playing 
football, happily. In the middle, there is a boy with a cough. It 
looks like the group to the right are making fun of the coughing 
boy. 
Points for conversation: (Try to ensure that the younger people 
in the group talk) Is the stigma that we see in the picture a form 
of bullying? How can we confront the problem of stigma in 
schools, especially relating to TB? 
  
 231 
 
Drawing 10: 
Usefulness: This drawing deals with the stigma that can be found 
in the health posts. So, it’s important that there are no TB 
program personnel in the Clubs in order that the TB patients can 
express themselves freely. This drawing relates very well with 
drawing 7. 
¿What can we see? The healthcare professional is covering her 
mouth and turning her back on the patients in the waiting room. 
Ironically, in the background there is a poster concerning the 
clinical journey of TB patients: the healthcare professional 
should take note! 
Points for conversation: Can someone tell us about their 
experience in the healthpost (good/bad)? What are the 
healthpost’s responsibilities and the patient’s rights? 
 
Drawing 11 
Usefulness: This is an emotive example of the negative effects of 
TB and stigma as much from healthpost personnel as in the 
community. Use it cautiously.  
¿What can we see? We can see a family taking their relative 
(who appears to have TB) to the healthpost in a wheelbarrow. 
We may imagine that the patient’s clinical episode is severe 
given his weakness. Also, the family appears poor given the 
mode of transporting their relative. Sadly, members of the 
public and the guard are watching and gossiping about the 
scene. 
Points for conversation: How can we avoid a scene such as this? 
(prompt diagnosis, active case finding etc)? 
 
Drawing 12 
Usefulness: Stigma even exists between patients. Sometimes 
people with TB can be differentiated as they have to use a 
different entrance at the healthpost or give a sputum simple etc. 
The drawing also touches on the issue of confidentiality. 
¿What can we see? A division can be seen between the 3 patients 
on the right and the patient on the left with suspected TB. The 
ladies are whispering about her and the man seems to hear by 
chance about the possible diagnosis. The TB patient looks sad 
and ashamed. 
Points for conversation: Doe this situation really occur in the 
healthposts? Why? What could we as TB affected people and the 
healthpost do to overcome this problem?  
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DRAWINGS 13-18: EMPOWERMENT (SECOND PART OF THE TB 
CLUB) 
 
Drawing 13 
Usefulness: This drawing, the opposite of drawing 2, is essential 
with respect to the empowerment section. In it we find the 
positive aspectes relating to adherence and cure of TB. The 
drawing encompasses all the things which our socioeconomic 
intervention aims to combat. 
¿What can we see? The same young man, contrary to what we 
saw in drawing 2, appears happy: he is thinking about his cure, 
finding/continuing work, having  loving family, and that now he 
is a facilitator supporting others (CRUCIAL POINT FOR 
CONVERSATION). 
Points for conversation: How did this young man’s life become 
positive? How can we do the same?  
Drawing 14 
Usefulness: This drawing is the opposite to drawing 8. We can 
also appreciate how important support from people at home is 
(be it wife, husband, relative or friend). Besides this, we can also 
note the importance of active case finding to prevent TB (the 
wife in this case has less risk of getting infected and her husband 
a greater chance of cure) 
¿What can we see? The lady is worried about her husband’s or 
relative’s cough. So, they go together to the health post to 
promptly get diagnosed and start treatment! 
Points for conversation: ¿What do we do if a relative, friend, or 
other person has a cough? What is active case-finding and how 
can it benefit a facilitator by doing it? 
 
Drawing 15 
Usefulness: This drawing captures empowerment. It is an 
example of leaving behind self-stigma and learning to respect 
oneself. 
¿What can we see? A confident woman says to other women she 
knows that she is going to take her anti-TB treatment. While a 
couple of the women seem shocked, the lady on the left seems 
calm and free of prejudice. 
Points for conversation: Is having TB our fault? Is there any one 
amongst us who wants to have TB? When do TB patients stop 
being contagious? Would any of you speak so freely as this lady? 
If so/not, why? 
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Drawing 16 
Usefulness: This drawing would be most usefully employed 
towards the end of the TB Club. It encompasses the whole of 
the positive process of the TB Club: sharing, belonging, and 
mutual support. 
¿What can we see? There is a TB Club functioning well. Its 
members are interacting and sharing their experiences and 
listening actively. In the background, we can appreciate the TB 
Club agreements and the empowerment solutions. 
Points for conversation: Which parts of the TB Club have been 
the most informative / useful for you? What have we learnt in 
today’s TB Club? What are we going to do if we confront stigma 
in the Street / healthpost / home? 
 
Drawing 17 
Usefulness: This drawing illustrates the part of our intervention 
in which patients can become a facilitator and support other 
patients recently diagnosed. Active case finding is also a crucial 
part to this process. 
¿What can we see? A facilitator / member of the IPSYD team is 
sharing her positive experience in order to empower and 
encourage other new patients.  
Points of conversation: What advice would you give to a patient 
newly diagnosed with TB today? As patients and ex-patients or 
people affected by TB, what experiences have we had that 
might be useful to share? 
 
 
Drawing 18 
Usefulness: This picture encompasses all the support necessary 
to empower us to fight against stigma and get cured. The 
sources of support are various and we must not forget that 
there is always someone on which we can count. The patients 
can count on us. 
¿What can we see? Active case finding by partner/relative, 
friends offering support, the staff of the healthpost and the 
patient working in conjunction to cure TB, and the avoidance of 
transmitting TB at home. 
Points for conversation: Who can we personally count on to 
support us? ¿Before our sputum test become negative, how can 
we avoid transmitting TB in the first weeks of treatment? 
  
 234 
 
Strategies for using the Becerra drawings 
 
As we have seen, the drawings can be grouped according to the major themes on which they are focused. This may 
be of great value as, remember, we will be dividing TB Clubs into male patients, female patients, and contacts (both 
sexes) according to their differing experiences. It is also worthwhile remembering that the age of members of the 
TB Club will vary a lot from very young or adolescent to elderly patients. 
 
If there is anyone in the Club that has already attended many interactive community meetings, then: a) they can 
help alot regarding the dynamic of the group and b) they can be specifically asked to choose a drawing about which 
they have not spoken or a drawing about which they have talked previously but now their opinion / experience has 
changed and they may want to revisit the theme. 
 
Drawings about patients 
 Female patients – Number 6 & 15 
 Male patients – Numbers 8 & 14 
 Patients of either sex – Numbers 1, 3, 4, 7, 10 & 11 
 
Drawings about stigma related to the healthpost / healthcare facility 
 Numbers 7, 10, and 11 
 
Before and after / juxtaposing drawings 
 Number 2 with 13 
 Number 6 with 15 
 Number 8 with 14 
 
Drawings focusing on contacts 
 Numbers 3, 4, 5, 9, and 12 
 
Drawings focusing on children 
 Numbers 5 and 9 
 
Drawings concerning empowerment 
 Numbers 13 to 18 
 
NB: The Becerra drawings were adapted from original drawings from the resource 
“Understanding and challenging TB stigma: a toolkit for action” from the Zambart project. 
This resource can be accessed and is freely available to download from 
http://targets.lshtm.ac.uk/resources/Publications/TB_and_Stigma_Eng2.pdf  
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Document 9: Feedback form for interactive community meetings 
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Document 10: DOUBLE incentives card 
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Document 11: SIMPLE incentives card 
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Document 12: Reading material for patients opening their bank 
accounts 
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Document 13: IPSYD Facilitator Training Process 
 
IPSYD Team Facilitators: Role, recruitment, and selection 
 
Who are facilitators?  
 A facilitator is a person, normally a patient or ex-patient, who has a vocation to support 
families affected by TB. 
 The term “facilitator” is equivalent to “promoter”. 
 
What does a facilitator do?  
 The specific role of a facilitator is to support families affected by TB to complete the TB 
program goals and receive the corresponding conditional cash transfers of the IPSYD 
project. This is achieved through meeting with patients/contacts in the healthpost, home 
visits, and leading interactive community meetings (educational workshops and TB clubs) 
 Facilitators will only work with “supported” patients and their families 
 
How are facilitators selected? 
 Facilitators are selected by the adequate completion of their own conditions with respect 
to the TB program. This means that a patients who doesn’t take their own medicine and 
whose contacts don’t attend the healthpost for their TB screening will not be invited to 
train to be a facilitator 
 Those selected to become facilitators will also have shown good interpersonal and 
communication skills 
 Beside completing their own conditions, a facilitator will be a person with a strong 
commitment to and vocation towards TB patients and their families 
 A facilitator will need to have sufficient availability to appropriately complete their 
important role 
 
How are facilitators trained? 
 The IPSYD team has developed a facilitator training plan. Within the plan, apart from 
practical sessions observing and running a home visit and interactive community 
meeting, every month we offer a half-day training day that consists of: 
o General learning concerning TB: the bacteria, transmission, treatment, contacts 
o Explanation of the IPSYD project and conditional cash transfers  
o Explanation of the work of the research nurses, research nurse assistants, and 
facilitators of the IPSYD project 
o Educational and psychological workshop: working in teams, leadership, and 
interaction/communication 
 One can only become a facilitator after attending a half-day training session, two home 
visits and two interactive community meetings (the first as observers and the second as 
active members/leaders of the IPSYD team)   
 
What type of reimbursement/payment will a facilitator receive for their 
work? 
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 Each time that a patient completes a condition and receives a bank transfer, the 
corresponding facilitator (i.e. who supports that family) also receives a bank transfer (of 
approximately 20% the value of that the patient receives, Document 15)  
 A facilitator can support more than one family at the same time in their community 
 For the main part, facilitators are going to work in the same community in which they 
live. Due to this, facilitators will not normally receive a reimbursement for their transport 
given that it is hoped they will be within walking distance of their patients’ houses 
 
What are the criteria by which a facilitator will not be able to continue 
working with the IPSYD team? 
 A facilitator will be unable to continue their work with the IPSYD team when they are unable 
to adequately carry out their role (Figure): 
o Anonymous feedback of their patients reveals low output or a lack of courtesy 
o A facilitator cannot maintain confidentiality of their patients 
o In cases of dishonesty, robbery, or falsification of reports or documents 
o In cases of the facilitator threatening behaviour or bribery of the patients and/or their 
family  
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Flow Chart of Facilitator Training 
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Specific roles of facilitators 
 
Goal Method Desired result 
Support and coordinate 
with the IPSYD research 
nurses and research nurse 
technicians to carry out 
day-to-day project 
activities 
 To have frequent meetings in 
the healthpost 
 To undertake household visits 
to families failing to meet their 
conditions outside of those 
realised by the nurses 
 Organise and undertake 
interactive community 
meetings in their community 
 Collect sputum samples during 
the prevalence survey 
 Expand the reach of the 
IPSYD team 
 Support patients and their 
families to comply with 
the TB program norms 
and receive their 
incentives 
 Measure the impact of our 
intervention with respect 
to the TB rates in 
supported versus 
comparison communities 
Help patients and their 
families to identify and 
express emotions, needs, 
desires and concerns 
 Facilitators can share their 
personal experiences: benefits, 
difficulties, advice to achieve 
success 
 Lead the TB Clubs using 
activities developed by the 
IPSYD team 
 Active participation by all 
participants in the TB 
Club and Educational 
Workshop 
 TB Club that functions 
independently (even post 
IPSYD intervention) 
 Recruitment of other 
facilitators 
Support patients and their 
contacts to adhere to the 
TB program norms of 
adherence and successful 
completion of treatment 
and adherence 
 Leadership of TB Clubs 
 Home visits 
 Meetings in the healthpost  
 Education and companionship 
 Increase adherence and 
treatment completion 
 Increase empowerment 
 
Support patients and their 
families to reduce the 
personal barriers with 
which to meet the 
challenge of adherence 
and treatment completion 
 To assist during TB Club so 
that the participants can 
identify and express any 
emotions and beliefs that might 
prevent good treatment 
adherence and completion 
 Reduce stigma 
 Increase empowerment  
 Increase adherence and 
treatment completion 
 
Monitor and document 
attendance at the 
interactive community 
meetings 
 Good documentation 
 Feedback 
 Identification of 
participants at high risk of 
not completing the 
conditions 
 Stimulate participation  
Train new facilitators  Organise and lead facilitator 
training 
 Create sustainable and 
transferable facilitator 
training 
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Document 14: Example of facilitator training session material 
 
FACILITATOR TRAINING: GENERIC METHODOLOGICAL GUIDE 
 
“WORKING TOGETHER WITH COMMUNITIES TOWARDS HEALTH” 
 
General objectives:  
o Train new facilitators from the supported communities in order that they may start working with new TB patients and their families 
o Through an educational session and professional/psychological workshop, offer the participants a formal, transferable and certified training, which will be 
essential for their work with the project but also may be useful as future evidence of professional development 
 
Specific objectives (in brackets the existing project materials revised in each objective are shown): 
 
o Ensure that the participants have a general understanding of the methods of TB prevention and control aswell as TB treatment and adherence (Patient 
mini-flipchart) 
o Ensure that the participants understand the TB Program goals underlying the IPSYD project conditions for the conditional cash transfers (Incentives card) 
o Revise the key messages concerning responsible spending and saving (Project handout and bank handouts and materials) 
o Educate the participants about their role as facilitators and the role of the other members of the IPSYD team (IPSYD Project team activity checklist) 
o Involve the participants in a psychological/professional workshop and activity concerning working in teams, leadership and interaction (Summary of TB 
Clubs previously prepared by Frank Fernandez, and role play activities by Tom Wingfield) 
o Ensure that the participants understand, value and are able to draw on their own personal characteristics with respect to becoming  facilitator and reinforce 
the positive feelings they have about themselves (throughout the session and final feedback) 
 
Outputs:  
o Prior to the training session, each potential participant must receive the Reading material (incentives card, mini-flipchart or handout, bank material, and 
IPSYD team field activity check list) 
o At the beginning, the participants do an exam consisting of 10 multiple choice questions 
o The participants define and answer in their own words the educational questions from the educational workshop activity 
o The participants value and put into practice the messages concerning home economy and reflect such messages on a flipchart 
o The participants take the same 10 question multiple choice exam that they did at the beginning of the session  
o The participants receive a formal certificate at the end of the training detailing the educational aspects covered (TB, home economy, working in teams, 
leadership, interaction and communication) and give feedback to improve the session 
 
 
 
Responsible members of the team: Tom Wingfield, Marco Tovar, Rosario Montoya, Frank Fernandez, Douglas Huff and the IPSYD team  
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PROCESS 
/THEME 
OBJECTIVE CONTENT METHODS TIME MATERIALS STAFF MEMBER OUTPUT 
 
Prior activities 
 
Preparation of the 
space in which to 
develop the training 
session 
 
Group the seats in an 
appropriate manner and 
get projector set up 
 
Participative 
 
 
60 min. 
(13:30-
14:30) 
 
 
Chairs, table, projector, 
laptop, plugs and 
extension, pens, 
paper, balloons, etc. 
 
IPSYD team 
 
 
 
Prepared and appropriate space ready to receive 
participants and undertake activities   
 
Pre- and post-training examination 
 
Reception of 
participants and 
pre-course exam 
 
Register all the 
participants 
 
Ensure participants 
complete the 10 
question precourse 
exam 
 
 
Registration 
 
Precourse exam 
 
Participative 
 
 
15 min. 
(14:45 -
15:00) 
 
 
Attendance sheet 
Pencils 
Printed attendance 
sheet (generated from 
database) 
Precourse exam 
Name bade 
 
 
Tom and Charo 
 
Assistance from 
existing facilitators 
 
 
Attendance register completed by each participant 
 
IPSYD team members explain the precourse test to 
the facilitators and assist them if they have any 
questions 
 
The participants can be identified by name with their 
badges and get to know one another 
 
Welcome greeting 
and presentation 
 
Present the contents of 
the training day 
 
Themes and times, 
presenters 
 
Presentation 
 
 
5 min 
 
 
Copy of program of the 
training day 
Projector and laptop 
 
Tom 
 
The participants are orientated to the central themes of 
the training day and are encouraged in the fact that 
they have been chosen to be facilitators 
 
Group activity 
 
Generate confidence 
and break the ice 
 
Group the participants 
according to a number 
previously list on their 
name badge 
 
Activity, 
participative 
 
5 min 
 
Free and appropriate 
space with which to 
organise the two 
groups 
 
Charito 
 
 
 
The participants feel more at ease with each other and 
have more confidence amongst the group 
 
Education 
workshop about 
the IPSYD team, 
peoples roles and 
the roles of the 
facilitators 
 
Orientate the 
participants around TB 
and conditional cash 
transfers 
 
Explain how the IPSYD 
project functions 
 
Explain what is the role 
of the facilitator and 
how they can benefit 
 
Revision of TB 
 
Incentives 
 
Spending and saving 
responsibly 
 
The role of our team and 
the facilitators 
 
Participative and 
activity 
 
Presentation and 
activity 
 
Presentation and 
activity 
 
 
Presentation  
 
15 min 
 
 
15 mins 
 
15 mins 
 
 
15 mins 
 
Powerpoint and 
posters, pens, paper, 
mini-flip chart as a 
reference 
Incentives card 
(poster-size or PPT) 
Bank leaflet  
 
Cards with key team 
activities ordered 
 
Pilar / Mari Haro 
 
 
Natalie / Charito 
 
 
Charo / Carlos 
 
Tom 
 
Powerpoint with appropriate answers 
 
Incentives card with incentives covered and the 
participants have to guess what the incentive is (for 
example, doses missed etc) 
The group notes positive and negative things that the 
patients and their families can buy with the incentives 
 
Place all the activities cards in the appropriate place in 
the appropriate time from recruitment to final follow-up. 
Take a photo at the end 
 
Professional/psych
ological workshop: 
being a facilitator 
 
Focus on the abilities 
needed to complete 
the role of facilitator 
successfully 
 
 
Working in a team, 
leadership and 
communication 
 
Facilitating TB Clubs: ho 
to facilitate! 
 
Presentation and 
activity 
 
Presentation and 
activity (role play of 
Tb Club) 
 
25 mins 
 
35 mins 
 
 
 
Projector, laptop, 
slides 
 
Roleplay guide / 
techniques to use 
during TB Clubs 
 
Tom 
 
Mari Haro / Jessica / 
Charito 
 
Tom  
 
Explore what a team is. Generate a list of abilities that 
make a person work well in teams.  
 
Do a role play of a TB Club planting different 
participants to act out difficult aspects. Critique good 
things and things to be improved about the practice 
Feedback, 
postcourse exam, 
close and 
certificates 
Repeat the exam post-
course to reinforce 
messages learnt 
Summarise session 
Post-course exam (revise 
together) 
Certificates 
Participative 20 mins Pencils and exam Tom and Charo Leave with the feeling of having learnt something and 
have the evidence of such learning in hand 
(certificates).  
Reinforce the key themes prior to leaving 
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Document 14: Facilitator training (cont.) 
 
Role play: Training new facilitators to run TB Clubs: a practical session 
 
Roles of participants: 
 
o IPSYD Facilitator Supervisor/Trainer:  
 Supports and advised the supervisor in training 
 
o Facilitator in training:  
 During the role play supports and facilitates the TB Club members to express their 
thoughts and feelings about living with or being affected by TB 
 Asks the TB Club members to describe the Becerra drawings to stimulate conversation if 
necessary 
 
o 2/4 people undertake the role of TB Club members (i.e. pretend to be patients below – can vary)  
 Club Member #1:  
 Woman, 26 years old, a mother of a daughter of 2 years old  
 Her husband mistreats her at home and ignores her 
 She would love to share these feelings but is ashamed and upset 
 Club Member #2:  
 40 year old male 
 Is annoyed because he has lost his job (he believes due to his TB diagnosis) 
 He speaks out angrily and dominates the conversation 
 Club Member #3: 
 Woman or man 15 years of age 
 Doesn’t identify with the other Tb Club members, thinks they’re old fogeys 
 Appears extemely bored and speaks on his phone 
 Club Member #4: 
 Woman, 60 years old 
 Doesn’t seem to understand the TB Club or the pictures she’s shown 
 Responds in an inappropriate way to questions asked due to lack of understanding 
 
o Observer who notes and feeds back at the end:  
 What did the facilitator in training do well? 
 What could the facilitator in training do to improve the results of the TB Club? 
 
After 10 minutes, everyone changes roles and the practice TB Club is repeated (i.e. the observer 
becomes a patient, a patient becomes a facilitator in training leading the Club, and a facilitator in 
training becomes an observer etc).
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Appendix 2: Bound copy of “Defining catastrophic costs and comparing their 
importance for adverse tuberculosis outcome with multi-drug resistance: a 
prospective cohort study, Peru.” PLOS Medicine. 2014 Jul 15;11(7):e1001675. 
doi: 10.1371/journal.pmed.1001675 
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Appendix 3: Bound copy of “The seasonality of tuberculosis, sunlight, vitamin 
D, and household crowding.” J Infect Dis. 2014 Sep 1;210(5):774-83. doi: 
10.1093/infdis/jiu121. Epub 2014 Mar 4 
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Appendix 4: Bound copy of “Designing and implementing a socioeconomic 
intervention to enhance TB control: operational evidence from the CRESIPT 
project in Peru.” BMC Public Health. 2015 Aug 21;15(1):810. doi: 
10.1186/s12889-015-2128-0 
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END OF THESIS 
